Document

Large Accelerated Filer

Accelerated Filer

Non-accelerated Filer

¨ (Do not check if a smaller reporting company)

Smaller Reporting Company

0000799729-17-000015.txt : 20170209 0000799729-17-000015.hdr.sgml : 20170209 20170208190042 ACCESSION NUMBER: 0000799729-17-000015 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 74 CONFORMED PERIOD OF REPORT: 20161231 FILED AS OF DATE: 20170209 DATE AS OF CHANGE: 20170208 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PAREXEL INTERNATIONAL CORP CENTRAL INDEX KEY: 0000799729 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 042776269 STATE OF INCORPORATION: MA FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-21244 FILM NUMBER: 17583978 BUSINESS ADDRESS: STREET 1: 195 WEST ST CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 7814879900 MAIL ADDRESS: STREET 1: 195 WEST ST CITY: WALTHAM STATE: MA ZIP: 02451 10-Q 1 prxlq2-1712312016.htm 10-Q Document

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended December 31, 2016

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number: 000-21244

PAREXEL INTERNATIONAL CORPORATION

(Exact name of registrant as specified in its charter)




Massachusetts		04-2776269
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

195 West Street Waltham, Massachusetts		02451
(Address of principal executive offices)		(Zip Code)

(781) 487-9900

Registrant’s telephone number, including area code

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ý No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ý No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No ý

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: As of February 6, 2017, there were 50,954,585 shares of common stock outstanding.

PAREXEL INTERNATIONAL CORPORATION

INDEX




Part I. Financial Information	2

Item 1. Financial Statements	2

Condensed Consolidated Balance Sheets (Unaudited): December 31, 2016 and June 30, 2016	2

Condensed Consolidated Statements Of Income and Comprehensive Income (Unaudited): Three and Six Months Ended December 31, 2016 and 2015	3

Condensed Consolidated Statements Of Cash Flows (Unaudited): Six Months Ended December 31, 2016 and 2015	4

Notes To Condensed Consolidated Financial Statements (Unaudited)	5

Item 2. Management’s Discussion And Analysis Of Financial Condition And Results Of Operations	23

Item 3. Quantitative And Qualitative Disclosures About Market Risk	36

Item 4. Controls And Procedures	37

Part II. Other Information	38

Item 1. Legal Proceedings	38

Item 1A. Risk Factors	38

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	39

Item 5. Other Information	39

Item 6. Exhibits	39

Signatures	40

Exhibit Index	41

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

PAREXEL INTERNATIONAL CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)

(in millions)



	December 31, 2016			June 30, 2016
ASSETS
Current assets:
Cash and cash equivalents	$	252.4		$	248.6
Billed accounts receivable, net	640.5			506.1
Unbilled accounts receivable, net	277.6			327.9
Prepaid expenses	26.7			23.3
Income taxes receivable	17.3			25.2
Other current assets	59.6			50.1
Total current assets	1,274.1			1,181.2
Property and equipment, net	252.4			259.3
Goodwill	441.0			389.2
Other intangible assets, net	203.6			130.7
Non-current deferred tax assets	27.4			27.1
Long-term income taxes receivable	9.9			10.4
Other assets	38.0			38.3
Total assets	$	2,246.4		$	2,036.2
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Notes payable and current portion of long-term debt	$	20.8		$	16.6
Accounts payable	102.4			62.6
Deferred revenue	453.7			420.2
Accrued expenses	36.3			35.0
Accrued restructuring charges, current portion	5.6			14.6
Accrued employee benefits and withholdings	137.9			176.4
Income taxes payable	17.2			21.6
Other current liabilities	27.4			22.4
Total current liabilities	801.3			769.4
Long-term debt, net of current portion	756.9			484.8
Non-current deferred tax liabilities	16.9			19.3
Long-term income tax liabilities	30.9			31.5
Long-term deferred revenue	37.3			38.3
Other liabilities	68.0			59.5
Total liabilities	1,711.3			1,402.8
Stockholders’ equity:
Preferred stock	—			—
Common stock	0.5			0.5
Additional paid-in capital	—			31.4
Retained earnings	691.7			737.5
Accumulated other comprehensive loss	(157.1		)	(136.0		)
Total stockholders’ equity	535.1			633.4
Total liabilities and stockholders’ equity	$	2,246.4		$	2,036.2

The accompanying notes are an integral part of the condensed consolidated financial statements.

PAREXEL INTERNATIONAL CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME

(UNAUDITED)

(in millions, except per share data)



	Three Months Ended						Six Months Ended
	December 31, 2016			December 31, 2015			December 31, 2016			December 31, 2015
Service revenue	$	534.4		$	518.5		$	1,031.1		$	1,030.6
Reimbursement revenue	77.8			85.7			157.6			158.8
Total revenue	612.2			604.2			1,188.7			1,189.4
Direct costs	350.9			332.5			678.6			675.7
Reimbursable out-of-pocket expenses	77.8			85.7			157.6			158.8
Selling, general and administrative	95.6			97.4			187.8			192.3
Depreciation	19.1			17.9			38.4			35.9
Amortization	7.2			5.7			12.7			11.4
Restructuring charge	1.6			10.4			0.3			25.2
Total costs and expenses	552.2			549.6			1,075.4			1,099.3
Income from operations	60.0			54.6			113.3			90.1
Interest expense, net	(2.8		)	(2.1		)	(5.4		)	(3.7		)
Miscellaneous (expense) income, net	(17.7		)	(0.1		)	(18.5		)	1.7
Total other expense	(20.5		)	(2.2		)	(23.9		)	(2.0		)
Income before income taxes	39.5			52.4			89.4			88.1
Provision for income taxes	17.7			13.0			29.8			23.8
Net income	$	21.8		$	39.4		$	59.6		$	64.3

Earnings per common share
Basic	$	0.42		$	0.74		$	1.14		$	1.19
Diluted	$	0.41		$	0.73		$	1.12		$	1.17
Weighted average shares outstanding
Basic	52.0			53.3			52.4			54.1
Diluted	52.7			54.0			53.2			54.9

Comprehensive income
Net income	$	21.8		$	39.4		$	59.6		$	64.3
Unrealized (loss) gain on derivative instruments, net of taxes	(1.1		)	(0.1		)	1.1			(2.2		)
Foreign currency translation adjustment	(26.0		)	(12.2		)	(22.2		)	(27.2		)
Total comprehensive (loss) income	$	(5.3	)	$	27.1		$	38.5		$	34.9

The accompanying notes are an integral part of the condensed consolidated financial statements.

PAREXEL INTERNATIONAL CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

(in millions)



	Six Months Ended
	December 31, 2016			December 31, 2015
Cash flow from operating activities:
Net income	$	59.6		$	64.3
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	51.1			47.3
Stock-based compensation	10.4			9.9
Excess tax benefit from stock-based compensation	—			(2.7		)
Unrealized forward contract loss on share repurchase	20.3			—
Deferred income taxes	(1.5		)	(7.1		)
Fair value adjustment of contingent consideration	(0.6		)	8.2
Other non-cash items	0.1			(0.1		)
Changes in operating assets and liabilities, net of effects from acquisitions	(27.9		)	(34.1		)
Net cash provided by operating activities	111.5			85.7
Cash flow from investing activities:
Acquisition of businesses, net of cash acquired	(148.3		)	—
Purchases of property and equipment	(33.2		)	(53.3		)
Net cash used in investing activities	(181.5		)	(53.3		)
Cash flow from financing activities:
Proceeds from issuance of common stock, net	12.8			10.2
Excess tax benefit from stock-based compensation	—			2.7
Payments for share repurchase	(200.0		)	(200.0		)
Borrowings under credit agreement/facility	419.2			475.0
Repayments under credit agreement/facility and other debt	(142.8		)	(358.9		)
Net cash provided by (used in) financing activities	89.2			(71.0		)
Effect of exchange rate changes on cash and cash equivalents	(15.4		)	(14.8		)
Net increase (decrease) in cash and cash equivalents	3.8			(53.4		)
Cash and cash equivalents at beginning of period	248.6			207.4
Cash and cash equivalents at end of period	$	252.4		$	154.0

Supplemental disclosures of cash flow information
Non-cash capital expenditures	$	4.7		$	6.3
Cash paid during the period for:
Interest	$	8.8		$	5.4
Income taxes, net of refunds	$	22.5		$	9.0

The accompanying notes are an integral part of the condensed consolidated financial statements.

PAREXEL INTERNATIONAL CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

NOTE 1. – BASIS OF PRESENTATION

The accompanying unaudited condensed consolidated financial statements of PAREXEL International Corporation (“PAREXEL,” the “Company,” “we,” “our” or “us”) have been prepared in accordance with generally accepted accounting principles ("GAAP") for interim financial information in the United States and the instructions of Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and notes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (primarily consisting of normal recurring adjustments) considered necessary for a fair presentation of the Company’s financial position as of December 31, 2016 and, results of operations for the three and six months ended December 31, 2016 and 2015 have been included. Operating results for the three and six months ended December 31, 2016 are not necessarily indicative of the results that may be expected for other quarters or the entire fiscal year. For further information, refer to the audited consolidated financial statements and footnotes thereto included in our Annual Report on Form 10-K for the fiscal year ended June 30, 2016 (the “2016 10-K”) filed with the Securities and Exchange Commission on September 9, 2016.

In the three and six month periods ended December 31, 2016, we recorded $2.4 million and $8.3 million, respectively, of adjustments related to revenue arrangements recognized in prior periods. The adjustments were recorded as reductions to service revenues in the consolidated statements of income and comprehensive income for the three and six months ended December 31, 2016. We concluded that the effect of these errors was not material to our consolidated financial statements for the current period, or any of the prior periods and, as such, these consolidated financial statements are not materially misstated.

Recently Issued Accounting Standards

In May 2014, the FASB issued ASU No. 2014-09 (“ASU 2014-09”), Revenue from Contracts with Customers (Topic 606), which provides that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve this core principle, an entity should apply the following steps: (1) identify the contract(s) with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when (or as) the entity satisfies a performance obligation. As originally issued, ASU 2014-09 will be effective prospectively for fiscal years and interim periods within those years beginning after December 15, 2016. On July 9, 2015, the FASB approved the proposal to defer the effective date of this standard by one year. Early adoption is permitted for annual periods beginning after December 16, 2016. The Company will adopt ASU 2014-09 effective July 1, 2018. We are assessing the impact of adopting ASU 2014-09 on our consolidated financial statements.

Subsequent to issuing ASU 2014-09, the FASB issued the following amendments concerning clarification of ASU 2014-09. In March 2016, the FASB issued ASU No. 2016-08 (“ASU 2016-08”), Revenue from Contracts with Customers (Topic 606), Principal versus Agent Considerations (Reporting Revenue Gross versus Net), which further clarifies the implementation guidance on principal versus agent considerations. The new guidance requires either a retrospective or a modified retrospective approach to adoption. In April 2016, the FASB issued ASU No. 2016-10, (“ASU 2016-10”) Revenue from Contracts with Customers (Topic 606), Identifying Performance Obligations and Licensing, which clarifies the identification of performance obligations and the licensing implementation guidance, while retaining the related principles for those areas. In May 2016, the FASB issued ASU No. 2016-12 (“ASU 2016-12”), Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients, which provides clarification on assessing the collectability criterion, presentation of sales taxes, measurement date for noncash consideration and completed contracts at transition. We are currently evaluating the impact these ASUs will have on our consolidated financial statements.

In January 2016, the FASB issued ASU No. 2016-01 (“ASU 2016-01”), Financial Instruments—Overall (Subtopic 825-10)Recognition and Measurement of Financial Assets and Financial Liabilities. This ASU is intended to provide users of financial statements with more useful information on the recognition, measurement, presentation, and disclosure of financial instruments. ASU 2016-01 is effective for fiscal years beginning after December 15, 2017, with early adoption permitted. We are assessing the impact of adopting ASU No. 2016-01 on our consolidated financial statements.

In February 2016, the FASB issued ASU No. 2016-02 (“ASU 2016-02”), Leases (Topic 842) Section A-Leases: Amendments to the FASB Accounting Standards Codification® Section B-Conforming Amendments Related to Leases: Amendments to the FASB Accounting Standards Codification® Section C-Background Information and Basis for Conclusions. This ASU requires an entity that leases assets to recognize on the balance sheet the assets and liabilities for the rights and obligations created by those leases. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, with early adoption permitted. We are assessing the impact of adopting ASU 2016-02 on our consolidated financial statements.

In March 2016, the FASB issued ASU No. 2016-05 (“ASU 2016-05”), Derivatives and Hedging (Topic 815): Effect of Derivative Contract Novations on Existing Hedge Accounting Relationships (a Consensus of the Emerging Issues Task Force). This ASU

PAREXEL INTERNATIONAL CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

clarifies that a change in the counterparty to a derivative instrument that has been designated as the hedging instrument under Topic 815 does not, in and of itself, require dedesignation of that hedging relationship provided that all other hedge accounting criteria continue to be met. ASU 2016-05 is effective for fiscal years beginning after December 15, 2016, with early adoption permitted. We are assessing the impact of adopting ASU 2016-05 on our consolidated financial statements.

Recently Adopted Accounting Standards

In the first quarter of our fiscal year ending June 30, 2017, the Company adopted ASU No. 2014-12 (“ASU 2014-12”), Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved After the Requisite Service Period. ASU 2014-12 requires that a performance target that affects vesting and could be achieved after the requisite service period be treated as a performance condition. A reporting entity should apply existing guidance in Accounting Standards Codification (“ASC”) 718, Compensation—Stock Compensation, as it relates to such awards. ASU 2014-12 permits using either of two methods: (i) prospective to all awards granted or modified after the effective date; or (ii) retrospective to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or modified awards thereafter, with the cumulative effect of applying ASU 2014-12 as an adjustment to the opening retained earnings balance as of the beginning of the earliest annual period presented in the financial statements. The adoption of this ASU did not have a material impact on our consolidated financial statements.

In the first quarter of our fiscal year ending June 30, 2017, the Company adopted ASU No. 2015-16 (“ASU 2015-16”), Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments. This ASU requires adjustments to provisional amounts that are identified during the measurement period of a business combination to be recognized in the reporting period in which the adjustment amounts are determined. Acquirers are no longer required to revise comparative information for prior periods as if the accounting for the business combination had been completed as of the acquisition date. The adoption of this ASU did not have a material impact on our consolidated financial statements.

In the first quarter of our fiscal year ending June 30, 2017, the Company adopted ASU No. 2015-03 (“ASU 2015-03”), Simplifying the Presentation of Debt Issuance Costs. ASU 2015-03 requires the presentation of debt issue costs in the consolidated balance sheets as a reduction to the related debt liability rather than as an asset. Amortization of debt issuance costs continues to be classified as interest expense. The adoption of this ASU did not have a material impact on our consolidated financial statements.

In the first quarter of our fiscal year ending June 30, 2017, the Company adopted ASU No. 2016-09 (“ASU 2016-09”), Compensation-Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. This ASU simplifies the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The following summarizes the effects of the adoption on the Company's unaudited condensed consolidated financial statements:

Income taxes - Upon adoption of this standard, all excess tax benefits and tax deficiencies (including tax benefits of dividends on share-based payment awards) are recognized as income tax expense or benefit in the income statement. The tax effects of exercised or vested awards are treated as discrete items in the reporting period in which they occur. The Company also recognizes excess tax benefits regardless of whether the benefit reduces taxes payable in the current period. As a result, the Company recognized discrete adjustments to income tax expense for six months ended December 31, 2016, in the amount of $2.3 million related to excess tax benefits. The Company has applied the modified retrospective adoption approach beginning in Fiscal Year 2017. This cumulative-effect adjustment related to tax assets that had previously arisen from tax deductions for equity compensation expenses that were greater than the compensation recognized for financial reporting. These assets had been excluded from the deferred tax assets and liabilities totals on the balance sheet as a result of certain realization requirements previously included in ASC 718. Prior periods have not been adjusted.

Forfeitures - Prior to adoption, share-based compensation expense was recognized on a straight line basis, net of estimated forfeitures, such that expense was recognized only for share-based awards that are expected to vest. A forfeiture rate was estimated annually and revised, if necessary, in subsequent periods if actual forfeitures differed from initial estimates. Upon adoption, the Company will no longer apply a forfeiture rate and instead will account for forfeitures as they occur. As we previously estimated forfeitures to determine stock-based compensation expense, this change resulted in a cumulative-effect adjustment as of July 1, 2016 to reduce retained earnings by $0.6 million.

Statements of Cash Flows - The Company historically accounted for excess tax benefits on the Statement of Cash Flows as a financing activity. Upon adoption of this standard, excess tax benefits are classified as an operating activity. The Company has elected to adopt this portion of the standard on a prospective basis beginning in Fiscal Year 2017. Prior periods have not been adjusted.

Earnings Per Share - The Company uses the treasury stock method to compute diluted earnings per share, unless the effect would be anti-dilutive. Under this method, the Company will no longer be required to estimate the tax rate and apply it to the dilutive share calculation for determining the dilutive earnings per share. The Company has applied this methodology beginning in Fiscal Year 2017, and prior periods have not been adjusted.

PAREXEL INTERNATIONAL CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

Upon adoption, no other aspects of ASU 2016-09 had a material effect on the Company's unaudited condensed consolidated financial statements or related footnote disclosures.

NOTE 2. – ACQUISITIONS

The pro forma effects of the acquisition described below are not significant to the Company's reported results for any period presented. Accordingly, no pro forma financial statements have been presented herein.

We accounted for these acquisitions as business combinations in accordance with FASB ASC Topic 805, "Business Combinations." We allocate the amount that we pay for each acquisition to the assets we acquire and liabilities we assume based on their fair values at the dates of acquisition, including identifiable intangible assets. We base the fair value of identifiable intangible assets acquired in a business combination on detailed valuations that use information and assumptions determined by management and that consider management's best estimates of inputs and assumptions that a market participant would use. We allocate any excess purchase price over the fair value of the net tangible and identifiable intangible assets acquired to goodwill. The use of alternative valuation assumptions, including estimated revenue projections, growth rates, cash flows, discount rates, and estimated useful lives, could result in different purchase price allocations and amortization expense in current and future periods.

ExecuPharm, Inc.

On October 3, 2016, we acquired all of the capital stock of privately owned ExecuPharm, Inc. ("ExecuPharm"), a leading global functional service provider, based in Pennsylvania. ExecuPharm provides clinical monitoring or study management, along with associated operational activities such as onboarding, training, line management, performance management and policy administration.

We paid approximately $148.9 million for the capital stock of ExecuPharm, plus the potential for us to pay an additional $20 million if specific financial targets for ExecuPharm are achieved, and $5.0 million for management retention bonuses. In addition, we made a 338(h)(10) tax election with respect to the ExecuPharm acquisition. Under the 338(h)(10) election, ExecuPharm was deemed to have sold and repurchased its assets at fair market value. In connection with this election, the Company will provide the seller with a tax gross-up payment, which is expected to be paid during the fourth quarter of our Fiscal Year 2017, in the estimated amount of $9.3 million. We funded the acquisition through the use of existing cash held within the United States and $100 million from our credit agreement as defined in Note 10. We will include ExecuPharm results of operations in our Clinical Research Services business segment.

The components of the consideration transferred in conjunction with the ExecuPharm acquisition and the preliminary allocation of that consideration is as follows (in millions):



Total consideration transferred:
Cash paid, net of cash acquired	$	148.5
Fair value of contingent consideration	9.4
Deferred payment	9.3
Net purchase price	$	167.2
Preliminary allocation of consideration transferred:
Accounts receivable	$	29.2
Other current assets	0.1
Property and equipment, net	0.9
Definite-lived intangible assets	87.1
Goodwill	58.6
Total assets acquired	175.9
Current liabilities	8.7
Total liabilities assumed	8.7
Net assets acquired:	$	167.2

The goodwill of $58.6 million arising from the ExecuPharm acquisition largely reflects the potential synergies and expansion of our service offerings across products and markets complementary to our existing service offering and markets. All of the goodwill is expected to be deductible for tax purposes.

PAREXEL INTERNATIONAL CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

The following are the preliminary identifiable intangible assets acquired and their respective estimated useful lives, based on preliminary valuations (dollars in millions):

Health Advances Acquisition

On January 19, 2016, we entered into a definitive agreement to acquire all of the outstanding equity securities of Health Advances, LLC (“Health Advances”), an independent life sciences strategy consulting firm. Health Advances combines clinical, scientific, and business expertise to provide strategic advice to executives leading life sciences companies and investors. The acquisition closed on February 10, 2016 and is part of the PAREXEL Consulting Services (“PC”) segment.

The net purchase price for the acquisition was approximately $67.1 million, plus the potential to pay up to an additional $15.8 million over a thirty-six month period following the acquisition date if Health Advances achieves certain financial targets. We funded the acquisition with credit facilities.

The components of the consideration transferred in conjunction with the Health Advances acquisition and the preliminary allocation of that consideration is as follows (in millions):



Total consideration transferred:
Cash paid, net of cash acquired	$	67.1
Fair value of contingent consideration	4.5
Net purchase price	$	71.6
Preliminary allocation of consideration transferred:
Accounts receivable	$	4.0
Other current assets	0.7
Property and equipment, net	1.0
Deferred tax assets	0.2
Definite-lived intangible assets	15.0
Goodwill	52.5
Total assets acquired	73.4
Current liabilities	1.8
Total liabilities assumed	1.8
Net assets acquired:	$	71.6

The amounts above represent our preliminary fair value estimates as of December 31, 2016 and may be subject to subsequent adjustment as we obtain additional information during the measurement period and finalize our fair value estimates. During the six months ended December 31, 2016, we received a working capital adjustment payment from the sellers of $0.2 million.

The goodwill of $52.5 million arising from the Health Advances acquisition largely reflects the potential synergies and expansion of our service offerings across products and markets complementary to our existing service offering and markets. All of the goodwill is expected to be deductible for tax purposes.

The following are the preliminary identifiable intangible assets acquired and their respective estimated useful lives, as determined based on preliminary valuations (dollars in millions):



	Amount		Estimated Useful Life (Years)
Customer relationships	$	11.6	10
Technology	1.8		3
Trade name	1.6		5
Total	$	15.0

PAREXEL INTERNATIONAL CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

The Medical Affairs Company, LLC

On February 1, 2017, the Company entered into a definitive agreement to acquire The Medical Affairs Company, LLC, a leading provider of outsourced medical affairs services to the pharmaceutical, biotechnology, and medical device industries. The acquisition is expected to close during the third quarter of our Fiscal Year 2017.

NOTE 3. – EQUITY AND EARNINGS PER SHARE

We have authorized 5.0 million shares of preferred stock at $0.01 par value. As of December 31, 2016 and June 30, 2016, we had no shares of preferred stock issued and outstanding.

We have authorized 150.0 million shares of common stock at $0.01 par value. As of December 31, 2016 and June 30, 2016, respectively, we had 50.9 million and 52.9 million shares of common stock issued and outstanding.

We compute basic earnings per share by dividing net income for the period by the weighted average number of common shares outstanding during the period. We compute diluted earnings per share by dividing net income by the weighted average number of common shares plus the dilutive effect of outstanding stock options and restricted stock awards and units. The following table outlines the basic and diluted earnings per share computations:



(in millions, except per share data)	Three Months Ended				Six Months Ended
	December 31, 2016		December 31, 2015		December 31, 2016		December 31, 2015
Net income attributable to common stock	$	21.8	$	39.4	$	59.6	$	64.3
Weighted average number of shares outstanding, used in computing basic earnings per share	52.0		53.3		52.4		54.1
Dilutive common stock equivalents	0.7		0.7		0.8		0.8
Weighted average number of shares outstanding used in computing diluted earnings per share	52.7		54.0		53.2		54.9
Basic earnings per share	$	0.42	$	0.74	$	1.14	$	1.19
Diluted earnings per share	$	0.41	$	0.73	$	1.12	$	1.17
Anti-dilutive equity instruments (excluded from the calculation of diluted earnings per share)	0.6		1.4		0.8		1.2

Share Repurchase Plan

Fiscal Year 2017 Share Repurchase

On October 26, 2016, we announced that our Board of Directors approved a share repurchase program (the “2017 Program”) authorizing the repurchase of up to $200.0 million of our common stock to be financed with cash on hand, cash generated from operations, existing credit facilities, or new financing. On November 21, 2016, we entered into an agreement (the “2017 Agreement”) to purchase shares of our common stock from HSBC, National Association (“HSBC”), for an aggregate purchase price of $200.0 million pursuant to an accelerated share purchase program. Pursuant to the 2017 Agreement, in November 2016, we paid $200.0 million to HSBC and received from HSBC 2.8 million shares of our common stock, representing 80% of the estimated shares to be repurchased by us under the 2017 Agreement. The shares were repurchased at a price of $57.51 per share, which was the closing price of our common stock on the Nasdaq Global Select Market on November 21, 2016. These shares were canceled and restored to the status of authorized and unissued shares. As of December 31, 2016, we recorded the $160.0 million payment, which represents the 80% of the shares we repurchased, as a decrease to equity in our consolidated balance sheet, consisting of decreases in common stock and additional paid-in capital. As additional paid-in capital was reduced to zero, the remainder was applied as a reduction in retained earnings. The remaining $40.0 million, which is an advanced payment accounted for as a forward share repurchase contract, was recorded as within other current assets within the condensed consolidated balance sheet. During the three months ended December 31, 2016, the fair value of the forward share repurchase contract in the amount of $40.0 million decreased by $20.3 million.

Fiscal Year 2016 Share Repurchase

PAREXEL INTERNATIONAL CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

price of our common stock on the Nasdaq Global Select Market on September 16, 2015. These shares were canceled and restored to the status of authorized and unissued shares. As of December 31, 2016, we recorded the $200.0 million payment to WF as a decrease to equity in our consolidated balance sheet, consisting of decreases in common stock and additional paid-in capital. As additional paid-in capital was reduced to zero, the remainder was applied as a reduction in retained earnings.

On February 10, 2016, we received 0.9 million shares representing the final settlement of the 2016 Agreement and the 2016 Program was completed. Pursuant to the 2016 Program, we repurchased 3.2 million shares of our common stock at an average price of $62.92 per share from September 2015 to February 2016.

NOTE 4. – ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)

The following table reflects the activity for the components of accumulated other comprehensive income (loss), net of tax, for the six months ended December 31, 2016:



(in millions)	Foreign Currency			Unrealized Gain/Loss on Derivatives			Total
Balance as of June 30, 2016	$	(130.5	)	$	(5.5	)	$	(136.0	)
Other comprehensive loss before reclassifications	(22.2		)	(3.6		)	(25.8		)
Loss reclassified from accumulated other comprehensive income	—			4.7			4.7
Net current-period other comprehensive (loss) gain	$	(22.2	)	$	1.1		$	(21.1	)
Balance as of December 31, 2016	$	(152.7	)	$	(4.4	)	$	(157.1	)

The change in our translation adjustment was due primarily to the movements in the Japanese Yen (JPY), Great British Pound (GBP) and Euro (EUR) exchange rates against the United States Dollar (USD). The USD strengthened by 12.1%, 8.2% and 4.9% versus the JPY, GBP and EUR, respectively, between June 30, 2016 and December 31, 2016. The movement in the JPY, GBP and EUR represented $3.0 million, $8.4 million and $8.6 million, respectively, out of the $22.2 million foreign currency translation adjustment during the six months ended December 31, 2016. The remaining foreign currency translation adjustment is attributable to the USD appreciation against other major world-wide currencies, including Chinese Yuan, Canadian Dollar, Argentine Peso and Ukrainian Hryvnia.

The details regarding pre-tax loss on derivative instruments reclassified to net income from accumulated other comprehensive income (loss) for the three and six months ended December 31, 2016 and 2015 are presented below:



	Three Months Ended						Affected Line in the Consolidated Statements of Income
(in millions)	December 31, 2016			December 31, 2015			Affected Line in the Consolidated Statements of Income
Interest rate contracts	$	(0.2	)	$	(0.1	)	Interest expense, net
Foreign exchange contracts	(2.1		)	(0.2		)	Service Revenue
Foreign exchange contracts	(0.7		)	(1.8		)	Direct Costs
Total	$	(3.0	)	$	(2.1	)



	Six Months Ended						Affected Line in the Consolidated Statements of Income
(in millions)	December 31, 2016			December 31, 2015			Affected Line in the Consolidated Statements of Income
Interest rate contracts	$	(0.2	)	$	(0.3	)	Interest expense, net
Foreign exchange contracts	(4.8		)	(0.4		)	Service Revenue
Foreign exchange contracts	(0.8		)	(4.6		)	Direct Costs
Total	$	(5.8	)	$	(5.3	)

The amounts of loss reclassified from accumulated other comprehensive income into net income are net of taxes of $0.7 million, and $1.2 million for the three and six months ended December 31, 2016, respectively.

The amounts of loss reclassified from accumulated other comprehensive income into net income are net of taxes of $0.8 million, and $2.1 million for the three and six months ended December 31, 2015, respectively.

PAREXEL INTERNATIONAL CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

NOTE 5. – STOCK-BASED COMPENSATION

We account for stock-based compensation according to FASB ASC 718, “Compensation—Stock Compensation.” The classification of compensation expense within the consolidated statements of income is presented in the following table:



(in millions)	Three Months Ended				Six Months Ended
	December 31, 2016		December 31, 2015		December 31, 2016		December 31, 2015
Direct costs	$	1.1	$	1.0	$	2.2	$	2.2
Selling, general and administrative	4.5		3.8		8.2		7.7
Total stock-based compensation	$	5.6	$	4.8	$	10.4	$	9.9

On December 3, 2015, the Company's shareholders approved a new share-based compensation plan, the 2015 Stock Incentive Plan (the “2015 Plan”). The 2015 Plan allows for the issuance of up to the sum of (i) 3.0 million shares of PAREXEL common stock plus (ii) up to an additional 3.4 million shares of PAREXEL common stock from awards under the Existing Plans (as defined below), which expire, terminate or are otherwise surrendered, canceled, forfeited, or repurchased by the Company. The Company stopped making awards under its Existing Plans upon approval of the 2015 Plan by its shareholders. The term “Existing Plans” refers collectively to the Company’s 2005 Stock Incentive Plan, 2007 Stock Incentive Plan, and 2010 Stock Incentive Plan.

The 2015 Plan allows for the grant of incentive stock options intended to qualify under Section 422 of the Internal Revenue Code of 1986, as amended, nonstatutory stock options, stock appreciation rights, restricted stock, restricted stock units and other stock-based awards, which are referred to collectively as “Awards.” The 2015 Plan became effective upon approval by the Company’s shareholders. No Awards may be made under the 2015 Plan after December 3, 2025.

NOTE 6. RESTRUCTURING CHARGES

In June 2015, the Board of Directors approved a plan (the “Margin Acceleration Program”) to restructure our operations to improve the productivity and efficiency of the Company, simplify the organization, and streamline decision-making, thereby enhancing client engagement. The Margin Acceleration Program is company-wide. The activities under the Margin Acceleration Program were substantially complete as of June 30, 2016. In Fiscal Years 2015 and 2016, we recorded restructuring charges of $20.0 million and $27.8 million, respectively. In the first quarter of Fiscal Year 2017, we recorded a benefit of $1.3 million, while in the second quarter of Fiscal Year 2017, we recorded a restructuring charge of $1.6 million related to the Margin Acceleration Program.

Changes in the restructuring accrual during the first six months of Fiscal Year 2016 are summarized below:



	Balance at		Charges/(Benefits)			Payments/Foreign Currency Exchange/Other			Balance at
	June 30, 2016		Charges/(Benefits)			Payments/Foreign Currency Exchange/Other			December 31, 2016
2015 Margin Acceleration Program
Employee severance	$	10.5	$	(0.5	)	$	(6.8	)	$	3.2
Facilities-related	7.1		0.8			(2.8		)	5.1
Pre-Fiscal Year 2012 Restructuring Plans
Facilities-related	0.1		—			—			0.1
Total	$	17.7	$	0.3		$	(9.6	)	$	8.4

PAREXEL INTERNATIONAL CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

Net restructuring charges by segment are as follows:



	Six Months Ended
(dollars in millions)	December 31, 2016			December 31, 2015
CRS	$	(0.7	)	$	12.2
PC	(0.1		)	0.7
PI	2.6			7.6
Segment Total	1.8			20.5
Corporate restructuring charges	(1.5		)	4.7
Total restructuring charges	$	0.3		$	25.2

2017 Restructuring Plan

On January 6, 2017, the Company approved a plan to restructure its operations to improve the productivity and efficiency of the company, simplify the organization, and streamline decision-making, thereby enhancing client engagement. The restructuring initiative is company-wide. These actions are expected to result in pre-tax charges in the range of $25.0 million to $35.0 million, all of which are anticipated to be cash expenditures.

NOTE 7. – SEGMENT INFORMATION

We have three reportable segments: Clinical Research Services (“CRS”), PAREXEL Consulting Services (“PC”), and PAREXEL Informatics (“PI”).

•

CRS constitutes our core business and includes all phases of clinical research from Early Phase (encompassing the early stages of clinical testing that range from first-in-man through proof-of-concept studies) to Phase II-III and Phase IV, which we include in our PAREXEL Access product offering, formerly known as Peri/Post Approval Services. Our services include clinical trials management and biostatistics, commercialization, data management and clinical pharmacology, as well as related medical advisory, patient recruitment, clinical supply and drug logistics, pharmacovigilance, and investigator site services. We aggregate Early Phase and PAREXEL Access with Phase II-III due to economic similarities in these operating segments.

•

PC provides technical expertise and advice in such areas as drug development, regulatory affairs, product pricing and reimbursement, commercialization and strategic compliance. It also provides a full spectrum of market development, product development and targeted communication services in support of product launch. Our PC consultants identify alternatives and propose solutions to address client issues associated with product development, registration, and commercialization.

•

PI provides information technology solutions designed to help improve clients’ product development and regulatory submission processes. PI offers a portfolio of products and services that includes medical imaging services, ClinPhone^® RTSM, IMPACT^® clinical trials management systems (“CTMS”), DataLabs^® electronic data capture, web-based portals, systems integration, electronic patient-reported outcomes, and LIQUENT InSight® Regulatory Information Management (“RIM”) solutions.

We evaluate our segment performance and allocate resources based on service revenue and gross profit (service revenue less direct costs), while other operating costs are allocated and evaluated on a geographic basis. Accordingly, we do not include the impact of selling, general, and administrative expenses, depreciation and amortization expense, other income (expense), and income tax expense in segment profitability. We attribute revenue to individual countries based upon the revenue earned in the respective countries; however, inter-segment transactions are not included in service revenue. Furthermore, we have a global infrastructure supporting our business segments, and therefore assets are not identified by reportable segment.

PAREXEL INTERNATIONAL CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

Our segment results were as follows:



(in millions)	Three Months Ended				Six Months Ended
	December 31, 2016		December 31, 2015		December 31, 2016		December 31, 2015
Service revenue
CRS	$	408.9	$	407.1	$	785.2	$	817.3
PC	54.6		41.4		109.6		80.7
PI	70.9		70.0		136.3		132.6
Total service revenue	$	534.4	$	518.5	$	1,031.1	$	1,030.6
Direct costs
CRS	$	284.5	$	274.4	$	546.6	$	561.9
PC	30.9		20.8		61.3		41.0
PI	35.5		37.3		70.7		72.8
Total direct costs	$	350.9	$	332.5	$	678.6	$	675.7
Gross profit
CRS	$	124.4	$	132.7	$	238.6	$	255.4
PC	23.7		20.6		48.3		39.7
PI	35.4		32.7		65.6		59.8
Total gross profit	$	183.5	$	186.0	$	352.5	$	354.9

NOTE 8. – INCOME TAXES

We determine our global provision for corporate income taxes in accordance with ASC 740, “Income Taxes.” We recognize our deferred tax assets and liabilities based upon the effect of temporary differences between the book and tax basis of recorded assets and liabilities. Further, we follow a methodology in which we identify, recognize, measure, and disclose in our financial statements the effects of any uncertain tax return reporting positions that we have taken or expect to take. The methodology is based on the presumption that all relevant tax authorities possess full knowledge of those tax reporting positions, as well as all of the pertinent facts and circumstances. Our quarterly effective income tax rate reflects management’s estimates of our annual projected profitability in the various taxing jurisdictions in which we operate. Since the statutory tax rates differ in the jurisdictions in which we operate, changes in the distribution of profits and losses may have a significant impact on our effective income tax rate.

For the three months ended December 31, 2016 and 2015, we had effective income tax rates of 44.8% and 24.8%, respectively. The tax rate for the three months ended December 31, 2016 was higher than the expected statutory rate of 35% primarily due to the non-deductibility of the unrealized loss on the fair value adjustment of $20.3 million in connection with the accelerated share repurchase program, which increased the tax rate by15.2%, and was partially offset by the favorable effect of statutory tax rates applicable to income earned outside the United States on the projected annual effective tax rate. The tax rate for the three months ended December 31, 2015 was lower than the expected statutory rate of 35% primarily as a result of the favorable effect of statutory tax rates applicable to income earned outside the United States on the projected annual effective tax rate.

For the six months ended December 31, 2016 and 2015, we had effective income tax rates of 33.3% and 27.0%, respectively. The tax rates for these periods were lower than the expected statutory rate of 35% primarily as a result of the favorable effect of statutory tax rates applicable to income earned outside the United States on the projected annual effective tax rate. The tax rate for the six months ended December 31, 2016, benefited 2.5% from the adoption of ASU 2016-09 as discussed in Note 1 to these condensed consolidated financial statements, and increased by 6.1% due to the non-deductibility of the unrealized loss on the fair value adjustment of $20.3 million in connection with accelerated share repurchase program.

As of December 31, 2016, we had $28.9 million of gross unrecognized tax benefits, of which $18.7 million would impact the effective tax rate if recognized. As of June 30, 2016, we had $29.5 million of gross unrecognized tax benefits, of which $18.9 million would impact the effective tax rate if recognized. The reserves for unrecognized tax positions primarily relate to exposures for income tax matters such as changes in the jurisdiction in which income is taxable. The $0.7 million net decrease in gross unrecognized tax benefits is primarily attributable to currency translation adjustments.

As of December 31, 2016, we do not anticipate that the liability for unrecognized tax benefits for uncertain tax positions could decrease over the next 12 months primarily as a result of the expiration of statutes of limitations and settlements with tax authorities.

We recognize interest and penalties related to income tax matters in income tax expense. As of December 31, 2016 and June 30, 2016, $3.5 million and $3.4 million, respectively, of gross interest and penalties were included in the liability for unrecognized

PAREXEL INTERNATIONAL CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

tax benefits. For the six month periods ended December 31, 2016 and 2015, expenses of $0.2 million and $0.4 million, respectively, were recorded for interest and penalties related to tax matters.

We are subject to U.S. federal income tax, as well as income tax in multiple states, local and foreign jurisdictions. Our U.S. federal, state and local income tax returns for the tax years 2005 to 2015 remain open for examination by the relevant tax authority. In foreign tax jurisdictions, the Company has open tax years dating back to 2002. The extended open tax years for these jurisdictions resulted from tax attributes carryover, including net operating losses or tax credits from those tax years.

We are subject to on-going tax audits in various jurisdictions. Tax authorities may disagree with certain positions we have taken and assess additional taxes. We regularly assess the likely outcomes of these audits in order to determine the appropriateness of our tax provision and have established contingency reserves for material, known tax exposures.

NOTE 9. – CREDIT AGREEMENTS

2016 Credit Agreement

On March 11, 2016, PAREXEL, certain subsidiaries of PAREXEL; Bank of America, N.A. (“Bank of America”), as Administrative Agent, Swingline Lender and L/C Issuer; Merrill Lynch, Pierce, Fenner & Smith Incorporated (“MLPFS”); HSBC Bank USA, N.A. (“HSBC”), U.S. Bank, N.A. (“US Bank”); TD Securities (USA) LLC (“TD Securities”) and Wells Fargo Securities, LLC (“Wells Fargo Securities”) as Joint Lead Arrangers and Joint Book Managers, HSBC, US Bank, TD Bank, N.A. (“TD Bank”) and Wells Fargo Bank, N.A. (“Wells Fargo Bank”) as Joint Syndication Agents, and the other lenders party thereto entered into an amended and restated credit agreement (the “2016 Credit Agreement”). The 2016 Credit Agreement provided for a five-year term loan and revolving credit facility in the principal amount of up to $750.0 million (collectively, the “Loan Amount”), plus additional amounts of up to $300.0 million of loans to be made available upon request of the Company subject to specified terms and conditions.

The 2016 Credit Agreement amends and restates the amended and restated credit agreement dated October 15, 2014, (the “2014 Credit Agreement”), by and among the Company, certain subsidiaries of the Company; Bank of America, as Administrative Agent, Swingline Lender and L/C Issuer; MLPFS; J.P. Morgan Securities LLC; HSBC; and US Bank, as Joint Lead Arrangers and Joint Book Managers; JPMorgan Chase Bank N.A., HSBC and US Bank, as Joint Syndication Agents, and the other lenders party thereto.

The 2016 Credit Agreement provides for a revolving credit facility in the principal amount of up to $350.0 million from time to time outstanding. A portion of the revolving credit facility is available for swingline loans of up to a sublimit of $100.0 million and for the issuance of standby letters of credit up to a sublimit of $10.0 million.

The 2016 Credit Agreement is intended to provide funds (i) for stock repurchases, (ii) for the issuance of letters of credit and (iii) for other general corporate purposes of PAREXEL and its subsidiaries, including permitted acquisitions.

On the closing date of March 11, 2016, after giving effect to the amendment and restatement of the 2014 Credit Agreement and the effectiveness of the 2016 Credit Agreement, the Company was obligated under the 2016 Credit Agreement for term loans in the principal amount of $400.0 million and revolving loans in the principal amount of $65.0 million.

As of December 31, 2016, we had $285.0 million of principal borrowed under the revolving credit facility and $392.5 million of principal borrowed under the term loan. The outstanding amount is presented net of debt issuance costs of approximately $2.9 million, in our consolidated balance sheet at December 31, 2016. As of December 31, 2016, we had borrowing availability of $165.0 million under the revolving credit facility. We used $100.0 million in borrowings under this credit facility in connection with our acquisition of ExecuPharm and $140.0 million to support our $200.0 million accelerated share repurchase program.

PAREXEL’s obligations under the 2016 Credit Agreement are guaranteed by certain material domestic subsidiaries of the Company, and the obligations, if any, of any foreign designated borrower are guaranteed by the Company and certain of its material domestic subsidiaries.

Borrowings (other than swingline loans) under the 2016 Credit Agreement bear interest, at PAREXEL’s determination, at a rate based on either (a) LIBOR plus a margin (not to exceed a per annum rate of 2.0%) based on a ratio of consolidated net funded debt to consolidated earnings before interest, taxes, depreciation and amortization (EBITDA) (the “Consolidated Net Leverage Ratio”) or (b) the highest of (i) prime, (ii) the federal funds rate plus 50 basis points, and (iii) the one month LIBOR rate plus 100 basis points (such highest rate, the “Alternate Base Rate”), plus a margin (not to exceed a per annum rate of 1.0%) based on the Consolidated Net Leverage Ratio. Swingline loans in U.S. dollars bear interest calculated at the Alternate Base Rate plus a margin (not to exceed a per annum rate of 1.0%). Loans outstanding under the 2016 Credit Agreement may be prepaid at any time in whole or in part without premium or penalty, other than customary breakage costs, if any, subject to the terms and conditions contained in the 2016 Credit Agreement. The 2016 Credit Agreement terminates, and any outstanding loans under it mature, on March 11, 2021.

PAREXEL INTERNATIONAL CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

Repayment of the principal borrowed under the revolving credit facility (other than a swingline loan) is due on March 11, 2021. A swingline loan under the 2016 Credit Agreement generally must be paid ten (10) business days after the loan is made. Repayment of principal borrowed under the term loan facility is as follows, with the final payment of all amounts outstanding, plus accrued interest, being due on March 11, 2021:


•	0.63% by quarterly term loan amortization payments to be made commencing June 30, 2016 and made on or prior to March 31, 2017;


•	1.25% by quarterly term loan amortization payments to be made on or after June 30, 2017, but on or prior to March 31, 2019;


•	1.88% by quarterly term loan amortization payments to be made on or after June 30, 2019, but on or prior to March 31, 2020;


•	2.50% by quarterly term loan amortization payments to be made on or after June 30, 2020, but prior to March 11, 2021; and


•	72.50% (or if less, the remaining principal amount of the term loan) on March 11, 2021.

To the extent not previously paid, all borrowings under the 2016 Credit Agreement must be repaid on March 11, 2021.

Interest due under the revolving credit facility (other than a swingline loan) and the term loan facility must be paid quarterly for borrowings with an interest rate determined with reference to the Alternate Base Rate. Interest must be paid on the last day of the interest period selected by the Company for borrowings determined with reference to LIBOR, provided that for interest periods of longer than three months, interest is required to be paid every three months. Interest under U.S. dollar swingline loans at the alternate base rate is payable quarterly.

The obligations of PAREXEL under the 2016 Credit Agreement may be accelerated upon the occurrence of an event of default under the 2016 Credit Agreement, which includes customary events of default, including payment defaults, defaults in the performance of affirmative and negative covenants, the inaccuracy of representations or warranties, bankruptcy- and insolvency-related defaults, cross defaults to material indebtedness, defaults relating to such matters as ERISA and judgments, and a change-of-control default.

The 2016 Credit Agreement contains negative covenants applicable to PAREXEL and its subsidiaries, including financial covenants requiring PAREXEL to comply with maximum net leverage ratios and minimum interest coverage ratios, as well as restrictions on liens, investments, indebtedness, fundamental changes, acquisitions, dispositions of property, specified restricted payments (including cash dividends and stock repurchases that would result in the Company exceeding an agreed-to Consolidated Net Leverage Ratio), transactions with affiliates, and other restrictive covenants. As of December 31, 2016, we were in compliance with all covenants under the 2016 Credit Agreement.

Under the terms of the 2016 Credit Agreement, neither we nor any of our subsidiaries may pay any dividend or make any other distribution with respect to any shares of capital stock except that (a) we and our subsidiaries may declare and pay dividends with respect to equity interests payable solely in additional shares of common stock, (b) our subsidiaries may declare and pay dividends and other distributions ratably with respect to their equity interests, (c) we may make payments pursuant to and in accordance with stock option plans or other benefit plans for management or employees of the Company and our subsidiaries, and (d) the Company and certain of its subsidiaries may make payments in connection with permitted repurchases of their respective capital stock.

In connection with the 2016 Credit Agreement, PAREXEL agreed to pay a commitment fee on the revolving loan commitment calculated as a percentage of the unused amount of the revolving loan commitment at a per annum rate of up to 0.250% (based on the Consolidated Net Leverage Ratio). To the extent there are letters of credit outstanding under the 2016 Credit Agreement, PAREXEL will pay letter of credit fees plus a fronting fee and additional charges. PAREXEL agreed to pay (i) Bank of America for its own account, an arrangement fee, (ii) to each of the lenders on the closing date, an upfront fee, and (iii) to Bank of America for its own account, an annual agency fee.

In May 2013, we entered into an interest rate swap agreement and hedged an additional principal amount of $100.0 million under a prior credit agreement, with a fixed interest rate of 0.73%. The interest rate swap agreement now hedges $100.0 million of principal under our 2016 Credit Agreement. These interest rate hedges were deemed to be fully effective in accordance with ASC 815 "Derivatives and Hedging", and, as such, unrealized gains and losses related to these derivatives are recorded as other comprehensive income in our consolidated balance sheets.

On October 1, 2015, we entered into a two-year interest rate swap agreement effective September 30, 2016, which now hedges an additional principal amount of $100.0 million under the 2016 Credit Agreement with a fixed interest rate 1.104%.

2016 Term Loan Agreement

PAREXEL INTERNATIONAL CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

to consolidated earnings before interest, taxes, depreciation and amortization (EBITDA) for the prior four fiscal quarters (the “Leverage Ratio”), or at a LIBOR rate plus a margin (such margin not to exceed a per annum rate of 1.750%) based on the Leverage Ratio. The Loan could have been prepaid at any time in whole or in part without premium or penalty, other than customary breakage costs, if any, subject to the terms and conditions of the loan agreement.

The proceeds of the Loan were advanced to the Company on February 12, 2016 and were used to repay borrowings under the Company’s 2014 Facility.

The obligations of PAREXEL under the Loan could have been accelerated upon the occurrence of an event of default under the Loan, which included customary events of default, including payment defaults, the inaccuracy of representations or warranties, and cross defaults to the 2014 Facility.

As of December 31, 2016, all outstanding amounts under the Loan were fully repaid with the proceeds from the 2016 Credit Agreement.

Master Financing Agreement

On June 12, 2015, we entered into a three-year, interest-free Master Financing Agreement for $7.1 million with General Electric Capital Corporation, (“GECC”), in conjunction with a software term license purchase. On June 30, 2015 we received the gross proceeds of $7.1 million from GECC. Repayment of the principal borrowed under the Master Financing Agreement is due annually on July 1 as follows:


•	$1.4 million made on or prior to July 1, 2015;


•	$2.8 million made on or prior to July 1, 2016; and


•	$2.9 million paid on or prior to July 1, 2017.

As of December 31, 2016, we had $2.9 million principal borrowed under the Master Financing Agreement.

2014 Credit Agreement

The 2014 Credit Agreement provided for a five-year term loan and revolving credit facility in the principal amount of up to $500.0 million (collectively, the “Loan Amount”), plus additional amounts of up to $300.0 million of loans to be made available upon request of the Company subject to specified terms and conditions. =The loan facility available under the 2014 Credit Agreement consisted of a term loan facility and a revolving credit facility. The principal amount of up to $200.0 million of the Loan Amount was available through the term loan facility, and the principal amount of up to $300.0 million of the Loan Amount was available through the revolving credit facility. A portion of the revolving credit facility was available for swingline loans of up to a sublimit of $100.0 million and for the issuance of standby letters of credit of up to a sublimit of $10.0 million.

Our obligations under the 2014 Credit Agreement were guaranteed by certain of our material domestic subsidiaries, and the obligations, if any, of any foreign designated borrower were guaranteed by us and certain of our material domestic subsidiaries.

The 2014 Credit Agreement was superseded by the 2016 Credit Agreement, and as of December 31, 2016 all outstanding amounts under the 2014 Credit Agreement were fully repaid.

Borrowings (other than swingline loans) under the 2014 Credit Agreement bore interest, at our determination, at a rate based on either (a) LIBOR plus a margin (not to exceed a per annum rate of 1.750%) based on the Leverage Ratio or (b) the highest of (i) prime, (ii) the federal funds rate plus 0.500%, and (iii) the one-month LIBOR rate plus 1.000% (such highest rate, the “Alternate Base Rate”), plus a margin (not to exceed a per annum rate of 0.750%) based on the Leverage Ratio. Swingline loans in U.S. dollars bear interest calculated at the Alternate Base Rate plus a margin (not to exceed a per annum rate of 0.750%).

Interest due under the revolving credit facility (other than a swingline loan) and the term loan facility had to be paid quarterly for borrowings with an interest rate determined with reference to the Alternate Base Rate. Interest had to be paid on the last day of the interest period selected by the Company for borrowings determined with reference to LIBOR; provided that for interest periods of longer than three months, interest is required to be paid every three months. Interest under U.S. dollar swingline loans at the alternate base rate is payable quarterly. Under the terms of the 2014 Credit Agreement, neither we nor any of our subsidiaries could have paid any dividend or made any other distribution with respect to any shares of capital stock except that (a) we and our subsidiaries could have declared and paid dividends with respect to equity interests payable solely in additional shares of common stock, (b) our subsidiaries could have declared and paid dividends and other distributions ratably with respect to their equity interests, (c) we could have made payments pursuant to and in accordance with stock option plans or other benefit plans for management or employees of the Company and our subsidiaries, and (d) the Company and certain of its subsidiaries could have made payments in connection with permitted repurchases of their respective capital stock.

PAREXEL INTERNATIONAL CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

fees plus a fronting fee and additional charges. We agreed to pay Bank of America (i) for its own account, an arrangement fee, (ii) for the account of each of the lenders, an upfront fee and (iii) for its own account, an annual agency fee.

In September 2011, we entered into an interest rate swap agreement, which hedged $100.0 million of principal under our prior debt obligations and carried a fixed interest rate of 1.30%. In September 2015, the interest rate swap agreement matured and the related accumulated other comprehensive income was reclassified to net income during the three months ended September 30, 2015.

Note Purchase Agreement

On July 25, 2013, we issued $100.0 million principal amount of 3.11% senior notes due July 25, 2020 (the “Notes”) for aggregate gross proceeds of $100.0 million in a private placement solely to accredited investors. The Notes were issued pursuant to a Note Purchase Agreement entered into by us with certain institutional investors on June 25, 2013 (the “Note Purchase Agreement”). Proceeds from the Notes were used to pay down $100.0 million of principal borrowed under the revolving credit facility of a previous credit agreement. We will pay interest on the outstanding balance of the Notes at a rate of 3.11% per annum, payable semi-annually on January 25 and July 25 of each year until the principal on the Notes shall have become due and payable. We may, at our option, upon notice and subject to the terms of the Note Purchase Agreement, prepay at any time all or part of the Notes in an amount not less than 10% of the aggregate principal amount of the Notes then outstanding, plus a Make-Whole Amount (as defined in the Note Purchase Agreement). The Notes become due and payable on July 25, 2020, unless payment is required to be made earlier under the terms of the Note Purchase Agreement.

The Note Purchase Agreement includes operational and financial covenants, with which we are required to comply, including, among others, maintenance of certain financial ratios and restrictions on additional indebtedness, liens, and dispositions. As of December 31, 2016, we were in compliance with all covenants under the Note Purchase Agreement.

In connection with the Note Purchase Agreement, certain of our subsidiaries entered into a Subsidiary Guaranty, pursuant to which such subsidiaries guaranteed our obligations under the Notes and the Note Purchase Agreement.

As of December 31, 2016, there was $100.0 million in aggregate principal amount outstanding under the Notes. The outstanding amounts are presented net of debt issuance cost of approximately $0.2 million in our consolidated balance sheets.

Receivable Purchase Agreement

On February 19, 2013, we entered into a receivables purchase agreement (the “Receivable Agreement”) with JPMorgan Chase Bank, N.A. (“JPMorgan”). Under the Receivable Agreement, we sell to JPMorgan or other investors on an ongoing basis certain of our trade receivables, together with ancillary rights and the proceeds thereof, which arise under contracts with a client, or its subsidiaries or affiliates. The Receivable Agreement includes customary representations and covenants on behalf of us, and may be terminated by either us or JPMorgan upon five business days' advance notice. The Receivable Agreement provides a mechanism for accelerating the receipt of cash due on outstanding receivables. We account for the transfer of our receivables with respect to which we have satisfied the applicable revenue recognition criteria in accordance with ASC 860, “Transfers and Servicing.” If we have not satisfied the applicable revenue recognition criteria for the underlying sales transaction, the transfer of the receivable is accounted for as a financing activity in accordance with ASC 470, “Debt.” The accounts receivable and short-term debt balances are derecognized from our consolidated balance sheets at the earlier of the factored receivable’s due date or when all of the revenue recognition criteria are met for those billed services. During the six months ended December 31, 2016, we transferred approximately $0.7 million of trade receivables. As of December 31, 2016 and June 30, 2016, no transfers were accounted for as a financing activity.

Additional Lines of Credit

On December 23, 2016, we entered into an unsecured line of credit with HSBC Bank, USA in the amount of $100.0 million. The line bears interest, at PAREXEL’s determination, at a base rate plus a margin (such margin not to exceed a per annum rate of 1.00%) based on a ratio of consolidated funded debt to consolidated earnings before interest, taxes, depreciation and amortization (EBITDA) for the prior four fiscal quarters (the “Leverage Ratio”), or at a LIBOR rate plus a margin (such margin not to exceed a per annum rate of 2.00%) based on the Leverage Ratio. We entered into this line of credit to facilitate business transactions. As of December 31, 2016, we had $100.0 million available under this line of credit.

We have an unsecured line of credit with JP Morgan UK of $4.5 million, which bears interest at an annual rate ranging between 2.00% and 4.00%. We entered into this line of credit to facilitate business transactions. At December 31, 2016, we had $4.5 million available for borrowing under this line of credit.

We have an unsecured uncommitted overdraft facility with ING Bank NV of 7.5 million Euros, which bears interest at an annual rate ranging between 2.00% and 4.00%. We entered into this line of credit to facilitate business transactions. At December 31, 2016, we had 7.5 million Euros available under this line of credit.

PAREXEL INTERNATIONAL CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

NOTE 10. – DEBT, COMMITMENTS, CONTINGENCIES AND GUARANTEES

As of December 31, 2016, our future minimum debt obligations related to the 2016 Credit Agreement and the Notes described in Note 9 above were as follows:



(in millions)	FY 2017		FY 2018		FY 2019		FY 2020		FY 2021		Thereafter		Total
Debt obligations (principal)	$	8.0	$	22.8	$	22.5	$	32.5	$	695.0	$	—	$	780.8

We have letter-of-credit agreements with banks totaling approximately $10.2 million guaranteeing performance under various operating leases and vendor agreements. Additionally, the borrowings under the 2016 Credit Agreement and the Notes are guaranteed by certain of our U.S. subsidiaries.

We periodically become involved in various claims and lawsuits that are incidental to our business. We are also regularly subject to, and are currently undergoing, audits by tax authorities in the United States and foreign jurisdictions for prior tax years. Although we believe our tax estimates are reasonable, and we intend to defend our positions through litigation if necessary, the final outcome of tax audits and related litigation is inherently uncertain and could be materially different than that reflected in our historical income tax provisions and accruals. Adverse outcomes of tax audits could also result in assessments of substantial additional taxes and/or fines or penalties relating to ongoing or future audits.

The above table does not include asset retirement obligations due to the uncertainty of the timing of the future cash outflows related to the restoration costs associated with returning certain facilities to their original condition upon termination of our long-term lease. As of December 31, 2016, the obligation expected to be incurred was $14.1 million.

The above table does not include contingent consideration due to the uncertainty regarding the amounts and timing of the future cash outflows related to the potential payments. As of December 31, 2016, we recorded contingent consideration liabilities of $14.0 million. See Note 12 to our consolidated financial statements included in this quarterly report for more information.

After consultation with counsel or other experts, we believe that no matters currently pending would, in the event of an adverse outcome, either individually or in the aggregate, have a material impact on our consolidated financial position, results of operations, or liquidity.

NOTE 11. – DERIVATIVES

We are exposed to certain risks relating to our ongoing business operations. The primary risks managed by using derivative instruments are interest rate risk and foreign currency exchange rate risk. Accordingly, we have instituted interest rate and foreign currency hedging programs that are accounted for in accordance with ASC 815.


•	Our interest rate hedging program is a cash flow hedge program designed to minimize interest rate volatility. We swap the difference between fixed and variable interest amounts calculated by reference to an agreed-upon notional principal amount, at specified intervals. Our interest rate contracts are designated as hedging instruments.

•

Our foreign currency hedging program is a cash flow hedge program designed to mitigate foreign currency exchange rate volatility due to the foreign currency exchange exposure related to intercompany and significant external transactions. This program also is intended to reduce the impact of foreign exchange rate risk on our direct costs and our service revenues. We primarily utilize forward currency exchange contracts and cross-currency swaps with maturities of no more than 12 months. These contracts are designated as hedging instruments.

We also enter into other economic hedges to mitigate foreign currency exchange risk related to intercompany and significant external transactions. These contracts are not designated as hedges in accordance with ASC 815.

During three month ended December 31, 2016, we entered into a forward share repurchase contract in connection with our 2017 accelerated share repurchase program with HSBC.

PAREXEL INTERNATIONAL CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

The following table presents the notional amounts and fair values of our derivatives as of December 31, 2016 and June 30, 2016. The gross position of all asset and liability amounts is reported in other current assets, other assets, other current liabilities, and other liabilities in our consolidated balance sheets.



(in millions)	December 31, 2016					June 30, 2016
	Notional Amount		Asset (Liability)			Notional Amount		Asset (Liability)
Derivatives designated as hedging instruments under ASC 815
Derivatives in an asset position:
Interest rate contracts	$	200.0	$	0.5		$	—	$	—
Foreign exchange contracts	59.9		2.4			81.2		3.5
Derivatives in a liability position:
Interest rate contracts	—		—			200.0		(1.3		)
Foreign exchange contracts	95.8		(7.6		)	103.3		(8.9		)
Total designated derivatives	$	355.7	$	(4.7	)	$	384.5	$	(6.7	)
Derivatives not designated as hedging instruments under ASC 815
Derivatives in an asset position:
Foreign exchange contracts	$	108.0	$	1.6		$	36.2	$	1.5
Forward share repurchase contract	$	200.0	$	19.7		$	—	$	—
Derivatives in a liability position:
Foreign exchange contracts	38.8		(1.7		)	48.0		(1.4		)
Total non-designated derivatives	$	346.8	$	19.6		$	84.2	$	0.1
Total derivatives	$	702.5	$	14.9		$	468.7	$	(6.6	)

Under certain circumstances, such as the occurrence of significant differences between actual cash payments and forecasted cash payments, the ASC 815 programs could be deemed ineffective. We record the effective portion of any change in the fair value of derivatives designated as hedging instruments under ASC 815 to other accumulated comprehensive loss in our consolidated balance sheets, net of deferred taxes, and any ineffective portion to miscellaneous income (expense), net in our consolidated statements of income. During the three months ended December 31, 2016 and 2015, we recorded losses of $0.6 million and $0.7 million, respectively, in miscellaneous income (expense), net in our consolidated statements of income to reflect ineffective portions of hedges. During the six months ended December 31, 2016 and 2015, we recorded losses of $0.4 million and $1.7 million, respectively, in miscellaneous income (expense), net in our consolidated statements of income to reflect ineffective portions of hedges.

The amounts recognized in other comprehensive income (loss), net of taxes, are presented below:



(in millions)	Three Months Ended						Six Months Ended
	December 31, 2016			December 31, 2015			December 31, 2016			December 31, 2015
Derivatives designated as hedging instruments under ASC 815
Interest rate contracts	$	1.4		$	0.7		$	1.9		$	0.2
Foreign exchange contracts	(2.5		)	(0.8		)	(0.8		)	(2.4		)
Total designated derivatives	$	(1.1	)	$	(0.1	)	$	1.1		$	(2.2	)

The unrealized gain (loss) on derivative instruments is net of $0.3 million and $0.4 million taxes, respectively, for the three months ended December 31, 2016 and 2015. The unrealized gain (loss) on derivative instruments is net of $0.5 million and $0.4 million taxes, respectively, for the six months ended December 31, 2016 and 2015.The estimated net amount of the existing losses that are expected to be reclassified into earnings within the next twelve months is $6.3 million.

The change in the fair value of derivatives not designated as hedging instruments under ASC 815 is recorded to miscellaneous (expense) income, net in our consolidated statements of income. The total gains and losses related to foreign exchange contracts not designated as hedging instruments were losses of $0.9 million and of $3.3 million for the three months ended December 31, 2016 and 2015, respectively. The total gains and losses related to foreign exchange contracts not designated as hedging instruments were losses of $0.8 million and of $3.6 million for the six months ended December 31, 2016 and 2015, respectively. The loss related to the forward share repurchase contract for the three months ended December 31, 2016 was $20.3 million.

The unrealized losses recognized are presented below:

PAREXEL INTERNATIONAL CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)



(in millions)	Three Months Ended						Six Months Ended
	December 31, 2016			December 31, 2015			December 31, 2016			December 31, 2015
Derivatives not designated as hedging instruments under ASC 815
Forward share repurchase contract	$	(20.3	)	$	—		$	(20.3	)	$	—
Foreign exchange contracts	(1.2		)	(0.1		)	(1.4		)	(0.7		)
Total non-designated derivative unrealized loss, net	$	(21.5	)	$	(0.1	)	$	(21.7	)	$	(0.7	)

NOTE 12. – FAIR VALUE MEASUREMENTS

We apply the provisions of ASC 820, “Fair Value Measurements and Disclosures” (“ASC 820”). ASC 820 defines fair value and provides guidance for measuring fair value and expands disclosures about fair value measurements. ASC 820 enables the reader of financial statements to assess the inputs used to develop those measurements by establishing a hierarchy for ranking the quality and reliability of the information used to determine fair value. ASC 820 requires that assets and liabilities carried at fair value be classified and disclosed in one of the following three categories:


•	Level 1 – Unadjusted quoted prices in active markets that are accessible to the reporting entity at the measurement date for identical assets and liabilities.

Marketable securities are held in foreign government treasury certificates that are actively traded and have original maturities over 90 days but less than one year. As of December 31, 2016, we did not hold any marketable securities.

Interest rate derivative instruments are measured at fair value using a market approach valuation technique. The valuation is based on an estimate of net present value of the expected cash flows using relevant mid-market observable data inputs and based on the assumption of no unusual market conditions or forced liquidation.


•	Level 2 – Inputs other than quoted prices in active markets for identical assets and liabilities that are observable either directly or indirectly for substantially the full term of the asset or liability. Level 2 inputs include the following:


◦	quoted prices for similar assets and liabilities in active markets


◦	quoted prices for identical or similar assets or liabilities in markets that are not active


◦	observable inputs other than quoted prices that are used in the valuation of the asset or liabilities (e.g., interest rate and yield curve quotes at commonly quoted intervals)


◦	inputs that are derived principally from or corroborated by observable market data by, correlation or other means


•	Level 3 – Unobservable inputs for the asset or liability (i.e., supported by little or no market activity). Level 3 inputs include management’s own assumptions about the assumptions that market participants would use in pricing the asset or liability (including assumptions about risk).

The following table sets forth by level, within the fair value hierarchy, our assets (liabilities) carried at fair value as of December 31, 2016:



(in millions)	Level 1		Level 2			Level 3			Total
Contingent consideration	$	—	$	—		$	(14.0	)	$	(14.0	)
Forward share repurchase contract	—		—			19.7			19.7
Interest rate derivative instruments	—		0.5			—			0.5
Foreign currency exchange contracts	—		(5.3		)	—			(5.3		)
Total	$	—	$	(4.8	)	$	5.7		$	0.9

The following table sets forth by level, within the fair value hierarchy, our assets (liabilities) carried at fair value as of June 30, 2016:



(in millions)	Level 1		Level 2			Level 3			Total
Contingent consideration	$	—	$	—		$	(5.2	)	$	(5.2	)
Interest rate derivative instruments	—		(1.3		)	—			(1.3		)
Foreign currency exchange contracts	—		(5.3		)	—			(5.3		)
Total	$	—	$	(6.6	)	$	(5.2	)	$	(11.8	)

PAREXEL INTERNATIONAL CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

Level 1 Estimates

Cash equivalents are measured at quoted prices in active markets. These investments are considered cash equivalents due to the short maturity (less than 90 days) of the investments.

Level 2 Estimates

Foreign currency exchange contracts are measured at fair value using a market approach valuation technique. The inputs to this technique utilize current foreign currency exchange forward market rates published by leading third-party financial news and data providers. These are observable data that represent the rates that the financial institution uses for contracts entered into at that date; however, they are not based on actual transactions, so they are classified as Level 2.

Level 3 Estimates

We have entered into a forward share repurchase contract in connection with our 2017 accelerated share repurchase program with HSBC. We recorded the $160.0 million payment, which represents the 80% of the shares we repurchased, as a decrease to equity in our consolidated balance sheet, consisting of decreases in common stock and additional paid-in capital. As additional paid-in capital was reduced to zero, the remainder was applied as a reduction in retained earnings. The remaining $40.0 million, which is an advance payment accounted for as a forward share repurchase contract, was recorded as within other current assets within the condensed consolidated balance sheet. The prepaid forward contract was initially valued at the transaction price of $40.0 million. The forward share repurchase contract was remeasured at fair value with market conditions based on the use of a Monte-Carlo Simulation Model. Increases or decreases in the fair value of our forward contract are primarily impacted by the Company's stock price. During the three months ended December 31, 2016, the fair value of the forward share repurchase contract decreased by $20.3 million from $40.0 million to $19.7 million. The change in fair value of $20.3 million was recorded in miscellaneous (expense) income, net.

The recurring Level 3 fair value measurements of our forward share repurchase contract asset include the following significant unobservable inputs:



	Forward Share
Unobservable Input	Repurchase Contract
Risk free rate	0.6%
Share price volatility	37.5
Contract term	0.4 years

Contingent consideration liabilities are re-measured to fair value each reporting period using projected financial targets, discount rates, probabilities of payment, and projected payment dates. Projected contingent payment amounts are discounted back to the current period using a discounted cash flow model. Projected financial targets are based on our most recent internal operational budgets and may take into consideration alternate scenarios that could result in more or less profitability for the respective service line. Increases or decreases in projected financial targets and probabilities of payment may result in significant changes in the fair value measurements. Increases in discount rates and the time to payment may result in lower fair value measurements. Increases or decreases in any of those inputs in isolation may result in a significantly lower or higher fair value measurement.

In October 2016, we acquired ExecuPharm, Inc. (“ExecuPharm”), a leading global functional service provider, based in Pennsylvania. ExecuPharm provides clinical monitoring or study management, along with associated operational activities such as onboarding, training, line management, performance management, and policy administration. The purchase price for the ExcuPharm acquisition was approximately $148.9 million, plus the potential to pay up to an additional $20.0 million at the end of a two year period ending June 30, 2018 if ExecuPharm achieves specific financial targets. The contingent consideration related to the ExecuPharm acquisition is measured at fair value with market conditions based on the use of a Monte-Carlo Simulation Model. Increases or decreases in the fair value of our contingent consideration liability is primarily impacted by the likelihood of achieving financial targets, but also by changes in discount periods and rates.

The recurring Level 3 fair value measurements of our contingent consideration liability include the following significant unobservable inputs:

PAREXEL INTERNATIONAL CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)



	Health Advances	ExecuPharm
Unobservable Input	Range	Range
Risk free rate	1.3%	0.7%
Revenue volatility	26%	29%
Projected period of payment	Approximately 2 years	Approximately 2 years

The following table provides a summary of the change in our valuation of the fair value of the contingent consideration liability, which was determined by Level 3 inputs:



(in millions)
Balance at June 30, 2016	$	5.2
Additions of contingent consideration due to ExecuPharm acquistion	9.4
Change in fair value of contingent consideration for Health Advances	(0.6		)
Balance at December 31, 2016	$	14.0

The following table provides a summary of the change in our valuation of the fair value of the forward share repurchase contract asset, which was determined by Level 3 inputs:



(in millions)
Balance at June 30, 2016	$	—
Additions of forward share repurchase contract	40.0
Change in fair value of forward share repurchase contract	(20.3		)
Balance at December 31, 2016	$	19.7

For the three and six months ended December 31, 2016, there were no transfers among Level 1, Level 2, or Level 3 categories. Additionally, there were no changes in the valuation techniques used to determine the fair values of our Level 2 or Level 3 assets or liabilities. For the three and six months ended December 31, 2016, the change in the fair value of the contingent consideration for Health Advances, LLC (“Health Advances”) of $0.6 million was recorded in selling, general and administrative expense. During the three months ended December 31, 2016, the fair value of contingent consideration for Health Advances in the amount of $4.6 million decreased by $0.6 million from June 30, 2016. For the three and six months ended December 31, 2015, the change in the fair value of the contingent consideration for ClinIntel Limited ("ClinIntel") of $3.2 million and $8.2 million, respectively, was recorded in selling, general and administrative expense.

In February 2016, we acquired Health Advances, an independent life sciences strategy consulting firm. Health Advances combines clinical, scientific and business expertise to provide strategic advice to executives leading life sciences companies and investors. The purchase price for the Health Advances acquisition was approximately $67.1 million, plus the potential to pay up to an additional $15.8 million over a thirty-six month period following the acquisition date if Health Advances achieves specific financial targets. The contingent consideration related to the Health Advances acquisition is measured at fair value with market conditions based on the use of a Monte-Carlo Simulation Model. Increases or decreases in the fair value of our contingent consideration liability is primarily impacted by the likelihood of achieving financial targets, but also from changes in discount periods and rates.

In October 2014, we acquired ClinIntel, a provider of clinical randomization and trial supply management services, which are designed to make patient randomization and clinical supply chain solutions more efficient. The purchase price for the ClinIntel acquisition was approximately $8.8 million, plus the potential to pay up to an additional $16.2 million over a twenty-one month period following the acquisition date. To achieve the maximum payment of $16.2 million, billings of $13.4 million in the 21 month period needed to be achieved. As of December 31, 2016, we have no further contingent consideration in connection with this acquisition.

The fair value of the debt under the Notes was estimated to be $96.5 million as of December 31, 2016, and was determined using U.S. government treasury rates and Level 3 inputs, including a credit risk adjustment.

The carrying value of our current and long-term debt under the 2016 Credit Agreement approximates fair value because all of the debt bears variable-rate interest.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The financial information discussed below is derived from the Condensed Consolidated Financial Statements included in this Quarterly Report on Form 10-Q. The financial information set forth and discussed below is unaudited but, in the opinion of our management, includes all adjustments (primarily consisting of normal recurring adjustments) considered necessary for a fair presentation of such information. Our results of operations for a particular quarter may not be indicative of results expected during subsequent fiscal quarters or for the entire fiscal year.

This Quarterly Report on Form 10-Q includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Section 27A of the Securities Act of 1933, as amended. For this purpose, any statements contained in this Quarterly Report on Form 10-Q regarding our strategy, future operations, financial position, future revenue, projected costs, prospects, plans and objectives of management, other than statements of historical facts, are forward-looking statements. The words “anticipates,” “believes,” “estimates,” “expects,” “appears,” “intends,” “may,” “plans,” “projects,” “would,” “could,” “should,” “targets,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We cannot guarantee that we actually will achieve the plans, intentions, or expectations expressed or implied in our forward-looking statements. There are a number of important factors that could cause actual results, levels of activity, performance or events to differ materially from those expressed or implied in the forward-looking statements we make. These important factors are described under the heading “Critical Accounting Policies and Estimates” in our Annual Report on Form 10-K for the fiscal year ended June 30, 2016, filed with the Securities and Exchange Commission (the “SEC”) on September 9, 2016 (the “2016 10-K”), and under “Risk Factors” set forth in Part II, Item 1A below. In light of these risks, uncertainties, assumptions and factors, the forward-looking events discussed herein may not occur and our actual performance and results may vary from those anticipated or otherwise suggested by such statements. You are cautioned not to place undue reliance on these forward-looking statements. Although we may elect to update forward-looking statements in the future, we specifically disclaim any obligation to do so, even if our estimates change, and you should not rely on those forward-looking statements as representing our views as of any date subsequent to the date of this Quarterly Report on Form 10-Q.

BUSINESS OVERVIEW

We are a leading biopharmaceutical outsourcing services company, providing a broad range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and advanced technology products and services to the worldwide pharmaceutical, biotechnology, and medical device industries. Our primary objective is to provide quality solutions for managing the biopharmaceutical product lifecycle with the goal of reducing the time, risk, and cost associated with the development and commercialization of new therapies. Since our incorporation in 1983, we have developed significant expertise in processes and technologies supporting this strategy. Our product and service offerings include: clinical trials management, observational studies and patient/disease registries, data management, biostatistical analysis, epidemiology, health economics / outcomes research, pharmacovigilance, medical communications, clinical pharmacology, patient recruitment, clinical supply and drug logistics, post-marketing surveillance, regulatory and product development and commercialization consulting, health policy and reimbursement and market access consulting, medical imaging services, regulatory information management (“RIM”) solutions, ClinPhone randomization and trial supply management services (“RTSM”), electronic data capture systems (“EDC”), clinical trial management systems (“CTMS”), web-based portals, systems integration, patient diary applications, and other product development tools and services. We believe that our comprehensive services, depth of therapeutic area expertise, global footprint and related access to patients, and sophisticated information technology, along with our experience in global drug development and product launch services, represent key competitive strengths. We have three reporting segments: Clinical Research Services (“CRS”), PAREXEL Consulting Services (“PC”), and PAREXEL Informatics (“PI”).

•

CRS constitutes our core business and includes all phases of clinical research from Early Phase (encompassing the early stages of clinical testing that range from first-in-man through proof-of-concept studies) to Phase II-III and Phase IV, which we include in our PAREXEL Access product offering, formerly known as Peri/Post Approval Services. Our services include clinical trials management and biostatistics, data management and clinical pharmacology, as well as related medical advisory, patient recruitment, pharmacovigilance, and investigator site services. CRS also includes our clinical supply and drug logistics business. We have aggregated Early Phase and PAREXEL Access with Phase II-III due to economic similarities in these operating segments.

•

PC provides technical expertise and advice in such areas as drug development, regulatory affairs, product pricing and reimbursement, commercialization, and strategic compliance. It also provides a full spectrum of market development, product development, and targeted communications services in support of product launch. Our PC consultants identify alternatives and propose solutions to address client issues associated with product development, registration and commercialization.


•	PI provides information technology solutions designed to help improve clients’ product development and regulatory submission processes. PI offers a portfolio of products and services that includes medical imaging services, ClinPhone^®

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION

AND RESULTS OF OPERATIONS (Continued)

RTSM, IMPACT^® CTMS, DataLabs^® EDC, web-based portals, systems integration, electronic patient reported outcomes (“ePRO”) and LIQUENT InSight® RIM platform. These services are often bundled together and integrated with other applications to provide an eClinical solution for our clients. In addition, PI's portfolio of services is increasingly being embedded with that of CRS, to provide our clients with an integrated offering.

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

This discussion and analysis of our financial condition and results of operations are based on our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, revenues and expenses, and other financial information. On an ongoing basis, we evaluate our estimates and judgments. We base our estimates on historical experience and on various other factors that we believe to be reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions.

For further information on our other critical accounting policies, please refer to the consolidated financial statements and footnotes thereto included in the 2016 10-K.

RESULTS OF OPERATIONS

Three and Six Months Ended December 31, 2016 Compared With Three and Six Months Ended December 31, 2015:

Revenue

Our service revenue by segment is as follows:



(dollar amounts in millions)	Three Months Ended						Six Months Ended
	December 31, 2016		December 31, 2015		Increase/(Decrease)%		December 31, 2016		December 31, 2015		Increase/(Decrease)%
Service revenue
CRS	$	408.9	$	407.1	0.4	%	$	785.2	$	817.3	(3.9	)%
PC	54.6		41.4		31.9	%	109.6		80.7		35.8	%
PI	70.9		70.0		1.3	%	136.3		132.6		2.8	%
Total service revenue	$	534.4	$	518.5	3.1	%	$	1,031.1	$	1,030.6	—	%

ANALYSIS BY SEGMENT

Service revenue increased by $15.9 million, or 3.1%, to $534.4 million for the three months ended December 31, 2016 from $518.5 million for the same period in the fiscal year ended June 30, 2016 ("Fiscal Year 2016"). Service revenue increased by $0.5 million to $1,031.1 million for the six months ended December 31, 2016 from $1,030.6 million for the same period in Fiscal Year 2016.

CRS

In the three months ended December 31, 2016, CRS service revenue increased $1.8 million, or 0.4%, to $408.9 million from $407.1 million for the same period in Fiscal Year 2016. The increase was primarily due to $28.8 million from the acquisition of ExecuPharm, Inc. ("ExecuPharm") in the second quarter of the fiscal year ending June 30, 2017 ("Fiscal Year 2017"), partially offset by lower revenue in Phase II/III due to a high number of cancellations for active studies and large late phase studies reaching completion. In the six months ended December 31, 2016, CRS service revenue decreased by $32.1 million, or 3.9%, to $785.2 million from $817.3 million for the same period in Fiscal Year 2016. The decrease was primarily due to a high number of cancellations for active studies and large late phase studies reaching completion, partially offset by growth in our early-phase business due to increased business volumes and $28.8 million from the acquisition of ExecuPharm.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION

AND RESULTS OF OPERATIONS (Continued)

PC service revenue increased by $13.2 million, or 31.9%, to $54.6 million for the three months ended December 31, 2016 from $41.4 million for the same period in Fiscal Year 2016. The increase was due to new partnerships, an increase in the number of projects, and an additional $8.4 million in revenue from the acquisition of Health Advances, LLC ("Health Advances") in the third quarter of Fiscal Year 2016. PC service revenue increased by $28.9 million, or 35.8%, to $109.6 million for the six months ended December 31, 2016 from $80.7 million for the same period in Fiscal Year 2016. The increase was due to new partnerships, an increase in the number of projects and an additional $17.4 million in revenue from the acquisition of Health Advances in the third quarter of Fiscal Year 2016.

Service revenue increased by $0.9 million, or 1.3%, to $70.9 million in the three months ended December 31, 2016 from $70.0 million in the same period in Fiscal Year 2016. Service revenue increased by $3.7 million, or 2.8% to $136.3 million, in the six months ended December 31, 2016 from $132.6 million in the same periods in Fiscal Year 2016. The increases in service revenue during the three and six months ended December 31, 2016 from the same periods in Fiscal Year 2016, were primarily driven by contributions from new business awards and higher demand for technology usage in clinical trials.

Reimbursement Revenue

Reimbursement revenue consists of reimbursable out-of-pocket expenses incurred on behalf of, and reimbursable by, clients. Reimbursement revenue does not yield any gross profit to us, nor does it have an impact on our net income.

Direct Costs

Our direct costs and service gross profit by segment are as follows:



(dollar amounts in millions)	Three Months Ended						Six Months Ended
	December 31, 2016		December 31, 2015		Increase/(Decrease)%		December 31, 2016		December 31, 2015		Increase/(Decrease)%
Direct costs
CRS	$	284.5	$	274.4	3.7	%	$	546.6	$	561.9	(2.7	)%
PC	30.9		20.8		48.6	%	61.3		41.0		49.5	%
PI	35.5		37.3		(4.8	)%	70.7		72.8		(2.9	)%
Total direct costs	$	350.9	$	332.5	5.5	%	$	678.6	$	675.7	0.4	%
Gross profit
CRS	$	124.4	$	132.7	(6.3	)%	$	238.6	$	255.4	(6.6	)%
PC	23.7		20.6		15.0	%	48.3		39.7		21.7	%
PI	35.4		32.7		8.3	%	65.6		59.8		9.7	%
Total gross profit	$	183.5	$	186.0	(1.3	)%	$	352.5	$	354.9	(0.7	)%

Direct costs increased by $18.4 million, or 5.5% to $350.9 million in the three months ended December 31, 2016 from $332.5 million for the three months ended December 31, 2015. In the three months ended December 31, 2016, direct costs as a percentage of total service revenue, increased to 65.7% from 64.1% compared to the same period in Fiscal Year 2016. Direct costs increased by $2.9 million, or 0.4% to $678.6 million in the six months ended December 31, 2016 from $675.7 million for the six months ended December 31, 2015. As a percentage of total service revenue, direct costs for the six months ended December 31, 2016 increased to 65.8% from 65.6% for the respective period in Fiscal Year 2016. For the three and six months ended December 31, 2016 compared to the same periods in Fiscal Year 2016 gross margin decreased primarily due to margin contraction in the CRS and PC segments, partially offset by increases in the PI segment and savings resulting from our Margin Acceleration Program ("MAP").

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION

AND RESULTS OF OPERATIONS (Continued)

CRS

Direct costs increased by $10.1 million, or 3.7%, to $284.5 million in the three months ended December 31, 2016 from $274.4 million for the three months ended December 31, 2015. For the three months ended December 31, 2016 compared to the same period in Fiscal Year 2016, CRS direct costs increased primarily due to the acquisition of ExecuPharm in the second quarter of Fiscal Year 2017, partially offset by decreases due to lower business volumes, lower variable compensation expense and cost savings in connection with our MAP. Direct costs decreased $15.3 million, or 2.7%, to $546.6 million in the six months ended December 31, 2016 from $561.9 million for six months ended December 31, 2015. For the six months ended December 31, 2016 compared to the same period in Fiscal Year 2016, CRS direct costs decreased primarily due to lower business volume, lower fixed and variable compensation expense and lower cost incurred in connection with our MAP, partially offset by increases from the acquisition of ExecuPharm. As a percentage of service revenue, direct costs increased to 69.6% in the three months ended December 31, 2016 from 67.4% for the same period in Fiscal Year 2016, and increased to 69.6% for the six months ended December 31, 2016 from 68.8% for the same period in Fiscal Year 2016. The increase in the three and six months ended December 31, 2016 was due primarily to lower gross margins contributed by ExecuPharm, which was acquired on October 3, 2017, partially offset by lower labor costs as a result of the MAP.

Direct costs increased by $10.1 million, or 48.6%, to $30.9 million in the three months ended December 31, 2016 from $20.8 million for the same period in Fiscal Year 2016. Direct costs increased $20.3 million, or 49.5% to $61.3 million in the six months ended December 31, 2016 from $41.0 million for the same period in Fiscal Year 2016. Direct costs increased in the three and six months ended December 31, 2016 compared to the same periods in Fiscal Year 2016 due primarily to increased business volume and increased retention bonuses in connection with our acquisition of Health Advances in the third quarter of Fiscal Year 2016. As a percentage of service revenue, direct costs increased to 56.6% for the three months ended December 31, 2016 from 50.2% for the same period in Fiscal Year 2016 and increased to 55.9% from 50.8% in the six month comparison due primarily to less favorable revenue mix.

Direct costs decreased by $1.8 million, or 4.8%, to $35.5 million in the three months ended December 31, 2016 from $37.3 million for the same period in Fiscal Year 2016. Direct costs decreased by $2.1 million, or 2.9% to $70.7 million in the six months ended December 31, 2016 from $72.8 million in the same period in Fiscal Year 2016. Direct costs decreased in the three and six months ended December 31, 2016 compared to the same periods in Fiscal Year 2016 primarily due to service revenue mix and lower costs due to our MAP. As a percentage of service revenue, direct costs in the three months ended December 31, 2016, decreased to 50.1% from 53.3% for the same period in Fiscal Year 2016. In the six months ended December 31, 2016 direct costs as a percentage of service revenue decreased to 51.9% from 54.9% for the same period in Fiscal Year 2016. Direct costs as a percentage of service revenue decreased in the three and six months ended December 31, 2016 from the same periods in Fiscal Year 2016 primarily due to higher business volume, increased staff utilization due to increased project volume, and lower costs due to our MAP.

Selling, General and Administrative ("SG&A")

SG&A expense is summarized as follows:



(dollar amounts in millions)	Three Months Ended								Six Months Ended
	December 31, 2016			December 31, 2015			Increase/(Decrease)%		December 31, 2016			December 31, 2015			Increase/(Decrease)%
Selling, general and administrative	$	95.6		$	97.4		(1.8	)%	$	187.8		$	192.3		(2.3	)%
% of service revenues	17.9		%	18.8		%			18.2		%	18.7		%

SG&A expense was relatively flat for the three months ended December 31, 2016, decreasing 1.8% compared to the same period in Fiscal Year 2016. SG&A expense decreased 2.3%, for the six months ended December 31, 2016 compared to the same period in Fiscal Year 2016. The decrease in SG&A for the three months ended December 31, 2016 was primarily due to lower fixed and variable compensation expense, a $3.8 million reduction in the losses from the changes in fair value of contingent consideration, a favorable foreign exchange impact of $3.5 million and the effect of efficiency initiatives for our support functions. The decrease in SG&A for the six months ended December 31, 2016 was primarily due to lower fixed and variable compensation expenses, an $8.8 million reduction in the losses from the changes in fair value of contingent consideration, a favorable foreign exchange impact of $9.1 million and the effect of efficiency initiatives for our support functions. These decreases were partially offset by lower amounts of labor being capitalized on information technology infrastructure projects. SG&A expense as a percentage of service revenue decreased 0.9% and 0.5% for the three and six months ended December 31, 2016, respectively, primarily due a decrease in the change fair value of contingent consideration.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION

AND RESULTS OF OPERATIONS (Continued)

Depreciation and Amortization

Depreciation and amortization expense is summarized as follows:



(dollar amounts in millions)	Three Months Ended								Six Months Ended
	December 31, 2016			December 31, 2015			Increase/(Decrease)%		December 31, 2016			December 31, 2015			Increase/(Decrease)%
Depreciation and amortization	$	26.3		$	23.6		11.4	%	$	51.1		$	47.3		8.0	%
% of service revenues	4.9		%	4.6		%			5.0		%	4.6		%

Depreciation and amortization expense increased by 11.4% and 8.0% in the three and six months ended December 31, 2016 respectively, compared to the same periods in Fiscal Year 2016 due primarily to amortization expense attributable to our acquisition of ExecuPharm in the second quarter of Fiscal Year 2017 and our acquisition of Health Advances in the third quarter of Fiscal Year 2016.

Restructuring Charge

Restructuring charge is summarized as follows:



(dollar amounts in millions)	Three Months Ended						Six Months Ended
	December 31, 2016		December 31, 2015		Increase/(Decrease)%		December 31, 2016		December 31, 2015		Increase/(Decrease)%
Restructuring charge	$	1.6	$	10.4	(84.6	)%	$	0.3	$	25.2	(98.8	)%

In June 2015, we adopted the MAP to restructure our operations to improve the productivity and efficiency of the Company simplify the organization, and streamline decision-making, thereby enhancing client engagement. For the three and six months ended December 31, 2016 , we recorded a net $1.6 million and a net $0.3 million, respectively, restructuring charge to the MAP, which consisted of changes in estimates on employee separation benefits and lease termination costs. For the three and six months ended December 31, 2015, we recorded a net $10.4 million and $25.2 million respectively, restructuring charge to the MAP. In the second quarter of 2016 this charge was composed of $6.7 million of employee separation benefits and $3.7 million of lease termination related costs.

From the announcement of the program through December 31, 2016, we recorded a net $48.1 million restructuring charge related to the MAP, which consisted of $38.0 million of employee separation benefits and $10.1 million of lease termination related costs. The MAP is company wide. The activities under the MAP were substantially complete as of December 31, 2016.

On January 6, 2017, we approved a plan to further restructure our operations to improve the productivity and efficiency of the company, simplify the organization, and streamline decision-making, thereby enhancing client engagement. The restructuring initiative is company-wide. These actions are expected to result in pre-tax charges in the range of $25 million to $35 million, all of which are anticipated to be cash expenditures. We expect to record a pre-tax charge in the third quarter of Fiscal Year 2017 in the range of $20 million to $27 million, with the remainder of the charges to be incurred by the end of the fiscal year ending June 30, 2018 (“Fiscal Year 2018”). The charges will include approximately $24 million to $32 million in employee separation costs and approximately $1 million to $3 million in other costs. We anticipate completing restructuring activities by the end of Fiscal Year 2018, and we expect the charges to result in annual pre-tax savings of approximately $7 million to $10 million over the course of Fiscal Year 2017 and approximately $30 million to $40 million on an annualized basis when fully completed.

Income from Operations



(dollar amounts in millions)	Three Months Ended								Six Months Ended
	December 31, 2016			December 31, 2015			Increase/(Decrease)%		December 31, 2016			December 31, 2015			Increase/(Decrease)%
Income from operations	$	60.0		$	54.6		9.9	%	$	113.3		$	90.1		25.7	%
Operating margin	11.2		%	10.5		%			11.0		%	8.7		%

The increase in income from operations in the three months ended December 31, 2016 was primarily due to increased service revenue and decreased restructuring charges, partially offset by increases in direct costs, depreciation, and amortization compared to the same period in Fiscal Year 2016. The operating margin remained relatively flat in the three months ended December 31, 2016 compared to the same period in Fiscal Year 2016. The increase in both income from operations and in operating margin in the six months ended December 31, 2016 was due primarily to a $25.2 million charge related to the MAP in the six months ended December 31, 2015, partially offset by higher direct costs, depreciation and amortization in the period ended December 31, 2016.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION

AND RESULTS OF OPERATIONS (Continued)

Other Expense, net

Other expense, net is summarized as follows:



(dollar amounts in millions)	Three Months Ended								Six Months Ended
	December 31, 2016			December 31, 2015			Increase/(Decrease)%		December 31, 2016			December 31, 2015			Increase/(Decrease)%
Interest expense, net	$	(2.8	)	$	(2.1	)	33.3	%	$	(5.4	)	$	(3.7	)	45.9	%
Miscellaneous (expense) income	(17.7		)	(0.1		)	>1000%		(18.5		)	1.7			>1000%
Other expense, net	$	(20.5	)	$	(2.2	)	831.8	%	$	(23.9	)	$	(2.0	)	1,095.0	%

Net interest expense increased in the three and six months ended December 31, 2016 compared to the same periods in Fiscal Year 2016 as a result of higher debt balances.

The increases in miscellaneous expense in the three and six months ended December 31, 2016 of $17.6 million and $20.2 million, respectively, was due primarily to a $20.3 million reduction in fair value to our forward share repurchase contract, partially offset by foreign currency exchange gains which were driven by the Great British Pound and the Euro.

Taxes

The following table presents the provision for income taxes and our effective tax rate for the three and six months ended December 31, 2016 and 2015:



(dollar amounts in millions)	Three Months Ended								Six Months Ended
	December 31, 2016			December 31, 2015			Increase/(Decrease)%		December 31, 2016			December 31, 2015			Increase/(Decrease)%
Provision for income taxes	$	17.7		$	13.0		36.2	%	$	29.8		$	23.8		25.2	%
Effective tax rate	44.8		%	24.8		%			33.3		%	27.0		%

The tax rates for the three and six months ended December 31, 2016 and 2015 each benefited from a favorable distribution of taxable income among lower tax rate foreign jurisdictions and the United States. The tax rate for the six months ended December 31, 2016 benefited 2.5% from the adoption of ASU 2016-09, Compensation-Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting, as further described in Note 1 to our consolidated financial statements included in this quarterly report. The tax rates for the three and six months ended December 31, 2016 increased by 15.2% and 6.1%, respectively, due to the non-deductibility of the unrealized loss on the fair value adjustment of $20.3 million in connection with the accelerated share repurchase program.

LIQUIDITY AND CAPITAL RESOURCES

Since our inception, we have financed our operations and growth with cash flow from operations, proceeds from the sale of equity securities, and credit facilities. Investing activities primarily reflect the costs of capital expenditures for property and equipment as well as the funding of business acquisitions and the purchases of marketable securities. As of December 31, 2016, we had cash and cash equivalents of approximately $252.4 million. The majority of our cash and cash equivalents is held in foreign countries because excess cash generated in the United States is primarily used to repay our debt obligations. As of December 31, 2016 we did not hold any marketable securities. Foreign cash balances include unremitted foreign earnings, which are invested indefinitely outside of the United States. Our cash and cash equivalents are held in deposit accounts, which provide us with immediate and unlimited access to the funds. Repatriation of funds to the United States from non-U.S. entities may be subject to taxation or certain legal restrictions. Nevertheless, most of our cash resides in countries with few or no such legal restrictions.

DAYS SALES OUTSTANDING

Our operating cash flow is heavily influenced by changes in the levels of billed and unbilled receivables and deferred revenue. These account balances as well as days sales outstanding (“DSO”) in accounts receivable, net of deferred revenue, can vary based on contractual milestones and the timing and size of cash receipts. We calculate DSO by adding the end-of-period balances for billed and unbilled account receivables, net of deferred revenue (short-term and long-term) and the provision for losses on receivables, then dividing the resulting amount by the sum of total revenue plus investigator fees billed for the most recent quarter, and multiplying the resulting fraction by the number of days in the quarter. The following table presents the DSO, accounts receivable balances, and deferred revenue as of and for the three months ended December 31, 2016 and June 30, 2016:

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION

AND RESULTS OF OPERATIONS (Continued)



(in millions)	December 31, 2016		June 30, 2016
Billed accounts receivable, net	$	640.5	$	506.1
Unbilled accounts receivable, net	277.6		327.9
Total accounts receivable, net	918.1		834.0
Deferred revenue	491.0		458.5
Net receivables	$	427.1	$	375.5

DSO (in days)	55		48

DSO for the three months ended December 31, 2016 grew seven days compared with the three months ended June 30, 2016 due to project billing milestones and the timing of cash collections.

CASH FLOWS

Sources and uses of cash flows are summarized as follows:



	Six Months Ended
	December 31,						Percentage
(dollar amounts in millions)	2016			2015			Change
Net cash provided by operating activities	$	111.5		$	85.7		30.1	%
Net cash (used in) provided by investing activities	(181.5		)	(53.3		)	240.5	%
Net cash provided by (used in) financing activities	89.2			(71.0		)	(225.6	)%
Effect of exchange rate changes on cash	(15.4		)	(14.8		)	4.1	%
Net increase (decrease) in cash and cash equivalents	$	3.8		$	(53.4	)	(107.1	)%

Operating Activities

The cash flows provided by operating activities during the six months ended December 31, 2016 primarily resulted from $59.6 million in net income and $81.8 million in depreciation, amortization, stock-based compensation expenses and an unrealized forward contract loss on share repurchase partially offset by changes in working capital of $27.9 million. The changes in working capital were driven by a $64.9 million cash outflow due to increases in billed and unbilled accounts receivable and a $52.2 million cash outflow due to a decrease in accrued expenses and other current liabilities. These cash outflows were partially offset by a $42.8 million cash inflow due to an increase in deferred revenue and other liabilities and a $40.8 million cash inflow due to an increase in accounts payable. The increases in billed and unbilled accounts receivable are due to the timing of collections with large customers. The decrease in accrued expenses and other current liabilities was primarily attributable to the payment of Fiscal Year 2016 variable compensation. The increase in deferred revenue was due to the timing of the achievement of billing milestones compared with the delivery of units for revenue recognition purposes. The increase in accounts payable was primarily due to timing of payments.

The cash flows provided by operating activities during the six months ended December 31, 2015 primarily resulted from net income of $64.3 million, $57.2 million in depreciation, amortization and stock-based compensation expenses, and a decrease of $34.1 million in working capital.

Investing Activities

The net cash used in investing activities during the six months ended December 31, 2016 was primarily driven by $148.5 million used for the acquisition of ExecuPharm and capital expenditures of $33.2 million. The capital expenditures in the current year are lower than the prior year due primarily to decreased costs for system upgrades and improvements to the information technology infrastructure.

The net cash used in investing activities during the six months ended December 31, 2015, was primarily driven by capital expenditures of $53.3 million.

Financing Activities

During the six months ended December 31, 2016, we received a net $280.0 million under the 2016 Credit Agreement (as defined below) and $12.8 million in proceeds related to employee stock purchases. This was partially offset by payments of $200.0 million as part of the accelerated share repurchase program.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION

AND RESULTS OF OPERATIONS (Continued)

During the six months ended December 31, 2015, we paid $200.0 million as part of the accelerated share repurchase program. This was partially offset by the receipt of $12.9 million in proceeds related to employee stock purchases and borrowings of a net $116.1 million under the 2014 Credit Agreement (as defined below).

CREDIT AGREEMENTS

2016 Credit Agreement

On March 11, 2016, PAREXEL, certain subsidiaries of PAREXEL, Bank of America, N.A. (“Bank of America”), as Administrative Agent, Swingline Lender and L/C Issuer, Merrill Lynch, Pierce, Fenner & Smith Incorporated (“MLPFS”), HSBC Bank USA, National Association (“HSBC”), U.S. Bank, National Association (“US Bank”), TD Securities (USA) LLC (“TD Securities”) and Wells Fargo Securities, LLC (“Wells Fargo Securities”) as Joint Lead Arrangers and Joint Book Managers, HSBC, US Bank, TD Bank, N.A. (“TD Bank”) and Wells Fargo Bank, National Association (“Wells Fargo Bank”) as Joint Syndication Agents, and the other lenders party thereto entered into an amended and restated credit agreement (the “2016 Credit Agreement”) providing for a five-year term loan and revolving credit facility in the principal amount of up to $750.0 million (collectively, the “Loan Amount”), plus additional amounts of up to $300.0 million of loans to be made available upon request of the Company subject to specified terms and conditions.

The 2016 Credit Agreement amends and restates the amended and restated credit agreement dated as of October 15, 2014, by and among the Company, certain subsidiaries of the Company, Bank of America, as Administrative Agent, Swingline Lender and L/C Issuer, MLPFS, J.P. Morgan Securities LLC, HSBC, and US Bank, as Joint Lead Arrangers and Joint Book Managers, JPMorgan Chase Bank N.A., HSBC and US Bank, as Joint Syndication Agents, and the other lenders party thereto (the “2014 Credit Agreement”).

The 2016 Credit Agreement is intended to provide funds (i) for stock repurchases, (ii) for the issuance of letters of credit, and (iii) for other general corporate purposes of PAREXEL and its subsidiaries, including permitted acquisitions.

As of December 31, 2016, we had $285.0 million of principal borrowed under the revolving credit facility and $392.5 million of principal borrowed under the term loan. The outstanding amount is presented net of debt issuance costs of approximately $2.9 million in our consolidated balance sheet at December 31, 2016. As of December 31, 2016, we had borrowing availability of $165.0 million under the revolving credit facility. We used $100.0 million in borrowings under this credit facility in connection with our acquisition of ExecuPharm and $140.0 million to support our $200.0 million accelerated share repurchase program.

Borrowings (other than swingline loans) under the 2016 Credit Agreement bear interest, at PAREXEL’s determination, at a rate based on either (a) LIBOR plus a margin (not to exceed a per annum rate of 2.0%) based on a ratio of consolidated net funded debt to consolidated earnings before interest, taxes, depreciation and amortization (EBITDA) (the “Consolidated Net Leverage Ratio”) or (b) the highest of (i) prime, (ii) the federal funds rate plus 50 basis points, and (iii) the one month LIBOR rate plus 100 basis points (such highest rate, the “Alternate Base Rate”), plus a margin (not to exceed a per annum rate of 1.0%) based on the Consolidated Net Leverage Ratio. Swingline loans in U.S. dollars bear interest calculated at the Alternate Base Rate plus a margin (not to exceed a per annum rate of 1.0%). Loans outstanding under the 2016 Credit Agreement may be prepaid at any time in whole or in part without premium or penalty, other than customary breakage costs, if any, subject to the terms and conditions contained in the 2016 Credit Agreement. The 2016 Credit Agreement terminates and any outstanding loans under it mature on March 11, 2021.


•	0.63% by quarterly term loan amortization payments to be made commencing June 30, 2016 and made on or prior to March 31, 2017;


•	1.25% by quarterly term loan amortization payments to be made on or after June 30, 2017, but on or prior to March 31, 2019;

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION

AND RESULTS OF OPERATIONS (Continued)


•	1.88% by quarterly term loan amortization payments to be made on or after June 30, 2019, but on or prior to March 31, 2020;


•	2.50% by quarterly term loan amortization payments to be made on or after June 30, 2020, but prior to March 11, 2021; and


•	72.50% (or if less, the remaining principal amount of the term loan) on March 11, 2021.

To the extent not previously paid, all borrowings under the 2016 Credit Agreement must be repaid on March 11, 2021.

Interest due under the revolving credit facility (other than a swingline loan) and the term loan facility must be paid quarterly for borrowings with an interest rate determined with reference to the Alternate Base Rate. Interest must be paid on the last day of the interest period selected by the Company for borrowings determined with reference to LIBOR, provided that for interest periods of longer than three months, interest is required to be paid every three months. Interest under US dollar swingline loans at the alternate base rate is payable quarterly.

The 2016 Credit Agreement contains negative covenants applicable to PAREXEL and its subsidiaries, including financial covenants requiring PAREXEL to comply with maximum net leverage ratios and minimum interest coverage ratios, as well as restrictions on liens, investments, indebtedness, fundamental changes, acquisitions, dispositions of property, making specified restricted payments (including cash dividends and stock repurchases that would result in the Company exceeding an agreed to Consolidated Net Leverage Ratio), transactions with affiliates, and other restrictive covenants. As of December 31, 2016, we were in compliance with all covenants under the 2016 Credit Agreement.

In connection with the 2016 Credit Agreement, PAREXEL agreed to pay a commitment fee on the revolving loan commitment calculated as a percentage of the unused amount of the revolving loan commitment at a per annum rate of up to 0.250% (based on the Consolidated Net Leverage Ratio). To the extent there are letters of credit outstanding under the 2016 Credit Agreement, PAREXEL will pay letter of credit fees plus a fronting fee and additional charges. PAREXEL agreed to pay (i) Bank of America for its own account, an arrangement fee, (ii) each of the lenders on the closing date, an upfront fee, and (iii) to Bank of America for its own account, an annual agency fee.

In May 2013, we entered into an interest rate swap agreement and hedged an additional principal amount of $100.0 million under a prior credit agreement with a fixed interest rate of 0.73%. The interest rate swap agreement now hedges $100.0 million of principal under our 2016 Credit Agreement. These interest rate hedges were deemed to be fully effective in accordance with ASC 815 and, as such, unrealized gains and losses related to these derivatives are recorded as other comprehensive income in our consolidated balance sheets.

On October 1, 2015, we entered into a two year interest rate swap agreement effective September 30, 2016, which now hedges an additional principal amount of $100.0 million under the 2016 Credit Agreement with a fixed interest rate 1.104%.

2016 Term Loan Agreement

On February 10, 2016, PAREXEL entered into the Loan agreement with TD Bank, providing for a loan to the Company in the amount of $75.0 million (the “Loan”). The Loan would have matured on April 30, 2016 (the “Maturity Date”) unless earlier payment had been required under the terms of the Company loan agreement with TD Bank. The Loan bore interest, at PAREXEL’s determination, at a base rate plus a margin (such margin not to exceed a per annum rate of .750%) based on a ratio of consolidated funded debt to consolidated earnings before interest, taxes, depreciation and amortization (EBITDA) for the prior four fiscal quarters (the “Leverage Ratio”), or at a LIBOR rate plus a margin (such margin not to exceed a per annum rate of 1.750%) based on the Leverage Ratio. The Loan could have been prepaid at any time in whole or in part without premium or penalty, other than customary breakage costs, if any, subject to the terms and conditions of the loan agreement.

The proceeds of the Loan were advanced to the Company on February 12, 2016 and were used to repay borrowings under the Company’s 2014 Facility.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION

AND RESULTS OF OPERATIONS (Continued)

The obligations of PAREXEL under the Loan could have been accelerated upon the occurrence of an event of default under the Loan, which included customary events of default, including payment defaults, the inaccuracy of representations, or warranties and cross defaults to the 2014 Facility.

As of December 31, 2016, all outstanding amounts under the Loan were fully repaid with the proceeds from the 2016 Credit Agreement.

Master Financing Agreement

On June 12, 2015, we entered into a three year, interest free Master Financing Agreement for $7.1 million with General Electric Capital Corporation, (“GECC”), in conjunction with a software term license purchase. On June 30, 2015 we received the gross proceeds of $7.1 million from GECC. Repayment of the principal borrowed under the Master Financing Agreement is due annually on July 1st as follows:


•	$1.4 million made on or prior to July 1, 2015;


•	$2.8 million made on or prior to July 1, 2016; and


•	$2.9 million paid on or prior to July 1, 2017.

As of December 31, 2016, we had $2.9 million principal borrowed under the Master Financing Agreement.

2014 Credit Agreement

The 2014 Credit Agreement provided for a five-year term loan and revolving credit facility in the principal amount of up to $500.0 million (collectively, the “Loan Amount”), plus additional amounts of up to $300.0 million of loans to be made available upon request of the Company subject to specified terms and conditions. The loan facility available under the 2014 Credit Agreement consisted of a term loan facility and a revolving credit facility. The principal amount of up to $200.0 million of the Loan Amount was available through the term loan facility, and the principal amount of up to $300.0 million of the Loan Amount was available through the revolving credit facility. A portion of the revolving credit facility was available for swingline loans of up to a sublimit of $100.0 million and for the issuance of standby letters of credit of up to a sublimit of $10.0 million.

The 2014 Credit Agreement was superseded by the 2016 Credit Agreement, and as of December 31, 2016 all outstanding amounts under the 2014 Credit Agreement were fully repaid.

Borrowings (other than swingline loans) under the 2014 Credit Agreement bore interest, at our determination, at a rate based on either (a) LIBOR plus a margin (not to exceed a per annum rate of 1.750%) based on the Leverage Ratio or (b) the highest of (i) prime, (ii) the federal funds rate plus 0.500%, and (iii) the one month LIBOR rate plus 1.000% (such highest rate, the “Alternate Base Rate”), plus a margin (not to exceed a per annum rate of 0.750%) based on the Leverage Ratio. Swingline loans in U.S. dollars bear interest calculated at the Alternate Base Rate plus a margin (not to exceed a per annum rate of 0.750%).

In connection with the 2014 Credit Agreement, we agreed to pay a commitment fee on the revolving loan commitment calculated as a percentage of the unused amount of the revolving loan commitment at a per annum rate of up to 0.300% (based on the Leverage Ratio). To the extent there are letters of credit outstanding under the 2014 Credit Agreement, we would have paid letter of credit fees plus a fronting fee and additional charges. We agreed to pay Bank of America (i) for its own account, an arrangement fee, (ii) for the account of each of the lenders, an upfront fee and (iii) for its own account, an annual agency fee.

In September 2011, we entered into an interest rate swap agreement which hedged $100.0 million of principal under our prior debt obligations and carried a fixed interest rate of 1.30%. In September 2015, the interest rate swap agreement matured and the related accumulated other comprehensive income was reclassified to net income during the three months ended September 30, 2015.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION

AND RESULTS OF OPERATIONS (Continued)

Note Purchase Agreement

On July 25, 2013, we issued $100.0 million principal amount of 3.11% senior notes due July 25, 2020 (the “Notes”) for aggregate gross proceeds of $100.0 million in a private placement solely to accredited investors. The Notes were issued pursuant to a Note Purchase Agreement entered into by us with certain institutional investors on June 25, 2013 (the “Note Purchase Agreement”). Proceeds from the Notes were used to pay down $100.0 million of principal borrowed under the revolving credit facility of the 2013 Credit Agreement, as described below. We will pay interest on the outstanding balance of the Notes at a rate of 3.11% per annum, payable semi-annually on January 25 and July 25 of each year until the principal on the Notes shall have become due and payable. We may, at our option, upon notice and subject to the terms of the Note Purchase Agreement, prepay at any time all or part of the Notes in an amount not less than 10% of the aggregate principal amount of the Notes then outstanding, plus a Make-Whole Amount (as defined in the Note Purchase Agreement). The Notes become due and payable on July 25, 2020, unless payment is required to be made earlier under the terms of the Note Purchase Agreement.

The Note Purchase Agreement includes operational and financial covenants, with which we are required to comply, including, among others, maintenance of certain financial ratios and restrictions on additional indebtedness, liens and dispositions. As of December 31, 2016, we were in compliance with all covenants under the Note Purchase Agreement.

Receivable Purchase Agreement

On February 19, 2013, we entered into a receivables purchase agreement (the “Receivable Agreement”) with JPMorgan Chase Bank, N.A. (“JPMorgan”). Under the Receivable Agreement, we sell to JPMorgan or other investors on an ongoing basis certain of our trade receivables, together with ancillary rights and the proceeds thereof, which arise under contracts with a client, or its subsidiaries or affiliates. The Receivable Agreement includes customary representations and covenants on behalf of us, and may be terminated by either us or JPMorgan upon five business days' advance notice. The Receivable Agreement provides a mechanism for accelerating the receipt of cash due on outstanding receivables. We account for the transfer of our receivables with respect to which we have satisfied the applicable revenue recognition criteria in accordance with FASB ASC 860, “Transfers and Servicing.” If we have not satisfied the applicable revenue recognition criteria for the underlying sales transaction, the transfer of the receivable is accounted for as a financing activity in accordance with FASB ASC 470, “Debt.” The accounts receivable and short-term debt balances are derecognized from our consolidated balance sheets at the earlier of the factored receivable’s due date or when all of the revenue recognition criteria are met for those billed services. During the six months ended December 31, 2016, we transferred approximately $0.7 million of trade receivables. As of December 31, 2016 and June 30, 2016, no transfers were accounted for as a financing activity.

Additional Lines of Credit

On December 23, 2016, we entered into an unsecured line of credit with HSBC Bank, USA in the amount of $100.0 million. The line bears interest, at our determination, at a base rate plus a margin (such margin not to exceed a per annum rate of 1.00%) based on a ratio of consolidated funded debt to consolidated earnings before interest, taxes, depreciation and amortization (EBITDA) for the prior four fiscal quarters (the “Leverage Ratio”), or at a LIBOR rate plus a margin (such margin not to exceed a per annum rate of 2.00%) based on the Leverage Ratio. We entered into this line of credit to facilitate business transactions. As of December 31, 2016, we had $100.0 million available under this line of credit.

We have an unsecured line of credit with JP Morgan UK in the amount of $4.5 million that bears interest at an annual rate ranging from 2.00% to 4.00%. We entered into this line of credit to facilitate business transactions. As of December 31, 2016, we had $4.5 million available under this line of credit.

We have an unsecured uncommitted overdraft facility with ING Bank NV in the amount of 7.5 million Euros that bears interest at an annual rate ranging between 2.00% and 4.00%. We entered into this line of credit to facilitate business transactions. At December 31, 2016, we had 7.5 million Euros available for borrowing under this line of credit.

DEBT, COMMITMENTS, CONTINGENCIES AND GUARANTEES

As of December 31, 2016, our future minimum debt obligations related to the 2016 Credit Agreement and the Notes described above under “Credit Agreements” are as follows:



(in millions)	FY 2016		FY 2017		FY 2018		FY 2019		FY 2020		Thereafter		Total
Debt obligations (principal)	$	8.0	$	22.8	$	22.5	$	32.5	$	695.0	$	—	$	780.8

The above table does not include asset retirement obligations due to the uncertainty of the timing of the future cash outflows related to the restoration costs associated with returning certain facilities to their original condition upon termination of our long-term leases. As of December 31, 2016, the obligation expected to be incurred was $14.1 million.

We believe, after consultation with counsel or other experts, that no matters currently pending would, in the event of an adverse outcome, either individually or in the aggregate, have a material impact on our consolidated financial position, results of operations, or liquidity.

FINANCING NEEDS

Our primary cash needs are for operating expenses (such as salaries and fringe benefits, hiring and recruiting, business development and facilities), business acquisitions, capital expenditures, and repayment of principal and interest on our borrowings.

2016 Credit Agreement and Note Purchase Agreement

Our requirements for cash to pay principal and interest on our borrowings will increase significantly in future periods based on amounts borrowed under our 2016 Credit Agreement and the Notes. Our primary committed external source of funds is the 2016 Credit Agreement. Our principal source of cash is from the performance of services under contracts with our clients. If we are unable to generate new contracts with existing and new clients or if the level of contract cancellations increases, our revenue and cash flow would be adversely affected (see Part II, Item 1A “Risk Factors” for further detail on these risks). Absent a material adverse change in the level of our new business bookings or contract cancellations, we believe that our existing capital resources together with cash flow from operations and borrowing capacity under existing credit facilities will be sufficient to meet our foreseeable cash needs over the next twelve months and on a longer term basis. Depending upon our revenue and cash flow from operations, it is possible that we will require external funds to repay amounts outstanding under our 2016 Credit Agreement upon its maturity in 2021.

We expect to continue to acquire businesses that enhance our service and product offerings, expand our therapeutic expertise, and/or increase our global presence. Depending on their size, any future acquisitions may require additional external financing, and we may from time to time seek to obtain funds from public or private issuances of equity or debt securities. We may be unable to secure such financing at all or on terms acceptable to us, as a result of our outstanding borrowings, including our outstanding borrowings under the 2016 Credit Agreement.

Under the terms of the 2016 Credit Agreement, interest rates are fixed based on market indices at the time of borrowing and, depending upon the interest mechanism selected by us, may float thereafter. As a result, the amount of interest payable by us on our borrowings may increase if market interest rates change. However, we expect to mitigate the risk of increasing market interest rates with our hedging programs described below under Part I, Item 3 “Quantitative and Qualitative Disclosures About Market Risk - Foreign Currency Exchange Rates and Interest Rates.”

Share Repurchases

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION

AND RESULTS OF OPERATIONS (Continued)

of the shares we repurchased, as a decrease to equity in our consolidated balance sheet, consisting of decreases in common stock and additional paid-in capital. As additional paid-in capital was reduced to zero, the remainder was applied as a reduction in retained earnings. The remaining $40.0 million, which is an advanced payment accounted for as a forward share repurchase contract, was recorded as within other current assets within the condensed consolidated balance sheet. During the three months ended December 31, 2016, the fair value of the forward share repurchase contract in the amount of $40.0 million decreased by $20.3 million.

On September 14, 2015, we announced that our Board of Directors approved a share repurchase program (the “2016 Program”) authorizing the repurchase of up to $200.0 million of our common stock to be financed with cash on hand, cash generated from operations, existing credit facilities, or new financing. On September 15, 2015, we entered into an agreement (the “2016 Agreement”) to purchase shares of our common stock from Wells Fargo Bank, National Association (“WF”), for an aggregate purchase price of $200.0 million pursuant to an accelerated share purchase program. Pursuant to the 2016 Agreement, in September 2015, we paid $200.0 million to WF and received from WF 2.3 million shares of our common stock, representing 80% of the shares to be repurchased by us under the 2016 Agreement. The shares were repurchased at a price of $70.35 per share, which was the closing price of our common stock on the Nasdaq Global Select Market on September 16, 2015. These shares were canceled and restored to the status of authorized and unissued shares. As of December 31, 2016, we recorded the $200.0 million payment to WF as a decrease to equity in our consolidated balance sheet, consisting of decreases in common stock and additional paid-in capital. As additional paid-in capital was reduced to zero, the remainder was applied as a reduction in retained earnings.

On February 10, 2016 we received 0.9 million shares, representing the final settlement of the 2016 Agreement, and the 2016 Program was completed. Pursuant to the 2016 Program, we repurchased 3.2 million shares of our common stock at an average price of $62.92 per share from September 2015 to February 2016.

OFF-BALANCE SHEET ARRANGEMENTS

We have no material off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

INFLATION

We believe the effects of inflation generally do not have a material adverse impact on our operations or financial condition.

RECENTLY IMPLEMENTED AND ISSUED ACCOUNTING STANDARDS

See Note 1 to our condensed consolidated financial statements included in this Quarterly Report on Form 10-Q for more information on recently implemented and issued accounting standards.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

MARKET RISK

Market risk is the potential loss arising from adverse changes in market rates and prices, such as foreign currency exchange rates, interest rates, and other relevant market rates or price changes. In the ordinary course of business, we are exposed to market risk resulting from changes in foreign currency exchange rates and interest rates, and we regularly evaluate our exposure to such changes. Our overall risk management strategy seeks to balance the magnitude of the exposure and the costs and availability of appropriate financial instruments.

FOREIGN CURRENCY EXCHANGE RATES AND INTEREST RATES

For the six months ended December 31, 2016 and 2015, we derived approximately 58.6% and 55.8% of our consolidated service revenue, respectively, from operations outside of the United States. In addition, for the six months ended December 31, 2016 and 2015, our Euro denominated service revenue accounted for 11.3% and 9.9% of our consolidated service revenue, respectively. We have no significant operations in countries in which the economy is considered to be highly inflationary. Our financial statements are denominated in U.S. dollars. Accordingly, changes in exchange rates between foreign currencies and the U.S. dollar will affect the translation of financial results into U.S. dollars for purposes of reporting our consolidated financial results.

It is our policy to mitigate the risks associated with fluctuations in foreign exchange rates and in market rates of interest. Accordingly, we have instituted foreign currency hedging programs and an interest rate swap program. See Note 11 to our consolidated financial statements included in this Quarterly Report on Form 10-Q for more information on our hedging programs and interest rate swap program.

As of December 31, 2016, the programs with derivatives designated as hedging instruments under ASC 815 were deemed effective and the notional values of the derivatives were approximately $355.7 million, including two interest rate swaps agreements with a total notional value of $200.0 million. Under certain circumstances, such as the occurrence of significant differences between actual cash receipts and forecasted cash receipts, the ASC 815 programs could be deemed ineffective. In such an event, the unrealized gains and losses related to these derivatives, which are currently reported in accumulated other comprehensive income in our consolidated balance sheets, would be recognized in earnings. As of December 31, 2016, the estimated amount that could be recognized in earnings was a loss of approximately $4.4 million, net of tax.

As of December 31, 2016, the notional value of foreign exchange contract derivatives that were not designated as hedging instruments under ASC 815 was approximately $146.8 million.

During the six months ended December 31, 2016 and 2015, we recorded net foreign currency exchange gains of $1.0 million and $1.8 million, respectively. We also have exposure to additional foreign currency exchange rate risk as it relates to assets and liabilities that are not part of the economic hedge or designated hedging programs, but that risk is difficult to quantify at any given point in time.

Our exposure to changes in interest rates relates primarily to the amount of our long-term debt. The current portion of our long-term debt was $20.8 million as of December 31, 2016 and $16.6 million as of June 30, 2016. Long-term debt was $759.9 million as of December 31, 2016 and $487.8 million as of June 30, 2016. As of December 31, 2016, $100.0 million in aggregate principal amount outstanding under the Notes carried a fixed interest rate of 3.11%. As of December 31, 2016, $200.0 million of borrowings under our 2016 Credit Agreement were hedged under two interest rate swap agreement. Based on average total debt for the six months ended December 31, 2016, an increase in the average interest rate of 100 basis points would reduce our pre-tax earnings and cash flows by approximately $3.4 million on an annual basis.

ITEM 4. CONTROLS AND PROCEDURES

EVALUATION OF DISCLOSURE CONTROLS AND PROCEDURES

Our management, with the participation of our chief executive officer and interim chief financial officer (our principal executive officer and principal financial officer, respectively), evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2016. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended ( the “Exchange Act”), means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based upon that evaluation, our Chief Executive Officer and Interim Chief Financial Officer concluded that there was a material weakness in our internal control over financial reporting related to complex treasury transactions. Specifically, this material weakness is the result of the untimely identification of a contract term in the accelerated share repurchase agreement that resulted in a fair value adjustment loss of $20.3 million in the second quarter of Fiscal Year 2017. The remediation efforts related to the material weakness identified in the fiscal quarter ended December 31, 2016 are expected to include strengthening the accounting review of complex treasury related agreements by engaging outside specialists with expertise in the subject manner in a timelier manner when applicable and formalizing review protocols and timelines.

As a result of the above material weakness identified in the fiscal quarter ended December 31, 2016, and the previously reported material weaknesses related to revenue recognition in our CRS reporting segment and approval of invoices for payment and validation of vendors previously disclosed in our Annual Report on Form 10-K for the year ended June 30, 2016, and as described below, our disclosure controls and procedures were not effective as of December 31, 2016.

PREVIOUSLY REPORTED MATERIAL WEAKNESSES & REMEDIATION PROGRESS

As reported in Item 9A of our Annual Report on Form 10-K for the year ended June 30, 2016, our management concluded that our internal control over financial reporting was not effective as of that date because of material weaknesses in our internal control over financial reporting for revenue recognition in our CRS reporting segment and approval of invoices for payment and validation of vendors for a specific class of vendors within the expenditure process.

MANAGEMENT'S PLAN FOR REMEDIATION

Management is in the process of implementing a remediation plan intended to address the control deficiencies which resulted in the material weaknesses described above, which are not yet remediated. The revenue recognition remediation efforts are underway, which include the following: 1) enhanced contract amendment reviews and project revenue analytics; 2) increased revenue recognition training and communication of policies and procedures for finance and non-finance personnel; and 3) enhanced unit audit and reconciliation reviews for revenue at the project level. The vendor payment remediation efforts have largely been completed by verifying authenticity of the majority of this specific class of vendors and implementation of new invoice review guidelines.

CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING

Other than the identification of the material weaknesses and remediation efforts described above, there were no changes in our internal control over financial reporting that occurred during the fiscal quarter ended December 31, 2016 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

We periodically become involved in various claims and lawsuits that are incidental to our business. We believe, after consultation with counsel, that no matters currently pending would, in the event of an adverse outcome, have a material impact on our consolidated financial statements.

ITEM 1A. RISK FACTORS

In addition to the other information set forth in this report, you should carefully consider the factors discussed in Part I, Item 1A. “Risk Factors” in our Annual Report on Form 10-K for Fiscal Year 2016 filed with the SEC on September 9, 2016, which could materially affect our business, financial condition, and future operating results. The risks described in our Annual Report on Form 10-K are not the only risks that we face. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition, and operating results. There have been no material changes to the risk factors set forth in our Annual Report on Form 10-K for Fiscal Year 2016 other than the risk factors below:

We face risks arising from the restructuring of our operations.

In June 2015, we adopted a plan (the “Margin Acceleration Program”) to restructure our operations to improve the productivity and efficiency of the Company, simplify the organization, and streamline decision-making, thereby enhancing client engagement. For Fiscal Years 2016 and 2015, we recorded $27.8 million and $20.0 million, respectively, in restructuring charges related to the Margin Acceleration Program, which consisted of employee separation benefits and facility exit costs. On January 6, 2017, we approved a plan to restructure our operations to improve the productivity and efficiency of the company, simplify the organization, and streamline decision-making, thereby enhancing client engagement. The restructuring initiative is company-wide. These actions are expected to result in pre-tax charges in the range of $25.0 million to $35.0 million, all of which are anticipated to be cash expenditures. If we incur additional restructuring charges, our financial condition and results of operations may be adversely impacted.

Restructuring presents significant potential risks of events occurring that could adversely affect us, including a decrease in employee morale, the failure to achieve targeted cost savings and the failure to meet operational targets and customer requirements due to the loss of employees and any work stoppages that might occur.

Failure to achieve and maintain effective internal control in accordance with Section 404 of the Sarbanes-Oxley Act of 2002, and delays in completing our internal control audit and financial audit, could have a material adverse effect on our business and stock price.

As described in Item 9A, management assessments have identified material weaknesses in our internal control over financial reporting due to ineffective controls associated with revenue recognition in our CRS reporting segment, our approval of invoices and validation of vendors regarding a specific class of vendors, and complex treasury transactions. We have begun the process of implementing remedial actions to resolve these material weaknesses, but we have not yet completed remediation. During the course of our testing, we also may identify other significant deficiencies or material weaknesses, in addition to the ones already identified, which we may not be able to remediate in a timely manner. If we continue to have one or more material weaknesses in our internal control over financial reporting, we will not be able to conclude that we have effective internal control over financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act of 2002. Failure to achieve and maintain an effective internal control environment, or delays in completing our internal control audit and financial audit, could cause investors to lose confidence in our reported financial information, which could result in a decline in the market price of our common stock, and cause us to fail to meet our reporting obligations in the future, which in turn could impact our ability to raise equity financing if needed in the future. While we believe our reported revenue is accurate, until these deficiencies are substantially remediated, it is possible that internal control over financial reporting may not prevent or detect material errors in revenue reflected in our financial statements.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

The following table provides information about repurchases of our equity securities during the three months ended December 31, 2016:



Period	(a) Total Number of Share (or Units) Purchased	(b) Average Price Paid per Share (or Unit)		(c) Total Number of Shares (or Units) Purchased as Part of Publicly Announced Plans or Programs	(d) Approximate Dollar Value of Shares (or Units) that May Yet Be Purchased Under the Plans or Programs(1)
October 1, 2016-October 31, 2016	—	$	—	—	$—
November 1, 2016-November 30, 2016	2,782,125	$	57.51	2,782,125	$—
December 1, 2016-December 31, 2016	—	$	—	—	$—
Total	2,782,125			2,782,125

⁽¹⁾ On October 26, 2016, we announced that our Board of Directors approved the 2017 Program authorizing the repurchase of up to $200.0 million of our common stock to be financed with cash on hand, cash generated from operations, existing credit facilities, or new financing. On November 21, 2016, we entered into the 2017 Agreement to purchase shares of our common stock from HSBC, for an aggregate purchase price of $200.0 million pursuant to an accelerated share purchase program. Pursuant to the 2017 Agreement, in November 2016, we paid $200.0 million to HSBC and received from HSBC 2.8 million shares of our common stock, representing 80% of the estimated shares to be repurchased by us under the 2017 Agreement. The shares were repurchased at a price of $57.51 per share, which was the closing price of our common stock on the Nasdaq Global Select Market on November 21, 2016. These shares were canceled and restored to the status of authorized and unissued shares. During the three months ended December 31, 2016 the fair value of the forward share repurchase contract in the amount of $40.0 million decreased by $20.3 million.

ITEM 5. OTHER INFORMATION

None.

ITEM 6. EXHIBITS

See the Exhibit Index on the page immediately preceding the exhibits for a list of exhibits filed as part of this Quarterly Report on Form 10-Q, which Exhibit Index is incorporated by this reference.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.




		PAREXEL International Corporation


Date:	February 8, 2017	By: /s/ Josef H. von Rickenbach

		Josef H. von Rickenbach
		Chairman of the Board and Chief Executive Officer
		(Principal Executive Officer)


Date:	February 8, 2017	By: /s/ Emma Reeve

		Emma Reeve
		Corporate Vice President and Interim Chief Financial Officer
		(Principal Financial Officer)

EXHIBIT INDEX



Exhibit Number		Description

10.1		Letter Agreement Regarding Accelerated Share Repurchase Program by and between PAREXEL International Corporation and HSBC Bank USA, National Association, dated November 21, 2016 (filed as exhibit 10.1 to the Company’s Current Report on Form 8-K dated November 21, 2016 and incorporated herein by this reference).

10.2		Revolving Credit Facility - Letter Loan Agreement, dated December 23, 2016, between HSBC and PAREXEL International Corporation (filed as exhibit 10.1 to the Company’s Current Report on Form 8-K dated December 23, 2016 and incorporated herein by this reference).

10.3*		PAREXEL International Corporation 2013 Annual Incentive Award Plan.

31.1		Principal executive officer certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

31.2		Principal financial officer certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32.1		Principal executive officer certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

32.2		Principal financial officer certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101.INS		XBRL Instance Document

101.SCH		XBRL Taxonomy Extension Schema

101.CAL		XBRL Taxonomy Extension Calculation Linkbase

101.LAB		XBRL Taxonomy Extension Label Linkbase

101.PRE		XBRL Taxonomy Extension Presentation Linkbase

101.DEF		XBRL Taxonomy Extension Definition Linkbase

*Denotes management contract or any compensatory plan, contract or arrangement.

EX-10.3 2 prxl103q21712312016.htm EXHIBIT 10.3 Exhibit

PAREXEL INTERNATIONAL COMPANY

2013 ANNUAL INCENTIVE AWARD PLAN

I. General Purpose of Plan.

The PAREXEL International Company 2013 Annual Incentive Award Plan is designed to assist the Company and its Subsidiaries in attracting, retaining and providing incentives to Eligible Employees and to promote the identification of their interests with those of the Company’s shareholders by providing for the payment of Incentive Awards subject to the achievement of specified Performance Goals.

II. Definitions.

Terms not otherwise defined herein shall have the following meanings:

A. “Award Period” means the calendar year, except to the extent the Committee determines otherwise.

B. “Board” means the Board of Directors of the Company.

C. “Code” means the Internal Revenue Code of 1986, as amended.

D. “Committee” means the Compensation Committee of the Board, or any other committee appointed by the Board to administer the Plan; provided that the Committee shall be comprised solely of two or more directors eligible to serve on a committee making awards qualifying as “performance-based compensation” under Code Section 162(m).

E. “Company” means PAREXEL International Corporation, a Massachusetts corporation, and its successors and assigns and any corporation which shall acquire substantially all of its assets.

F. “Covered Employee” means a “covered employee” within the meaning of Section 162(m) of the Code.

G. “Eligible Employee” means an employee described in Section IV hereof.

H. “Incentive Award” means a contingent award made to a Participant that, subject to Section V hereof, entitles the Participant to cash payment to reflect the relative level of attainment of Performance Goals established by the Committee for an Award Period and such other factors as the Committee may determine.

I. “Participant” means any Eligible Employee who receives an Incentive Award under the Plan for an Award Period.

J. “Performance Goals” means one or more of the following objective performance measures, which shall be based on the relative or absolute attainment of specified levels of one or any combination of the following which may be determined pursuant to generally accepted accounting principles (“GAAP”) or on a non-GAAP basis, as determined by the Committee: (1) earnings per share, (2) earnings, (3) earnings growth, (4) earnings before interest, taxes and amortization (EBITA), (5) operating income, (6) operating margins, (7) revenues, (8) expenses, (9) stock price, (10) market share, (11) chargeoffs, (12) reductions in non-performing assets, (13) return on sales, assets, equity or investment, (14) regulatory compliance, (15) satisfactory internal or external audits, (16) improvement of financial ratings, (17) achievement of balance sheet or income statement objectives, (18) net cash provided from continuing operations, (19) stock price appreciation, (20) total shareholder return, (21) cost control, (22) strategic initiatives, (23) net operating profit after tax, (24) pre-tax or after-tax income, or (25) cash flow, and may be absolute in their terms or measured against or in relationship to other companies comparably, similarly or otherwise situated. The Committee may specify that such Performance Goals shall be adjusted to exclude any one or more of (i) extraordinary items and any other unusual or non-recurring items, (ii) discontinued operations, (iii) gains or losses on the dispositions of discontinued operations, (iv) the cumulative effects of changes in tax or accounting principles, (v) the writedown of any asset, (vi) charges for restructuring and rationalization programs, (vii) other non-cash charges or items, (viii) gains or losses related to financing activities, (ix) the effect of acquisitions, or (x) gains or losses as a result of foreign currency conversions or fluctuations in foreign currency exchange rates. Such Performance Goals: (I) may vary by Participant and may be different for different Awards; or (II) may be particular to a Participant or the department, branch, line of business, subsidiary or other unit in which the Participant works and may cover such period as may be specified by the Committee.

K. “Plan” means the PAREXEL International Corporation 2013 Annual Incentive Award Plan.

L. “Subsidiary” means a corporation of which at least 50% of the total combined voting power of all classes of stock is owned by the Company, either directly or through one or more other Subsidiaries.

III. Administration.

The Plan shall be administered by the Committee. The Committee shall have plenary authority, in its discretion, to determine the terms of all Incentive Awards, including, without limitation, the Eligible Employees to whom, and the time or times at which, Incentive Awards are made, the Award Period to which each Incentive Award shall relate, the actual dollar amount to be paid pursuant to an Incentive Award, the Performance Goals to which payment of Incentive Awards will be subject, and when payments pursuant to Incentive Awards shall be made (which payments may, without limitation, be made during or after an Award Period on a deferred basis or in installments). In making such determinations, the Committee may take into account the nature of the services rendered by the respective Eligible Employees, their present and potential contributions to the success of the Company and its Subsidiaries, and such other factors as the Committee in its discretion shall deem relevant. Subject to the express provisions of the Plan, the Committee shall have plenary authority to interpret the Plan, to prescribe, amend and rescind rules and regulations relating to it and to make all other determinations deemed necessary or advisable for the administration of the Plan. The determinations of the Committee pursuant to its authority under the Plan shall be conclusive and binding.

IV. Eligibility.

Incentive Awards may be granted only to executive officers of the Company or a Subsidiary.

V. Incentive Awards; Terms of Awards; Payment.

A. The Committee shall, in its sole discretion, determine which Eligible Employees shall receive Incentive Awards. For each Award Period with respect to which the Committee determines to make Incentive Awards, the Committee shall by resolution establish one or more Performance Goals applicable to such Incentive Awards and the other terms and conditions of the Incentive Awards. Such Performance Goals (including the determination of any adjustments permitted under Section II.5) and other terms and conditions shall be established by the Committee in its sole discretion as it shall deem appropriate and in the best interests of the Company and shall be established (1) within 90 days after the first day of the Award Period and (2) before 25% of the Award Period has elapsed.

B. After the end of each Award Period for which the Committee has granted Incentive Awards, the Committee shall determine the extent to which the Performance Goals established by the Committee for the Award Period have been achieved and shall authorize the Company to make Incentive Award payments to Participants in accordance with the terms of the Incentive Awards. In no event shall the amount paid to a Participant in accordance with the terms of Incentive Awards by reason of Performance Goal achievement exceed $3,000,000 in any calendar year. Unless otherwise determined by the Committee, no Incentive Award payments shall be made to a Participant unless the Participant is employed by the Company or a Subsidiary as of the end of the Award Period.

C. The Committee may at any time, in its sole discretion, cancel an Incentive Award or eliminate or reduce (but not increase) the amount payable pursuant to the terms of an Incentive Award without the consent of a Participant.

D. Incentive Award payments shall be subject to applicable federal, state and local withholding taxes and other applicable withholding in accordance with the Company’s payroll practices as from time-to-time in effect.

E. The Committee shall have the power to impose such other restrictions on Incentive Awards as it may deem necessary or appropriate to ensure that such Incentive Awards satisfy all requirements for “performance-based compensation” within the meaning of Section 162(m)(4)(C) of the Code, or any successor provision thereto. Prior to the payment of any Incentive Award, the Committee shall certify in writing (which may be substantiated by the inclusion of such a determination in the minutes of a meeting of the Committee) that the Performance Goals and other material terms applicable to such Incentive Award are satisfied.

VI. Transferability.

Incentive Awards shall not be subject to the claims of creditors and may not be assigned, alienated, transferred or encumbered in any way other than by will or pursuant to the laws of descent and distribution.

VII. Termination or Amendment.

The Committee may amend, modify or terminate the Plan in any respect at any time without the consent of Participants, provided that (a) no amendment or termination of the Plan after the end of an Award Period may adversely affect the rights of Participants with respect to their Incentive Awards for that Award Period, and (b) no amendment which would require shareholder approval under Section 162(m) of the Code may be effected without such shareholder approval.

VIII. Effectiveness of Plan and Awards.

The Plan and Incentive Awards granted hereunder shall be void ab initio unless the Plan is approved by a vote of the Company’s shareholders at the first shareholders’ meeting of the Company following adoption of the Plan by the Committee.

IX. Effective Date; Term of the Plan.

The Plan shall become effective on the date the Plan is approved by the Company’s shareholders. Incentive Awards may be granted under the Plan prior to such shareholder approval provided such Incentive Awards are specifically contingent upon the obtaining of such shareholder approval. Unless sooner terminated by the Committee pursuant to Section VII, to the extent necessary to ensure that Incentive Award payments made to Covered Employees may be deductible by the Company or Subsidiary for federal income tax purposes, the Plan shall terminate as of the date of the first meeting of the Company’s shareholders occurring during 2018, unless the term of the Plan is extended and reapproved at such shareholders’ meeting. No Incentive Awards may be awarded under the Plan after its termination. Termination of the Plan shall not affect any Incentive Awards outstanding on the date of termination and such awards shall continue to be subject to the terms of the Plan notwithstanding its termination.

X. General Provisions.

A. The establishment of the Plan shall not confer upon any Eligible Employee any legal or equitable right against the Company or any Subsidiary, except as expressly provided in the Plan.

B. The Plan does not constitute an inducement or consideration for the employment of any Eligible Employee, nor is it a contract between the Company, or any Subsidiary and any Eligible Employee. Participation in the Plan shall not give an Eligible Employee any right to be retained in the employ of the Company or any Subsidiary.

C. Nothing contained in this Plan shall prevent the Committee from adopting other or additional compensation arrangements, subject to shareholder approval if such approval is required, and such arrangements may be either generally applicable or applicable only in specific cases.

D. The Plan shall be governed, construed and administered in accordance with the laws of the Commonwealth of Massachusetts.

EX-31.1 3 prxl311q21712312016.htm EXHIBIT 31.1 Exhibit

Exhibit 31.1

CERTIFICATION

I, Josef H. von Rickenbach, certify that:

1. I have reviewed this quarterly report on Form 10-Q of PAREXEL International Corporation;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.



Date:	February 8, 2017	By: /s/ Josef H. von Rickenbach

		Josef H. von Rickenbach
		(Principal Executive Officer)

EX-31.2 4 prxl312q21712312016.htm EXHIBIT 31.2 Exhibit

Exhibit 31.2

CERTIFICATION

I, Emma Reeve, certify that:

1. I have reviewed this quarterly report on Form 10-Q of PAREXEL International Corporation;

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.



Date:	February 8, 2017	By: /s/ Emma Reeve

		Emma Reeve
		(Principal Financial Officer)

EX-32.1 5 prxl321q21712312016.htm EXHIBIT 32.1 Exhibit

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of PAREXEL International Corporation (the “Company”) for the period ended December 31, 2016 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Josef H. von Rickenbach, Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that, to his knowledge:



	(1)	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and



	(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.



Date:	February 8, 2017	By: /s/ Josef H. von Rickenbach

		Josef H. von Rickenbach
		Chairman of the Board and Chief Executive Officer

A signed original of this written statement required by Section 906 has been provided to PAREXEL International Corporation and will be retained by PAREXEL International Corporation and furnished to the Securities and Exchange Commission or its staff upon request.

EX-32.2 6 prxl322q21712312016.htm EXHIBIT 32.2 Exhibit

Exhibit 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of PAREXEL International Corporation (the “Company”) for the period ended December 31, 2016 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Emma Reeve, Interim Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that, to his knowledge:



	(1)	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and



	(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.



Date:	February 8, 2017	By: /s/ Emma Reeve

		Emma Reeve
		Corporate Vice President and Interim Chief Financial Officer

EX-101.INS 7 prxl-20161231.xml XBRL INSTANCE DOCUMENT 0000799729 2016-07-01 2016-12-31 0000799729 prxl:HealthAdvancesAcquisitionMember 2016-07-01 2016-12-31 0000799729 prxl:ExecuPharmInc.Member 2016-07-01 2016-12-31 0000799729 2017-02-06 0000799729 2016-06-30 0000799729 2016-12-31 0000799729 2016-10-01 2016-12-31 0000799729 2015-07-01 2015-12-31 0000799729 2015-10-01 2015-12-31 0000799729 prxl:A2015MarginAccelerationProgramMember 2016-07-01 2016-09-30 0000799729 2015-06-30 0000799729 2015-12-31 0000799729 us-gaap:AdditionalPaidInCapitalMember 2016-07-01 2016-12-31 0000799729 prxl:ExecuPharmInc.Member us-gaap:TradeNamesMember 2016-10-03 0000799729 prxl:ExecuPharmInc.Member us-gaap:TradeNamesMember 2016-10-03 2016-10-03 0000799729 prxl:ExecuPharmInc.Member us-gaap:CustomerRelationshipsMember 2016-12-31 0000799729 prxl:ExecuPharmInc.Member us-gaap:CustomerRelationshipsMember 2016-07-01 2016-12-31 0000799729 prxl:ExecuPharmInc.Member 2016-12-31 0000799729 prxl:HealthAdvancesAcquisitionMember 2016-12-31 0000799729 prxl:HealthAdvancesAcquisitionMember 2016-01-19 0000799729 prxl:HealthAdvancesAcquisitionMember 2016-02-10 2016-02-10 0000799729 prxl:ExecuPharmInc.Member us-gaap:PaymentDeferralMember 2016-10-03 0000799729 prxl:ExecuPharmInc.Member 2016-10-03 0000799729 prxl:ExecuPharmInc.Member 2016-10-03 2016-10-03 0000799729 prxl:ExecuPharmInc.Member 2016-02-10 2016-02-10 0000799729 prxl:HealthAdvancesAcquisitionMember us-gaap:CustomerRelationshipsMember 2016-07-01 2016-12-31 0000799729 prxl:HealthAdvancesAcquisitionMember us-gaap:TechnologyBasedIntangibleAssetsMember 2016-07-01 2016-12-31 0000799729 prxl:HealthAdvancesAcquisitionMember us-gaap:CustomerRelationshipsMember 2016-12-31 0000799729 prxl:HealthAdvancesAcquisitionMember us-gaap:TradeNamesMember 2016-01-19 2016-01-19 0000799729 prxl:HealthAdvancesAcquisitionMember us-gaap:TechnologyBasedIntangibleAssetsMember 2016-12-31 0000799729 prxl:HealthAdvancesAcquisitionMember us-gaap:TradeNamesMember 2016-01-19 0000799729 prxl:FY2017StockRepurchasePlanMemberDomainDomain 2016-07-01 2016-12-31 0000799729 prxl:FY2016StockRepurchasePlanMemberMemberDomain 2015-09-14 0000799729 prxl:FY2016StockRepurchasePlanMemberMemberDomain 2016-10-01 2016-12-31 0000799729 prxl:FY2017StockRepurchasePlanMemberDomainDomain 2016-10-26 0000799729 prxl:FY2016StockRepurchasePlanMemberMemberDomain 2015-07-01 2015-12-31 0000799729 prxl:FY2017StockRepurchasePlanMemberDomainDomain 2016-10-01 2016-12-31 0000799729 prxl:FY2016StockRepurchasePlanMemberMemberDomain 2016-02-10 2016-02-10 0000799729 prxl:FY2016StockRepurchasePlanMemberMemberDomain 2015-09-01 2016-02-29 0000799729 prxl:FY2017StockRepurchasePlanMemberDomainDomain 2015-07-01 2015-12-31 0000799729 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2016-07-01 2016-12-31 0000799729 us-gaap:AccumulatedTranslationAdjustmentMember 2016-07-01 2016-12-31 0000799729 currency:GBP 2016-07-01 2016-12-31 0000799729 currency:EUR 2016-07-01 2016-12-31 0000799729 currency:JPY 2016-07-01 2016-12-31 0000799729 us-gaap:ForeignExchangeContractMember us-gaap:SalesRevenueServicesNetMember 2015-10-01 2015-12-31 0000799729 us-gaap:ForeignExchangeContractMember us-gaap:SalesRevenueServicesNetMember 2016-10-01 2016-12-31 0000799729 us-gaap:InterestRateContractMember us-gaap:InterestExpenseMember 2015-10-01 2015-12-31 0000799729 us-gaap:ForeignExchangeContractMember us-gaap:CostOfSalesMember 2015-10-01 2015-12-31 0000799729 us-gaap:InterestRateContractMember 2016-10-01 2016-12-31 0000799729 us-gaap:ForeignExchangeContractMember us-gaap:CostOfSalesMember 2016-10-01 2016-12-31 0000799729 us-gaap:InterestRateContractMember us-gaap:InterestExpenseMember 2015-07-01 2015-12-31 0000799729 us-gaap:ForeignExchangeContractMember us-gaap:CostOfSalesMember 2015-07-01 2015-12-31 0000799729 us-gaap:ForeignExchangeContractMember us-gaap:CostOfSalesMember 2016-07-01 2016-12-31 0000799729 us-gaap:ForeignExchangeContractMember us-gaap:SalesRevenueServicesNetMember 2015-07-01 2015-12-31 0000799729 us-gaap:ForeignExchangeContractMember us-gaap:SalesRevenueServicesNetMember 2016-07-01 2016-12-31 0000799729 us-gaap:InterestRateContractMember 2016-07-01 2016-12-31 0000799729 us-gaap:CostOfSalesMember 2016-07-01 2016-12-31 0000799729 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2016-07-01 2016-12-31 0000799729 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2015-07-01 2015-12-31 0000799729 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2016-10-01 2016-12-31 0000799729 us-gaap:CostOfSalesMember 2015-07-01 2015-12-31 0000799729 us-gaap:CostOfSalesMember 2015-10-01 2015-12-31 0000799729 us-gaap:CostOfSalesMember 2016-10-01 2016-12-31 0000799729 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2015-10-01 2015-12-31 0000799729 prxl:A2015MarginAccelerationProgramMember 2015-07-01 2016-06-30 0000799729 us-gaap:MaximumMember prxl:A2017RestructingPlanMember 2017-01-06 2017-01-06 0000799729 prxl:A2015MarginAccelerationProgramMember 2014-07-01 2015-06-30 0000799729 us-gaap:MinimumMember prxl:A2017RestructingPlanMember 2017-01-06 2017-01-06 0000799729 us-gaap:OperatingSegmentsMember prxl:PIMember 2016-07-01 2016-12-31 0000799729 us-gaap:OperatingSegmentsMember prxl:CrsMember 2016-07-01 2016-12-31 0000799729 us-gaap:CorporateNonSegmentMember 2015-07-01 2015-12-31 0000799729 us-gaap:OperatingSegmentsMember 2015-07-01 2015-12-31 0000799729 us-gaap:OperatingSegmentsMember prxl:CrsMember 2015-07-01 2015-12-31 0000799729 us-gaap:OperatingSegmentsMember prxl:PCMember 2016-07-01 2016-12-31 0000799729 us-gaap:CorporateNonSegmentMember 2016-07-01 2016-12-31 0000799729 us-gaap:OperatingSegmentsMember prxl:PIMember 2015-07-01 2015-12-31 0000799729 us-gaap:OperatingSegmentsMember prxl:PCMember 2015-07-01 2015-12-31 0000799729 us-gaap:OperatingSegmentsMember 2016-07-01 2016-12-31 0000799729 prxl:FacilitiesRelatedChargesMember prxl:TwoThousandFifteenRestructuringPlanMemberDomain 2016-07-01 2016-12-31 0000799729 us-gaap:EmployeeSeveranceMember prxl:TwoThousandFifteenRestructuringPlanMemberDomain 2016-12-31 0000799729 prxl:FacilitiesRelatedChargesMember prxl:TwoThousandFifteenRestructuringPlanMemberDomain 2016-12-31 0000799729 prxl:TwoThousandFifteenRestructuringPlanMemberDomain 2016-06-30 0000799729 prxl:FacilitiesRelatedChargesMember prxl:TwoThousandFifteenRestructuringPlanMemberDomain 2016-06-30 0000799729 us-gaap:EmployeeSeveranceMember prxl:TwoThousandFifteenRestructuringPlanMemberDomain 2016-07-01 2016-12-31 0000799729 prxl:FacilitiesRelatedChargesMember prxl:TwoThousandElevenRestructuringPlanMember 2016-07-01 2016-12-31 0000799729 prxl:FacilitiesRelatedChargesMember prxl:TwoThousandElevenRestructuringPlanMember 2016-12-31 0000799729 prxl:FacilitiesRelatedChargesMember prxl:TwoThousandElevenRestructuringPlanMember 2016-06-30 0000799729 prxl:ClinicalResearchServicesMember 2016-07-01 2016-12-31 0000799729 prxl:ClinicalResearchServicesMember 2015-07-01 2015-12-31 0000799729 prxl:ParexelConsultingAndMedcomServicesMember 2016-10-01 2016-12-31 0000799729 prxl:ClinicalResearchServicesMember 2015-10-01 2015-12-31 0000799729 prxl:PerceptiveInformaticsIncMember 2015-07-01 2015-12-31 0000799729 prxl:PerceptiveInformaticsIncMember 2015-10-01 2015-12-31 0000799729 prxl:ParexelConsultingAndMedcomServicesMember 2015-07-01 2015-12-31 0000799729 prxl:PerceptiveInformaticsIncMember 2016-07-01 2016-12-31 0000799729 prxl:ParexelConsultingAndMedcomServicesMember 2015-10-01 2015-12-31 0000799729 prxl:PerceptiveInformaticsIncMember 2016-10-01 2016-12-31 0000799729 prxl:ClinicalResearchServicesMember 2016-10-01 2016-12-31 0000799729 prxl:ParexelConsultingAndMedcomServicesMember 2016-07-01 2016-12-31 0000799729 prxl:A2016CreditAgreementMember us-gaap:DebtInstrumentRedemptionPeriodFiveMember prxl:TermLoanMember 2016-03-11 0000799729 prxl:A2016TermLoanAgreementMember us-gaap:SeniorNotesMember 2016-02-10 0000799729 prxl:A2014CreditAgreementMember prxl:OneMonthLIBORPlusMarginMember 2014-07-01 2015-03-31 0000799729 prxl:A2016CreditAgreementMember 2016-03-11 2016-03-11 0000799729 prxl:A2016CreditAgreementMember us-gaap:RevolvingCreditFacilityMember 2016-03-11 0000799729 prxl:A2016CreditAgreementMember prxl:OneMonthLIBORPlusRateMember 2016-07-01 2016-09-30 0000799729 prxl:UncommittedOverdraftFacilityMember prxl:INGBankNVMember us-gaap:UnsecuredDebtMember us-gaap:MaximumMember 2016-06-30 0000799729 prxl:A2016CreditAgreementMember us-gaap:DebtInstrumentRedemptionPeriodTwoMember prxl:TermLoanMember 2016-03-11 0000799729 prxl:A2016CreditAgreementMember prxl:TermLoanMember 2016-03-11 0000799729 prxl:A2014CreditAgreementMember prxl:LIBORPlusMarginMember 2014-07-01 2015-03-31 0000799729 prxl:A2014CreditAgreementMember us-gaap:RevolvingCreditFacilityMember 2014-10-15 0000799729 us-gaap:InterestRateSwapMember 2016-07-01 2016-09-30 0000799729 prxl:JpMorganUkMember 2016-09-30 0000799729 2015-06-12 0000799729 prxl:JPMorganFactoringMember 2015-09-30 0000799729 prxl:JpmorganlocMember us-gaap:MinimumMember 2016-07-01 2016-09-30 0000799729 us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2016-06-30 0000799729 prxl:UncommittedOverdraftFacilityMember prxl:INGBankNVMember us-gaap:UnsecuredDebtMember us-gaap:MinimumMember 2016-06-30 0000799729 prxl:SeniorNotesduein2020Member us-gaap:SeniorNotesMember 2015-09-30 0000799729 prxl:HSBCMember 2016-12-31 0000799729 prxl:JPMorganFactoringMember 2016-07-01 2016-12-31 0000799729 prxl:A2014CreditAgreementMember prxl:TermLoanMember 2016-03-11 0000799729 prxl:JpmorganlocMember us-gaap:MaximumMember 2016-07-01 2016-09-30 0000799729 us-gaap:RevolvingCreditFacilityMember 2016-12-31 0000799729 prxl:A2014CreditAgreementMember 2014-10-15 0000799729 us-gaap:InterestRateSwapMember 2011-09-30 0000799729 prxl:A2016CreditAgreementMember prxl:TermLoanMember 2016-12-31 0000799729 prxl:UncommittedOverdraftFacilityMember prxl:INGBankNVMember us-gaap:UnsecuredDebtMember 2016-09-30 0000799729 prxl:SeniorNotesduein2020Member 2015-09-30 0000799729 prxl:A2016CreditAgreementMember us-gaap:DebtInstrumentRedemptionPeriodOneMember prxl:TermLoanMember 2016-03-11 0000799729 prxl:A2016TermLoanAgreementMember 2016-02-10 2016-02-10 0000799729 prxl:A2014CreditAgreementMember prxl:SwinglineLoanMember 2014-10-15 0000799729 prxl:A2014CreditAgreementMember 2016-03-11 0000799729 prxl:A2016CreditAgreementMember 2016-07-01 2016-09-30 0000799729 us-gaap:InterestRateSwapMember 2013-05-02 2013-05-31 0000799729 prxl:A2016CreditAgreementMember prxl:LIBORPlusMarginMember 2016-07-01 2016-09-30 0000799729 2013-05-31 0000799729 prxl:SeniorNotesduein2020Member us-gaap:SeniorNotesMember 2013-07-25 0000799729 prxl:A2014CreditAgreementMember prxl:TermLoanMember 2014-10-15 0000799729 prxl:A2016CreditAgreementMember 2014-10-15 0000799729 2015-10-01 0000799729 prxl:A2016CreditAgreementMember prxl:SwinglineLoanMember 2016-03-11 0000799729 prxl:INGBankNVMember 2016-12-31 0000799729 prxl:HSBCMember 2016-07-01 2016-12-31 0000799729 prxl:A2016TermLoanAgreementMember prxl:LIBORPlusMarginMember 2016-07-01 2016-09-30 0000799729 prxl:A2016CreditAgreementMember us-gaap:DebtInstrumentRedemptionPeriodFourMember prxl:TermLoanMember 2016-03-11 0000799729 prxl:A2014CreditAgreementMember prxl:OneMonthLIBORPlusRateMember 2016-07-01 2016-09-30 0000799729 prxl:A2016CreditAgreementMember us-gaap:DebtInstrumentRedemptionPeriodThreeMember prxl:TermLoanMember 2016-03-11 0000799729 prxl:A2016CreditAgreementMember 2016-12-31 0000799729 prxl:A2016CreditAgreementMember prxl:FederalFundsPlusMarginMember 2016-07-01 2016-12-31 0000799729 us-gaap:FairValueInputsLevel3Member 2016-12-31 0000799729 us-gaap:ForwardContractsMember us-gaap:NondesignatedMember 2016-12-31 0000799729 us-gaap:NondesignatedMember 2016-06-30 0000799729 us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2016-12-31 0000799729 us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2016-12-31 0000799729 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2016-06-30 0000799729 us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2016-06-30 0000799729 us-gaap:ForwardContractsMember us-gaap:NondesignatedMember 2016-06-30 0000799729 us-gaap:DesignatedAsHedgingInstrumentMember 2016-06-30 0000799729 us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2016-06-30 0000799729 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2016-12-31 0000799729 us-gaap:NondesignatedMember 2016-12-31 0000799729 us-gaap:DesignatedAsHedgingInstrumentMember 2016-12-31 0000799729 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NondesignatedMember 2015-07-01 2015-12-31 0000799729 us-gaap:ForwardContractsMember us-gaap:NondesignatedMember 2016-07-01 2016-12-31 0000799729 us-gaap:NondesignatedMember 2015-07-01 2015-12-31 0000799729 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2015-10-01 2015-12-31 0000799729 us-gaap:NondesignatedMember 2015-10-01 2015-12-31 0000799729 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2016-10-01 2016-12-31 0000799729 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2015-07-01 2015-12-31 0000799729 us-gaap:NondesignatedMember 2016-07-01 2016-12-31 0000799729 us-gaap:NondesignatedMember 2016-10-01 2016-12-31 0000799729 us-gaap:ForwardContractsMember us-gaap:NondesignatedMember 2016-10-01 2016-12-31 0000799729 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2016-07-01 2016-12-31 0000799729 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NondesignatedMember 2015-10-01 2015-12-31 0000799729 us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2016-10-01 2016-12-31 0000799729 us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2015-10-01 2015-12-31 0000799729 us-gaap:DesignatedAsHedgingInstrumentMember 2016-07-01 2016-12-31 0000799729 us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2015-10-01 2015-12-31 0000799729 us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2016-07-01 2016-12-31 0000799729 us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2016-07-01 2016-12-31 0000799729 us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2015-07-01 2015-12-31 0000799729 us-gaap:DesignatedAsHedgingInstrumentMember 2015-07-01 2015-12-31 0000799729 us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2016-10-01 2016-12-31 0000799729 us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2015-07-01 2015-12-31 0000799729 us-gaap:DesignatedAsHedgingInstrumentMember 2016-10-01 2016-12-31 0000799729 us-gaap:DesignatedAsHedgingInstrumentMember 2015-10-01 2015-12-31 0000799729 us-gaap:FairValueInputsLevel2Member 2016-06-30 0000799729 us-gaap:FairValueInputsLevel3Member 2016-06-30 0000799729 us-gaap:FairValueInputsLevel1Member 2016-06-30 0000799729 2016-10-03 2016-10-03 0000799729 us-gaap:ForwardContractsMember 2016-07-01 2016-12-31 0000799729 us-gaap:ForwardContractsMember 2016-12-31 0000799729 us-gaap:ForwardContractsMember 2016-06-30 0000799729 prxl:HealthAdvancesAcquisitionMember 2016-01-19 2016-01-19 0000799729 prxl:HealthAdvancesAcquisitionMember us-gaap:FairValueInputsLevel3Member 2016-12-31 0000799729 us-gaap:FairValueInputsLevel2Member 2016-12-31 0000799729 us-gaap:FairValueInputsLevel1Member 2016-12-31 xbrli:pure xbrli:shares iso4217:USD xbrli:shares iso4217:EUR iso4217:USD false --06-30 Q2 2017 2016-12-31 10-Q 0000799729 50954585 Large Accelerated Filer PAREXEL INTERNATIONAL CORP 468700000 100000000 384500000 84200000 702500000 355700000 346800000 0.0200 0.0100 100000000 100000000 4700000 4700000 0 14000000 200000 6300000 4700000 500000000 750000000 14100000 0.049 0.082 0.121 10000000 10000000 -25800000 -3600000 0.8 0.8 0.72500 0.02500 0.00630 0.01880 0.01250 700000

160

62.92

70.35

57.51

62600000

102400000

506100000

640500000

31500000

30900000

35000000

36300000

-5500000

-4400000

-130500000

-152700000

-136000000

-157100000

P5Y

P2Y

P15Y

P10Y

P3Y

31400000

5700000

11400000

7200000

12700000

1400000

1200000

600000

800000

1181200000

1274100000

2036200000

2246400000

167200000

71600000

15800000

20000000

5200000

14000000

4500000

4600000

600000

9400000

9300000

73400000

175900000

700000

100000

4000000

29200000

1800000

8700000

200000

87100000

85500000

15000000

11600000

1800000

15000000

1600000

87100000

1600000

1800000

8700000

1000000

900000

71600000

167200000

207400000

154000000

248600000

252400000

-53400000

3800000

6300000

0.01

150000000

52900000

50900000

500000

27100000

34900000

-5300000

38500000

85700000

158800000

77800000

157600000

549600000

1099300000

552200000

1075400000

600000

0.0075

0.01750

0.00750

0.01

0.02

0.01

0.01750

0.0050

100000000

780800000

7100000

0.005

0.003

0.0400

0.0200

0.04

0.02

0.0311

P5Y

7500000

200000

420200000

453700000

38300000

37300000

27100000

27400000

19300000

16900000

17900000

35900000

19100000

38400000

47300000

51100000

81200000

36200000

59900000

108000000

200000000

3500000

1500000

2400000

1600000

19700000

500000

-8900000

-1400000

-1300000

-7600000

-1700000

-6600000

-6700000

100000

14900000

-4700000

19600000

0.013

0.0073

0.01104

-2100000

-1800000

-200000

-100000

-5300000

-4600000

-400000

-300000

-3000000

-700000

-2100000

-200000

-5800000

-800000

-4800000

-200000

-700000

-1700000

-600000

-400000

-800000

700000

-100000

-2400000

200000

-2200000

-2500000

1400000

-1100000

-800000

1900000

1100000

-3300000

-3600000

-900000

-800000

103300000

48000000

200000000

95800000

38800000

332500000

274400000

20800000

37300000

675700000

561900000

41000000

72800000

350900000

284500000

30900000

35500000

678600000

546600000

61300000

70700000

0.74

1.19

0.42

1.14

0.73

1.17

0.41

1.12

-14800000

-15400000

0.248

0.270

0.448

0.333

176400000

137900000

2300000

2700000

P4M24D

0.29

0.26

37.50

0.01

Approximately 2 years

-8200000

600000

20300000

9400000

40000000

5200000

14000000

19700000

-5300000

19700000

389200000

441000000

52500000

58600000

186000000

132700000

20600000

32700000

354900000

255400000

39700000

59800000

183500000

124400000

23700000

35400000

352500000

238600000

48300000

65600000

52400000

88100000

39500000

89400000

3400000

3500000

13000000

23800000

17700000

29800000

9000000

22500000

25200000

17300000

10400000

9900000

7100000

1500000

34100000

27900000

130700000

203600000

-2100000

-3700000

-2800000

-5400000

5400000

8800000

-1300000

500000

10200000

1402800000

1711300000

2036200000

2246400000

769400000

801300000

11800000

6600000

5200000

-900000

4800000

-5700000

100000000

300000000

4500000

100000000

7500000

4500000

100000000

165000000

0.0025

285000000

392500000

200000000

16600000

20800000

96500000

8000000

1400000

695000000

32500000

22500000

2900000

22800000

2800000

484800000

756900000

-71000000

89200000

-53300000

-181500000

85700000

111500000

39400000

64300000

21800000

59600000

-2200000

-2000000

-20500000

-23900000

54600000

90100000

60000000

113300000

50100000

59600000

38300000

38000000

-12200000

-27200000

-26000000

-22200000

8600000

8400000

3000000

-21100000

800000

2100000

700000

1200000

-100000

-2200000

-1100000

1100000

400000

-400000

300000

-500000

22400000

27400000

59500000

68000000

100000

-100000

1700000

-17700000

-18500000

200000000

148900000

67100000

148500000

148300000

53300000

33200000

0.01

5000000

23300000

26700000

2400000

8300000

10200000

12800000

475000000

419200000

259300000

252400000

20300000

85700000

158800000

77800000

157600000

358900000

142800000

20000000

10400000

25200000

4700000

20500000

12200000

700000

7600000

27800000

1600000

300000

800000

-500000

-1500000

1800000

-700000

-100000

2600000

17700000

100000

7100000

10500000

8400000

100000

5100000

3200000

-1300000

14600000

5600000

-9600000

-2800000

-6800000

737500000

691700000

604200000

1189400000

612200000

1188700000

518500000

407100000

41400000

70000000

1030600000

817300000

80700000

132600000

534400000

408900000

54600000

70900000

1031100000

785200000

109600000

136300000

97400000

192300000

95600000

187800000

4800000

1000000

3800000

9900000

2200000

7700000

5600000

1100000

4500000

10400000

2200000

8200000

200000000

633400000

535100000

21600000

17200000

3200000

900000

2300000

2800000

200000000

327900000

277600000

-20300000

20300000

-100000

-700000

-1200000

-21500000

-1400000

-21700000

29500000

28900000

400000

200000

700000

18900000

18700000

700000

800000

700000

800000

54000000

54900000

52700000

53200000

53300000

54100000

52000000

52400000

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;"> (in millions, except per share data)</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Six Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net income attributable to common stock</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">21.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">39.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">59.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">64.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Weighted average number of shares outstanding, used in computing basic earnings per share</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">52.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">53.3</font></div></td><td style="vertical-align:bottom;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">52.4</font></div></td><td style="vertical-align:bottom;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">54.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Dilutive common stock equivalents</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Weighted average number of shares outstanding used in computing diluted earnings per share</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">52.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">54.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">53.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">54.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Basic earnings per share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.42</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.74</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.14</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.19</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Diluted earnings per share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.41</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.73</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.12</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.17</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Anti-dilutive equity instruments (excluded from the calculation of diluted earnings per share)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net restructuring charges by segment are as follows:</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:495px;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:213px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:122px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:122px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(dollars in millions)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">CRS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12.2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">PC</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">PI</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">    Segment Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">20.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Corporate restructuring charges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">    Total restructuring charges</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">25.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:40%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in millions)</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2015</font></div></td></tr><tr><td colspan="12" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Derivatives not designated as hedging instruments under ASC 815</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Forward share repurchase contract</font></div><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(20.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(20.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Foreign exchange contracts</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total non-designated derivative unrealized loss, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(21.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(21.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in millions)</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June 30, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Notional</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Asset</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Liability)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Notional</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Asset</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Liability)</font></div></td></tr><tr><td colspan="12" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Derivatives designated as hedging instruments under ASC 815</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Derivatives in an asset position:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Interest rate contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">200.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Foreign exchange contracts</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">59.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">81.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Derivatives in a liability position:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Interest rate contracts</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">200.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Foreign exchange contracts</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">95.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(7.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">103.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(8.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total designated derivatives</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">355.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(4.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">384.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(6.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td colspan="16" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Derivatives not designated as hedging instruments under ASC 815</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Derivatives in an asset position:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Foreign exchange contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">108.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">36.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Forward share repurchase contract</font></div><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">200.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">19.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Derivatives in a liability position:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Foreign exchange contracts</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">38.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">48.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total non-designated derivatives</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">346.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">19.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">84.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total derivatives</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">702.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">14.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">468.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(6.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">DERIVATIVES</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are exposed to certain risks relating to our ongoing business operations. The primary risks managed by using derivative instruments are interest rate risk and foreign currency exchange rate risk. Accordingly, we have instituted interest rate and foreign currency hedging programs that are accounted for in accordance with ASC 815. </font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our interest rate hedging program is a cash flow hedge program designed to minimize interest rate volatility. We swap the difference between fixed and variable interest amounts calculated by reference to an agreed-upon notional principal amount, at specified intervals. Our interest rate contracts are designated as hedging instruments. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our foreign currency hedging program is a cash flow hedge program designed to mitigate foreign currency exchange rate volatility due to the foreign currency exchange exposure related to intercompany and significant external transactions. This program also is intended to reduce the impact of foreign exchange rate risk on our direct costs and our service revenues. We primarily utilize forward currency exchange contracts and cross-currency swaps with maturities of no more than 12 months. These contracts are designated as hedging instruments.</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We also enter into other economic hedges to mitigate foreign currency exchange risk related to intercompany and significant external transactions. These contracts are not designated as hedges in accordance with ASC 815. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During three month ended </font><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font><font style="font-family:inherit;font-size:10pt;">, we entered into a forward share repurchase contract in connection with our 2017 accelerated share repurchase program with HSBC. </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents the notional amounts and fair values of our derivatives as of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">June 30, 2016</font><font style="font-family:inherit;font-size:10pt;">. The gross position of all asset and liability amounts is reported in other current assets, other assets, other current liabilities, and other liabilities in our consolidated balance sheets.</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in millions)</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June 30, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Notional</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Asset</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Liability)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Notional</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Asset</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Liability)</font></div></td></tr><tr><td colspan="12" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Derivatives designated as hedging instruments under ASC 815</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Derivatives in an asset position:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Interest rate contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">200.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Foreign exchange contracts</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">59.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">81.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Derivatives in a liability position:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Interest rate contracts</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">200.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Foreign exchange contracts</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">95.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(7.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">103.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(8.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total designated derivatives</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">355.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(4.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">384.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(6.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td colspan="16" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Derivatives not designated as hedging instruments under ASC 815</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Derivatives in an asset position:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Foreign exchange contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">108.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">36.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Forward share repurchase contract</font></div><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">200.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">19.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Derivatives in a liability position:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Foreign exchange contracts</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">38.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">48.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total non-designated derivatives</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">346.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">19.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">84.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total derivatives</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">702.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">14.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">468.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(6.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under certain circumstances, such as the occurrence of significant differences between actual cash payments and forecasted cash payments, the ASC 815 programs could be deemed ineffective. We record the effective portion of any change in the fair value of derivatives designated as hedging instruments under ASC 815 to other accumulated comprehensive loss in our consolidated balance sheets, net of deferred taxes, and any ineffective portion to miscellaneous income (expense), net in our consolidated statements of income. During the </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, we recorded losses of </font><font style="font-family:inherit;font-size:10pt;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, in miscellaneous income (expense), net in our consolidated statements of income to reflect ineffective portions of hedges. During the </font><font style="font-family:inherit;font-size:10pt;">six</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, we recorded losses of </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$1.7 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, in miscellaneous income (expense), net in our consolidated statements of income to reflect ineffective portions of hedges. </font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The amounts recognized in other comprehensive income (loss), net of taxes, are presented below:</font><font style="font-family:inherit;font-size:9pt;"> </font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:40%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in millions)</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Six Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2015</font></div></td></tr><tr><td colspan="12" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Derivatives designated as hedging instruments under ASC 815</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Interest rate contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Foreign exchange contracts</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total designated derivatives</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The unrealized gain (loss) on derivative instruments is net of </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;"> taxes, respectively, for the </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">. The unrealized gain (loss) on derivative instruments is net of </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;"> taxes, respectively, for the six months ended </font><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">.The estimated net amount of the existing losses that are expected to be reclassified into earnings within the next twelve months is </font><font style="font-family:inherit;font-size:10pt;">$6.3 million</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The change in the fair value of derivatives not designated as hedging instruments under ASC 815 is recorded to miscellaneous (expense) income, net in our consolidated statements of income. The total gains and losses related to foreign exchange contracts not designated as hedging instruments were losses of </font><font style="font-family:inherit;font-size:10pt;">$0.9 million</font><font style="font-family:inherit;font-size:10pt;"> and of </font><font style="font-family:inherit;font-size:10pt;">$3.3 million</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, respectively. The total gains and losses related to foreign exchange contracts not designated as hedging instruments were losses of </font><font style="font-family:inherit;font-size:10pt;">$0.8 million</font><font style="font-family:inherit;font-size:10pt;"> and of </font><font style="font-family:inherit;font-size:10pt;">$3.6 million</font><font style="font-family:inherit;font-size:10pt;"> for the six months ended </font><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, respectively. The loss related to the forward share repurchase contract for the three months ended </font><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font><font style="font-family:inherit;font-size:10pt;"> was </font><font style="font-family:inherit;font-size:10pt;">$20.3 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The unrealized losses recognized are presented below:</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:40%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in millions)</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2015</font></div></td></tr><tr><td colspan="12" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Derivatives not designated as hedging instruments under ASC 815</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Forward share repurchase contract</font></div><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(20.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(20.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Foreign exchange contracts</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total non-designated derivative unrealized loss, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(21.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(21.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:9pt;"></font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Contingent consideration</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(5.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(5.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Interest rate derivative instruments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Foreign currency exchange contracts</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(5.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(5.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(6.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(5.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(11.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr></table></div></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Contingent consideration</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(14.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(14.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Forward share repurchase contract</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">19.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">19.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Interest rate derivative instruments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Foreign currency exchange contracts</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(5.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(5.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(4.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">FAIR VALUE MEASUREMENTS</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We apply the provisions of ASC 820, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">“Fair Value Measurements and Disclosures”</font><font style="font-family:inherit;font-size:10pt;"> (“ASC 820”). ASC 820 defines fair value and provides guidance for measuring fair value and expands disclosures about fair value measurements. ASC 820 enables the reader of financial statements to assess the inputs used to develop those measurements by establishing a hierarchy for ranking the quality and reliability of the information used to determine fair value. ASC 820 requires that assets and liabilities carried at fair value be classified and disclosed in one of the following three categories:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 1</font><font style="font-family:inherit;font-size:10pt;"> – Unadjusted quoted prices in active markets that are accessible to the reporting entity at the measurement date for identical assets and liabilities.</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Marketable securities are held in foreign government treasury certificates that are actively traded and have original maturities over 90 days but less than one year. As of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font><font style="font-family:inherit;font-size:10pt;">, we did not hold any marketable securities. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest rate derivative instruments are measured at fair value using a market approach valuation technique. The valuation is based on an estimate of net present value of the expected cash flows using relevant mid-market observable data inputs and based on the assumption of no unusual market conditions or forced liquidation.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 2</font><font style="font-family:inherit;font-size:10pt;"> – Inputs other than quoted prices in active markets for identical assets and liabilities that are observable either directly or indirectly for substantially the full term of the asset or liability. Level 2 inputs include the following:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">◦</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">quoted prices for similar assets and liabilities in active markets</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">◦</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">quoted prices for identical or similar assets or liabilities in markets that are not active</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">◦</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">observable inputs other than quoted prices that are used in the valuation of the asset or liabilities (e.g., interest rate and yield curve quotes at commonly quoted intervals)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">◦</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">inputs that are derived principally from or corroborated by observable market data by, correlation or other means</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 3</font><font style="font-family:inherit;font-size:10pt;"> – Unobservable inputs for the asset or liability (i.e., supported by little or no market activity). Level 3 inputs include management’s own assumptions about the assumptions that market participants would use in pricing the asset or liability (including assumptions about risk).</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth by level, within the fair value hierarchy, our assets (liabilities) carried at fair value as of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Contingent consideration</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(14.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(14.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Forward share repurchase contract</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">19.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">19.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Interest rate derivative instruments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Foreign currency exchange contracts</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(5.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(5.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(4.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth by level, within the fair value hierarchy, our assets (liabilities) carried at fair value as of </font><font style="font-family:inherit;font-size:10pt;">June 30, 2016</font><font style="font-family:inherit;font-size:10pt;">:</font><font style="font-family:inherit;font-size:9pt;"> </font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Contingent consideration</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(5.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(5.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Interest rate derivative instruments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Foreign currency exchange contracts</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(5.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(5.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(6.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(5.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(11.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Level 1 Estimates</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash equivalents are measured at quoted prices in active markets. These investments are considered cash equivalents due to the short maturity (less than 90 days) of the investments.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Level 2 Estimates</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest rate derivative instruments are measured at fair value using a market approach valuation technique. The valuation is based on an estimate of net present value of the expected cash flows using relevant mid-market observable data inputs and based on the assumption of no unusual market conditions or forced liquidation.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign currency exchange contracts are measured at fair value using a market approach valuation technique. The inputs to this technique utilize current foreign currency exchange forward market rates published by leading third-party financial news and data providers. These are observable data that represent the rates that the financial institution uses for contracts entered into at that date; however, they are not based on actual transactions, so they are classified as Level 2.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Level 3 Estimates</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have entered into a forward share repurchase contract in connection with our 2017 accelerated share repurchase program with HSBC. We recorded the </font><font style="font-family:inherit;font-size:10pt;">$160.0 million</font><font style="font-family:inherit;font-size:10pt;"> payment, which represents the 80% of the shares we repurchased, as a decrease to equity in our consolidated balance sheet, consisting of decreases in common stock and additional paid-in capital. As additional paid-in capital was reduced to zero, the remainder was applied as a reduction in retained earnings. The remaining </font><font style="font-family:inherit;font-size:10pt;">$40.0 million</font><font style="font-family:inherit;font-size:10pt;">, which is an advance payment accounted for as a forward share repurchase contract, was recorded as within other current assets within the condensed consolidated balance sheet. The prepaid forward contract was initially valued at the transaction price of </font><font style="font-family:inherit;font-size:10pt;">$40.0 million</font><font style="font-family:inherit;font-size:10pt;">. The forward share repurchase contract was remeasured at fair value with market conditions based on the use of a Monte-Carlo Simulation Model. Increases or decreases in the fair value of our forward contract are primarily impacted by the Company's stock price. During the </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font><font style="font-family:inherit;font-size:10pt;">, the fair value of the forward share repurchase contract decreased by </font><font style="font-family:inherit;font-size:10pt;">$20.3 million</font><font style="font-family:inherit;font-size:10pt;"> from </font><font style="font-family:inherit;font-size:10pt;">$40.0 million</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">$19.7 million</font><font style="font-family:inherit;font-size:10pt;">. The change in fair value of </font><font style="font-family:inherit;font-size:10pt;">$20.3 million</font><font style="font-family:inherit;font-size:10pt;"> was recorded in miscellaneous (expense) income, net.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The recurring Level 3 fair value measurements of our forward share repurchase contract asset include the following significant unobservable inputs:</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:357px;border-collapse:collapse;text-align:left;"><tr><td colspan="2" rowspan="1"></td></tr><tr><td style="width:224px;" rowspan="1" colspan="1"></td><td style="width:133px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Forward Share</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Unobservable Input</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Repurchase Contract</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Risk free rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.6%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Share price volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">37.5</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Contract term</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.4 years</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contingent consideration liabilities are re-measured to fair value each reporting period using projected financial targets, discount rates, probabilities of payment, and projected payment dates. Projected contingent payment amounts are discounted back to the current period using a discounted cash flow model. Projected financial targets are based on our most recent internal operational budgets and may take into consideration alternate scenarios that could result in more or less profitability for the respective service line. Increases or decreases in projected financial targets and probabilities of payment may result in significant changes in the fair value measurements. Increases in discount rates and the time to payment may result in lower fair value measurements. Increases or decreases in any of those inputs in isolation may result in a significantly lower or higher fair value measurement. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2016, we acquired ExecuPharm, Inc. (“ExecuPharm”), a leading global functional service provider, based in Pennsylvania.  ExecuPharm provides clinical monitoring or study management, along with associated operational activities such as onboarding, training, line management, performance management, and policy administration. The purchase price for the ExcuPharm acquisition was approximately </font><font style="font-family:inherit;font-size:10pt;">$148.9 million</font><font style="font-family:inherit;font-size:10pt;">, plus the potential to pay up to an additional </font><font style="font-family:inherit;font-size:10pt;">$20.0 million</font><font style="font-family:inherit;font-size:10pt;"> at the end of a two year period ending June 30, 2018 if ExecuPharm achieves specific financial targets. The contingent consideration related to the ExecuPharm acquisition is measured at fair value with market conditions based on the use of a Monte-Carlo Simulation Model. Increases or decreases in the fair value of our contingent consideration liability is primarily impacted by the likelihood of achieving financial targets, but also by changes in discount periods and rates.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The recurring Level 3 fair value measurements of our contingent consideration liability include the following significant unobservable inputs:</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:82.65107212475633%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:54%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:22%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:22%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Health Advances</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">ExecuPharm</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Unobservable Input</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Range</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Range</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Risk free rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.3%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.7%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Revenue volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">26%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">29%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Projected period of payment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Approximately 2 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Approximately 2 years</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table provides a summary of the change in our valuation of the fair value of the contingent consideration liability, which was determined by Level 3 inputs:</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.66861598440545%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:69%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:3%;" rowspan="1" colspan="1"></td><td style="width:4%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:20%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance at June 30, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additions of contingent consideration due to ExecuPharm acquistion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in fair value of contingent consideration for Health Advances</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance at December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table provides a summary of the change in our valuation of the fair value of the forward share repurchase contract asset, which was determined by Level 3 inputs:</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.66861598440545%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:69%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:3%;" rowspan="1" colspan="1"></td><td style="width:4%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:20%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance at June 30, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additions of forward share repurchase contract</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in fair value of forward share repurchase contract</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(20.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance at December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the </font><font style="font-family:inherit;font-size:10pt;">three and six months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font><font style="font-family:inherit;font-size:10pt;">, there were no transfers among Level 1, Level 2, or Level 3 categories. Additionally, there were no changes in the valuation techniques used to determine the fair values of our Level 2 or Level 3 assets or liabilities. For the </font><font style="font-family:inherit;font-size:10pt;">three and six months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font><font style="font-family:inherit;font-size:10pt;">, the change in the fair value of the contingent consideration for Health Advances, LLC (“Health Advances”) of </font><font style="font-family:inherit;font-size:10pt;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;"> was recorded in selling, general and administrative expense. During the </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font><font style="font-family:inherit;font-size:10pt;">, the fair value of contingent consideration for Health Advances in the amount of </font><font style="font-family:inherit;font-size:10pt;">$4.6 million</font><font style="font-family:inherit;font-size:10pt;"> decreased by </font><font style="font-family:inherit;font-size:10pt;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;"> from </font><font style="font-family:inherit;font-size:10pt;">June 30, 2016</font><font style="font-family:inherit;font-size:10pt;">. For the </font><font style="font-family:inherit;font-size:10pt;">three and six months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">December 31, 2015</font><font style="font-family:inherit;font-size:10pt;">, the change in the fair value of the contingent consideration for ClinIntel Limited ("ClinIntel") of </font><font style="font-family:inherit;font-size:10pt;">$3.2 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$8.2 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, was recorded in selling, general and administrative expense. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, we acquired Health Advances, an independent life sciences strategy consulting firm. Health Advances combines clinical, scientific and business expertise to provide strategic advice to executives leading life sciences companies and investors. The purchase price for the Health Advances acquisition was approximately </font><font style="font-family:inherit;font-size:10pt;">$67.1 million</font><font style="font-family:inherit;font-size:10pt;">, plus the potential to pay up to an additional </font><font style="font-family:inherit;font-size:10pt;">$15.8 million</font><font style="font-family:inherit;font-size:10pt;"> over a thirty-six month period following the acquisition date if Health Advances achieves specific financial targets. The contingent consideration related to the Health Advances acquisition is measured at fair value with market conditions based on the use of a Monte-Carlo Simulation Model. Increases or decreases in the fair value of our contingent consideration liability is primarily impacted by the likelihood of achieving financial targets, but also from changes in discount periods and rates.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2014, we acquired ClinIntel, a provider of clinical randomization and trial supply management services, which are designed to make patient randomization and clinical supply chain solutions more efficient. The purchase price for the ClinIntel acquisition was approximately $8.8 million, plus the potential to pay up to an additional $16.2 million over a twenty-one month period following the acquisition date. To achieve the maximum payment of $16.2 million, billings of $13.4 million in the 21 month period needed to be achieved. As of December 31, 2016, we have no further contingent consideration in connection with this acquisition. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of the debt under the Notes was estimated to be </font><font style="font-family:inherit;font-size:10pt;">$96.5 million</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font><font style="font-family:inherit;font-size:10pt;">, and was determined using U.S. government treasury rates and Level 3 inputs, including a credit risk adjustment. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The carrying value of our current and long-term debt under the 2016 Credit Agreement approximates fair value because all of the debt bears variable-rate interest.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The recurring Level 3 fair value measurements of our contingent consideration liability include the following significant unobservable inputs:</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:82.65107212475633%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:54%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:22%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:22%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Health Advances</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">ExecuPharm</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Unobservable Input</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Range</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Range</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Risk free rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.3%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.7%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Revenue volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">26%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">29%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Projected period of payment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Approximately 2 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Approximately 2 years</font></div></td></tr></table></div></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The recurring Level 3 fair value measurements of our forward share repurchase contract asset include the following significant unobservable inputs:</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:357px;border-collapse:collapse;text-align:left;"><tr><td colspan="2" rowspan="1"></td></tr><tr><td style="width:224px;" rowspan="1" colspan="1"></td><td style="width:133px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Forward Share</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Unobservable Input</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Repurchase Contract</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Risk free rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.6%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Share price volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">37.5</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Contract term</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.4 years</font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table provides a summary of the change in our valuation of the fair value of the forward share repurchase contract asset, which was determined by Level 3 inputs:</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.66861598440545%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:69%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:3%;" rowspan="1" colspan="1"></td><td style="width:4%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:20%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance at June 30, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additions of forward share repurchase contract</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in fair value of forward share repurchase contract</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(20.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance at December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table provides a summary of the change in our valuation of the fair value of the contingent consideration liability, which was determined by Level 3 inputs:</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.66861598440545%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:69%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:3%;" rowspan="1" colspan="1"></td><td style="width:4%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:20%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance at June 30, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additions of contingent consideration due to ExecuPharm acquistion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in fair value of contingent consideration for Health Advances</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance at December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following are the preliminary identifiable intangible assets acquired and their respective estimated useful lives, as determined based on preliminary valuations (dollars in millions):</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:73.68421052631578%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:24%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:31%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Estimated Useful Life (Years)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Customer relationships</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">10</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Technology</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Trade name</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">   Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">15.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">The Medical Affairs Company, LLC </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 1, 2017, the Company entered into a definitive agreement to acquire The Medical Affairs Company, LLC, a leading provider of outsourced medical affairs services to the pharmaceutical, biotechnology, and medical device industries. The acquisition is expected to close during the third quarter of our Fiscal Year 2017.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:96.88109161793372%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:46%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in millions)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Foreign Currency</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized Gain/Loss on Derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;font-weight:bold;">Balance as of June 30, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(130.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(5.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(136.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other comprehensive loss before reclassifications</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(22.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(25.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Loss reclassified from accumulated other comprehensive income</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net current-period other comprehensive (loss) gain</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(22.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(21.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;font-weight:bold;">Balance as of December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(152.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(4.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(157.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:87.13450292397661%;border-collapse:collapse;text-align:left;"><tr><td colspan="11" rowspan="1"></td></tr><tr><td style="width:27%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:34%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Affected Line in the Consolidated Statements of Income </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in millions)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Interest rate contracts</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Interest expense, net</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Foreign exchange contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Service Revenue</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Foreign exchange contracts</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Direct Costs</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:87.13450292397661%;border-collapse:collapse;text-align:left;"><tr><td colspan="11" rowspan="1"></td></tr><tr><td style="width:27%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:34%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Affected Line in the Consolidated Statements of Income </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in millions)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Interest rate contracts</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Interest expense, net</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Foreign exchange contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(4.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Service Revenue</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Foreign exchange contracts</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(4.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Direct Costs</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(5.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(5.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The components of the consideration transferred in conjunction with the Health Advances acquisition and the preliminary allocation of that consideration is as follows (in millions): </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:69.00584795321637%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:26%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total consideration transferred:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">    Cash paid, net of cash acquired</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">67.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">    Fair value of contingent consideration</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Net purchase price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">71.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Preliminary allocation of consideration transferred:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">    Accounts receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">    Other current assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">    Property and equipment, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">    Deferred tax assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">    Definite-lived intangible assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">15.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">    Goodwill</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">52.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">          Total assets acquired</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">73.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">    Current liabilities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">         Total liabilities assumed</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Net assets acquired:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">71.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The components of the consideration transferred in conjunction with the Health Advances acquisition and the preliminary allocation of that consideration is as follows (in millions): </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:69.00584795321637%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:26%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total consideration transferred:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">    Cash paid, net of cash acquired</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">67.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">    Fair value of contingent consideration</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Net purchase price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">71.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Preliminary allocation of consideration transferred:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">    Accounts receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">    Other current assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">    Property and equipment, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">    Deferred tax assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">    Definite-lived intangible assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">15.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">    Goodwill</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">52.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">          Total assets acquired</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">73.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">    Current liabilities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">         Total liabilities assumed</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Net assets acquired:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">71.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:97.46588693957115%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:28%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance at</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Charges/(Benefits)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Payments/Foreign<br clear="none"/>Currency Exchange/Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance at</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June 30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015 Margin Acceleration Program</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Employee severance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">10.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(6.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Facilities-related</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Pre-Fiscal Year 2012 Restructuring Plans</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Facilities-related</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">17.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(9.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in millions)</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Six Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Service revenue</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">CRS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">408.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">407.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">785.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">817.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">PC</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">54.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">41.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">109.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">80.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">PI</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">70.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">70.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">136.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">132.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total service revenue</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">534.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">518.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,031.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,030.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Direct costs</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">CRS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">284.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">274.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">546.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">561.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">PC</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">30.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">20.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">61.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">41.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">PI</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">35.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">37.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">70.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">72.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total direct costs</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">350.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">332.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">678.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">675.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross profit</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">CRS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">124.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">132.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">238.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">255.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">PC</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">23.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">20.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">48.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">39.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">PI</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">35.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">32.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">65.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">59.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total gross profit</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">183.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">186.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">352.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">354.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net restructuring charges by segment are as follows:</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:495px;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:213px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:122px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:122px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(dollars in millions)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">CRS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12.2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">PC</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">PI</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">    Segment Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">20.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Corporate restructuring charges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">    Total restructuring charges</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">25.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SEGMENT INFORMATION</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have three reportable segments: Clinical Research Services (“CRS”), PAREXEL Consulting Services (“PC”), and PAREXEL Informatics (“PI”).</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">CRS constitutes our core business and includes all phases of clinical research from Early Phase (encompassing the early stages of clinical testing that range from first-in-man through proof-of-concept studies) to Phase II-III and Phase IV, which we include in our PAREXEL Access product offering, formerly known as Peri/Post Approval Services. Our services include clinical trials management and biostatistics, commercialization, data management and clinical pharmacology, as well as related medical advisory, patient recruitment, clinical supply and drug logistics, pharmacovigilance, and investigator site services. We aggregate Early Phase and PAREXEL Access with Phase II-III due to economic similarities in these operating segments.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">PC provides technical expertise and advice in such areas as drug development, regulatory affairs, product pricing and reimbursement, commercialization and strategic compliance. It also provides a full spectrum of market development, product development and targeted communication services in support of product launch. Our PC consultants identify alternatives and propose solutions to address client issues associated with product development, registration, and commercialization. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">PI provides information technology solutions designed to help improve clients’ product development and regulatory submission processes. PI offers a portfolio of products and services that includes medical imaging services, ClinPhone</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;"> RTSM, IMPACT</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;"> clinical trials management systems (“CTMS”), DataLabs</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;"> electronic data capture, web-based portals, systems integration, electronic patient-reported outcomes, and LIQUENT InSight® Regulatory Information Management (“RIM”) solutions. </font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We evaluate our segment performance and allocate resources based on service revenue and gross profit (service revenue less direct costs), while other operating costs are allocated and evaluated on a geographic basis. Accordingly, we do not include the impact of selling, general, and administrative expenses, depreciation and amortization expense, other income (expense), and income tax expense in segment profitability. We attribute revenue to individual countries based upon the revenue earned in the respective countries; however, inter-segment transactions are not included in service revenue. Furthermore, we have a global infrastructure supporting our business segments, and therefore assets are not identified by reportable segment.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our segment results were as follows:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in millions)</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Six Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Service revenue</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">CRS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">408.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">407.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">785.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">817.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">PC</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">54.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">41.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">109.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">80.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">PI</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">70.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">70.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">136.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">132.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total service revenue</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">534.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">518.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,031.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,030.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Direct costs</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">CRS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">284.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">274.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">546.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">561.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">PC</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">30.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">20.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">61.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">41.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">PI</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">35.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">37.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">70.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">72.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total direct costs</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">350.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">332.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">678.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">675.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross profit</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">CRS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">124.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">132.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">238.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">255.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">PC</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">23.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">20.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">48.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">39.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">PI</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">35.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">32.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">65.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">59.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total gross profit</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">183.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">186.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">352.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">354.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

EX-101.SCH 8 prxl-20161231.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2105100 - Disclosure - Accumulated Other Comprehensive Income link:presentationLink link:calculationLink link:definitionLink 2403402 - Disclosure - Acquisitions, Goodwill, and Other Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2403403 - Disclosure - Acquisitions, Goodwill, and Other Intangible Assets goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 2403404 - Disclosure - Acquisitions, Goodwill, and Other Intangible Assets intangibles (Details) link:presentationLink link:calculationLink link:definitionLink 2103100 - Disclosure - Acquisitions, Goodwill, and Other Intangible Assets (Notes) link:presentationLink link:calculationLink link:definitionLink 2303301 - Disclosure - Acquisitions, Goodwill, and Other Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - Basis Of Presentation link:presentationLink link:calculationLink link:definitionLink 2401402 - Disclosure - Basis Of Presentation change (Details) link:presentationLink link:calculationLink link:definitionLink 2401401 - Disclosure - Basis Of Presentation (Details) link:presentationLink link:calculationLink link:definitionLink 2401403 - Disclosure - Basis Of Presentation prior period adjustment (Details) link:presentationLink link:calculationLink link:definitionLink 2411403 - Disclosure - Commitments, Contingencies And Guarantees (Details) link:presentationLink link:calculationLink link:definitionLink 2405402 - Disclosure - Comprehensive Income (Schedule Of Comprehensive Income) (Details) link:presentationLink link:calculationLink link:definitionLink 2305301 - Disclosure - Comprehensive Income (Tables) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 1001001 - Statement - Condensed Consolidated Balance Sheets Parenthethical link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - Condensed Consolidated Statements Of Cash Flows link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - Condensed Consolidated Statements Of Cash Flows link:presentationLink link:calculationLink link:definitionLink 1002001 - Statement - Condensed Consolidated Statements of Comprehensive Income link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - Condensed Consolidated Statements Of Income link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - Condensed Consolidated Statements Of Income link:presentationLink link:calculationLink link:definitionLink 2110100 - Disclosure - Credit Agreements link:presentationLink link:calculationLink link:definitionLink 2410402 - Disclosure - Credit Agreements 2014 Credit Agreement (Details) link:presentationLink link:calculationLink link:definitionLink 2410404 - Disclosure - Credit Agreements 2016 Credit Agreement (Details) link:presentationLink link:calculationLink link:definitionLink 2410406 - Disclosure - Credit Agreements 2016 Credit Agreement (Details)1 link:presentationLink link:calculationLink link:definitionLink 2410405 - Disclosure - Credit Agreements 2016 Term Loan Agreement (Details) link:presentationLink link:calculationLink link:definitionLink 2410401 - Disclosure - Credit Agreements (Details) link:presentationLink link:calculationLink link:definitionLink 2410403 - Disclosure - Credit Agreements Master Financing Agreement (Details) link:presentationLink link:calculationLink link:definitionLink 2111100 - Disclosure - Debt, Commitments, Contingencies And Guarantees link:presentationLink link:calculationLink link:definitionLink 2411402 - Disclosure - Debt, Commitments, Contingencies And Guarantees Schedule of Contractual Obligation (Details) link:presentationLink link:calculationLink link:definitionLink 2311301 - Disclosure - Debt, Commitments, Contingencies And Guarantees Schedule of Contractual Obligation (Tables) link:presentationLink link:calculationLink link:definitionLink 2112100 - Disclosure - Derivatives link:presentationLink link:calculationLink link:definitionLink 2412403 - Disclosure - Derivatives (Schedule Of Change In The Fair Value Of Derivatives Designated As Hedging Instruments) (Details) link:presentationLink link:calculationLink link:definitionLink 2412404 - Disclosure - Derivatives (Schedule Of Change In The Fair Value Of Derivatives Not Designated As Hedging Instruments) (Details) link:presentationLink link:calculationLink link:definitionLink 2412402 - Disclosure - Derivatives (Schedule Of Notional Amounts And Fair Values Of Derivatives) (Details) link:presentationLink link:calculationLink link:definitionLink 2312301 - Disclosure - Derivatives (Tables) link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink 2104100 - Disclosure - Equity and Earnings Per Share link:presentationLink link:calculationLink link:definitionLink 2404403 - Disclosure - Equity and Earnings Per Share buyback (Details) link:presentationLink link:calculationLink link:definitionLink 2404402 - Disclosure - Equity and Earnings Per Share (Computation Of Basic And Diluted Earnings Per Common Share) (Details) link:presentationLink link:calculationLink link:definitionLink 2304301 - Disclosure - Equity and Earnings Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2114100 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 2414405 - Disclosure - Fair Value Measurements Fair Value Measurements Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2414404 - Disclosure - Fair Value Measurements Level 3 Rollforward (Details) link:presentationLink link:calculationLink link:definitionLink 2414402 - Disclosure - Fair Value Measurements (Schedule Of Fair Value Hierarchy, Assets (Liabilities) Carried At Fair Value) (Details) link:presentationLink link:calculationLink link:definitionLink 2314301 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 2414403 - Disclosure - Fair Value Measurements Unobservable Inputs (Details) link:presentationLink link:calculationLink link:definitionLink 2413403 - Disclosure - Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 2113101 - Disclosure - Goodwill Goodwill link:presentationLink link:calculationLink link:definitionLink 2113100 - Disclosure - Goodwill (Notes) link:presentationLink link:calculationLink link:definitionLink 2313302 - Disclosure - Goodwill (Tables) link:presentationLink link:calculationLink link:definitionLink 2109100 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 2409401 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 2107100 - Disclosure - Restructuring Charges link:presentationLink link:calculationLink link:definitionLink 2407402 - Disclosure - Restructuring Charges (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2407403 - Disclosure - Restructuring Charges (Schedule Of Charges Against The Restructuring Accrual) (Details) link:presentationLink link:calculationLink link:definitionLink 2307301 - Disclosure - Restructuring Charges (Tables) link:presentationLink link:calculationLink link:definitionLink 2108100 - Disclosure - Segment Information link:presentationLink link:calculationLink link:definitionLink 2408402 - Disclosure - Segment Information (Service Revenue, Direct Costs And Gross Profit On Service Revenue Of Reportable Segment) (Details) link:presentationLink link:calculationLink link:definitionLink 2308301 - Disclosure - Segment Information (Tables) link:presentationLink link:calculationLink link:definitionLink 2106100 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - Stock-Based Compensation (Classification Of Compensation Expense Within Consolidated Statements Of Income) (Details) link:presentationLink link:calculationLink link:definitionLink 2306301 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 2415403 - Disclosure - Subsequent Event (Details) link:presentationLink link:calculationLink link:definitionLink 2115100 - Disclosure - Subsequent Event (Notes) link:presentationLink link:calculationLink link:definitionLink 2115101 - Disclosure - Subsequent Event restructuring (Notes) link:presentationLink link:calculationLink link:definitionLink 2315302 - Disclosure - Subsequent Event (Tables) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 9 prxl-20161231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 10 prxl-20161231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 11 prxl-20161231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Business Combinations [Abstract] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Business Acquisition [Axis] Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Health Advances Acquisition [Member] Health Advances Acquisition [Member] Health Advances Acquisition [Member] ExecuPharm Inc. [Member] ExecuPharm Inc. [Member] ExecuPharm Inc. [Member] [Member] Class of Stock [Axis] Class of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] Business Acquisition [Line Items] Business Acquisition [Line Items] Fair Value Assumptions, Weighted Average Volatility Rate Fair Value Assumptions, Weighted Average Volatility Rate Schedule of Recognized Identified Assets Acquired and Liabilities Assumed Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block] Summary of Derivative Instruments by Hedge Designation [Abstract] Derivatives Derivative Instruments and Hedging Activities Disclosure [Text Block] Restructuring Charges [Abstract] Schedule of Restructuring and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] Consolidation Items [Axis] Consolidation Items [Axis] Consolidation Items [Domain] Consolidation Items [Domain] Operating Segments [Member] Operating Segments [Member] Corporate, Non-Segment [Member] Corporate, Non-Segment [Member] Segments [Axis] Segments [Axis] Segments [Domain] Segments [Domain] CRS [Member] CRS [Member] CRS [Member] PC [Member] PC [Member] PC [Member] PI [Member] PI [Member] PI [Member] Restructuring and Related Cost, by Type of Restructuring [Axis] Restructuring Type [Axis] Type of Restructuring [Domain] Type of Restructuring [Domain] Two Thousand Fifteen Restructuring Plan [Member] [Domain] Two Thousand Fifteen Restructuring Plan [Member] [Domain] Two Thousand Fifteen Restructuring Plan [Member] [Domain] Two Thousand Eleven Restructuring Plan [Member] Two Thousand Eleven Restructuring Plan [Member] Two Thousand Eleven Restructuring Plan [Member] Restructuring Cost [Axis] Restructuring Cost [Axis] Information by type of restructuring cost. Restructuring Cost [Domain] Restructuring Cost [Domain] Restructuring Cost [Domain] Employee Severance [Member] Employee Severance [Member] Facilities-Related Charges [Member] Facilities Related Charges [Member] Facilities Related Charges [Member] Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Balance at June 30, 2013 Restructuring Reserve Provisions/Adjustments Restructuring Charges Payments/Foreign Currency Exchange Payments for Restructuring Balance at September 30, 2013 Restructuring Reserve, Translation Adjustment Restructuring Reserve, Foreign Currency Translation Gain (Loss) 2014 Credit Agreement [Abstract] 2014 Credit Agreement [Abstract] Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Derivative Instrument [Axis] Derivative Instrument [Axis] Derivative Contract [Domain] Derivative Contract [Domain] Interest Rate Swap [Member] Interest Rate Swap [Member] Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] 2016 Credit Agreement [Member] 2016 Credit Agreement [Member] 2016 Credit Agreement [Member] 2014 Credit Agreement [Member] 2014 Credit Agreement [Member] 2014 Credit Agreement [Member] Senior Notes due in 2020 [Member] Senior Notes due in 2020 [Member] Senior Notes due in 2020 [Member] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Term Loan [Member] Term Loan [Member] Term Loan [Member] 2013 Credit Agreement [Member] 2013 Credit Agreement [Member] 2013 Credit Agreement Swingline Loan [Member] Swingline Loan [Member] Swingline Loan Revolving Credit Facility [Member] Revolving Credit Facility [Member] Senior Notes [Member] Senior Notes [Member] Variable Rate [Axis] Variable Rate [Axis] Variable Rate [Domain] Variable Rate [Domain] LIBOR Plus Margin [Member] LIBOR Plus Margin [Member] LIBOR Plus Margin [Member] Federal Funds Plus Margin [Member] Federal Funds Plus Margin [Member] Federal Funds Plus Margin [Member] One Month LIBOR Plus Rate [Member] One Month LIBOR Plus Rate [Member] One Month LIBOR Plus Rate [Member] One Month LIBOR Plus Margin [Member] One Month LIBOR Plus Margin [Member] One Month LIBOR Plus Margin [Member] Debt Instrument, Redemption, Period [Axis] Debt Instrument, Redemption, Period [Axis] Debt Instrument, Redemption, Period [Domain] Debt Instrument, Redemption, Period [Domain] Debt Instrument, Redemption, Period One [Member] Debt Instrument, Redemption, Period One [Member] Debt Instrument, Redemption, Period Two [Member] Debt Instrument, Redemption, Period Two [Member] Debt Instrument, Redemption, Period Three [Member] Debt Instrument, Redemption, Period Three [Member] Debt Instrument, Redemption, Period Four [Member] Debt Instrument, Redemption, Period Four [Member] Debt Instrument [Line Items] Debt Instrument [Line Items] Line of Credit Facility, Remaining Borrowing Capacity Line of Credit Facility, Remaining Borrowing Capacity Long-term Debt Long-term Debt Deferred Finance Costs, Noncurrent, Net Debt Issuance Costs, Noncurrent, Net Long-term Line of Credit Long-term Line of Credit Credit facility, maximum borrowing capacity Credit facility, maximum borrowing capacity Credit facility, maximum borrowing capacity under term loan and revolver combined Line of Credit Facility, Current Borrowing Capacity Line of Credit Facility, Current Borrowing Capacity Term Loan, Quarterly Principal Payment Percentage Term Loan, Quarterly Principal Payment Percentage Term Loan, Quarterly Principal Payment Percentage Letters of Credit, maximum issuance amount Letters of Credit, maximum issuance amount The total amount of the contingent obligations allowed to issue under letters of credit as of the reporting date Debt Instrument, Basis Spread on Variable Rate Debt Instrument, Basis Spread on Variable Rate Debt Instrument, Face Amount Debt Instrument, Face Amount Line of Credit Facility, Unused Capacity, Commitment Fee Percentage Line of Credit Facility, Unused Capacity, Commitment Fee Percentage Amount Of Debt Hedged By Interest Rate Derivatives Amount Of Debt Hedged By Interest Rate Derivatives Amount of debt hedged by interest rate derivatives. Derivative, Fixed Interest Rate Derivative, Fixed Interest Rate Long-term Debt, Gross Long-term Debt, Gross Debt Instrument, Interest Rate, Stated Percentage Debt Instrument, Interest Rate, Stated Percentage Document And Entity Information [Abstract] Document and Entity Information [Abstract] Document Information [Table] Document Information [Table] Document Information, Document [Axis] Document Information, Document [Axis] Document [Domain] Document [Domain] Document Information [Line Items] Document Information [Line Items] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Statement of Cash Flows [Abstract] Statement [Table] Statement [Table] ClinIntel Acquisition [Member] ClinIntel Acquisition [Member] ClinIntel Acquisition [Member] Balance Sheet [Axis] Scenario [Axis] Scenario, Unspecified [Domain] Scenario, Unspecified [Domain] Statement [Line Items] Statement [Line Items] Cash flow from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Net Income (Loss) Attributable to Parent Depreciation and amortization Depreciation, Depletion and Amortization Share-based Compensation Share-based Compensation Excess Tax Benefit from Share-based Compensation, Operating Activities Excess Tax Benefit from Share-based Compensation, Operating Activities Provision for Other Credit Losses Provision for Other Credit Losses Deferred income taxes Increase (Decrease) in Deferred Income Taxes Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Other Noncash (Income) Expense Other Noncash Income (Expense) Changes in operating assets and liabilities Increase (Decrease) in Operating Capital Net cash provided by (used in) operating activities: Net Cash Provided by (Used in) Operating Activities Cash flow from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Payments to Acquire Businesses, Net of Cash Acquired Payments to Acquire Businesses, Net of Cash Acquired Payments to Acquire Marketable Securities Payments to Acquire Marketable Securities Proceeds from Sale and Maturity of Marketable Securities Proceeds from Sale and Maturity of Marketable Securities Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Proceeds from Sale of Property, Plant, and Equipment Proceeds from Sale of Property, Plant, and Equipment Proceeds from Collection of Notes Receivable Proceeds from Collection of Notes Receivable Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Cash flow from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] (Payments) proceeds from issuance of common stock Proceeds from Issuance of Common Stock Payments for Repurchase of Common Stock Payments for Repurchase of Common Stock Excess Tax Benefit from Share-based Compensation, Financing Activities Excess Tax Benefit from Share-based Compensation, Financing Activities business combination, contingent consideration arrangement, payment business combination, contingent consideration arrangement, payment business combination, contingent consideration arrangement, payment Borrowing under credit agreement/facility Proceeds from Lines of Credit Repayments of Lines of Credit Repayments of Lines of Credit Proceeds under factoring agreement Proceeds under factoring agreement Proceeds received from factoring agreement for sales of accounts receivable did not meet revenue recognition criterion. Payments of Financing Costs Payments of Financing Costs Net cash (used in) provided by financing activities Net Cash Provided by (Used in) Financing Activities Effect of exchange rate changes on cash and cash equivalents Effect of Exchange Rate on Cash and Cash Equivalents Net increase (decrease) in cash and cash equivalents Cash and Cash Equivalents, Period Increase (Decrease) Cash and cash equivalents at beginning of period Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents at end of period Supplemental disclosures of cash flow information Supplemental Cash Flow Information [Abstract] Capital expenditure paid but incurred in prior periods Capital expenditure paid but incurred in prior periods Capital expenditure paid but incurred in prior periods Non-cash debt settlement under factoring agreement Non-cash Debt Settlement Under Factoring Arrangement Non-cash Debt Settlement Under Factoring Arrangement Interest Interest Paid, Net Income taxes, net of refunds Income Taxes Paid, Net Earnings Per Share [Abstract] Equity and Earnings Per Share Earnings Per Share [Text Block] Accounting Policies [Abstract] New Accounting Pronouncements or Change in Accounting Principle [Table] New Accounting Pronouncements or Change in Accounting Principle [Table] Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Additional Paid-in Capital [Member] Additional Paid-in Capital [Member] New Accounting Pronouncements or Change in Accounting Principle [Line Items] New Accounting Pronouncements or Change in Accounting Principle [Line Items] Employee Service Share-based Compensation, Tax Benefit Realized from Exercise of Stock Options Employee Service Share-based Compensation, Tax Benefit Realized from Exercise of Stock Options Acquisitions, Goodwill, and Other Intangible Assets Business Combination Disclosure [Text Block] Debt Disclosure [Abstract] Schedule of Short-term Debt [Table] Schedule of Short-term Debt [Table] Short-term Debt, Type [Axis] Short-term Debt, Type [Axis] Short-term Debt, Type [Domain] Short-term Debt, Type [Domain] 2016 Term Loan Agreement [Member] 2016 Term Loan Agreement [Member] 2016 Term Loan Agreement [Member] Short-term Debt [Line Items] Short-term Debt [Line Items] Derivative Instruments, Gain (Loss) by Hedging Relationship, by Income Statement Location, by Derivative Instrument Risk [Table] Derivative Instruments, Gain (Loss) [Table] Derivative, by Nature [Axis] Derivative, Name [Domain] Forward Contracts [Member] Forward Contracts [Member] Foreign Exchange Contracts [Member] Foreign Exchange Contract [Member] Cross-Currency Interest Rate Swap Contracts [Member] Cross Currency Interest Rate Contract [Member] Derivative Instruments, Gain (Loss) by Hedging Relationship [Axis] Hedging Relationship [Axis] Hedging Relationship [Domain] Hedging Relationship [Domain] Derivatives Not Designated As Hedging Instruments [Member] Not Designated as Hedging Instrument [Member] Derivative Instruments, Gain (Loss) [Line Items] Derivative Instruments, Gain (Loss) [Line Items] Unrealized Gain (Loss) on Derivatives Unrealized Gain (Loss) on Derivatives Unrealized Gain (Loss) on Derivatives and Commodity Contracts Unrealized Gain (Loss) on Derivatives and Commodity Contracts Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net Fair value of derivatives not designated as hedging instruments Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net Unrealized Gain on Foreign Currency Derivatives, before Tax Unrealized Gain on Foreign Currency Derivatives, before Tax Fair Value Disclosures [Abstract] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Financial Instrument [Axis] Financial Instrument [Axis] Financial Instruments [Domain] Financial Instruments [Domain] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Selling, General And Administrative [Member] Selling, General and Administrative Expenses [Member] Liability Class [Axis] Liability Class [Axis] Fair Value by Liability Class [Domain] Fair Value by Liability Class [Domain] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value Assumptions, Expected Term Fair Value Assumptions, Expected Term Fair Value Inputs, Discount Rate Fair Value Inputs, Discount Rate Fair Value, Measurement Inputs, Disclosure [Text Block] Fair Value, Measurement Inputs, Disclosure [Text Block] Accelerated Share Repurchases, Cash or Stock Settlement Accelerated Share Repurchases, Cash or Stock Settlement Contingent Consideration [Roll Forward] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Balance at June 30, 2015 Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value Additions of contingent consideration due to Health Advances acquisition Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases Change in fair value of contingent consideration EX-101.PRE 12 prxl-20161231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 13 R1.htm IDEA: XBRL DOCUMENT

Document And Entity Information - shares	6 Months Ended
Document And Entity Information - shares	Dec. 31, 2016	Feb. 06, 2017
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Dec. 31, 2016
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	Q2
Entity Registrant Name	PAREXEL INTERNATIONAL CORP
Entity Central Index Key	0000799729
Current Fiscal Year End Date	--06-30
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		50,954,585

XML 14 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets - USD ($) $ in Millions	Dec. 31, 2016	Jun. 30, 2016
ASSETS
Cash and cash equivalents	$ 252.4	$ 248.6
Billed and unbilled accounts receivable, net	640.5	506.1
Unbilled Receivables, Current	277.6	327.9
Prepaid expenses	26.7	23.3
Income taxes receivable	17.3	25.2
Other current assets	59.6	50.1
Total current assets	1,274.1	1,181.2
Property and equipment, net	252.4	259.3
Goodwill	441.0	389.2
Other intangible assets, net	203.6	130.7
Non-current deferred tax assets	27.4	27.1
Long-term income taxes receivable	9.9	10.4
Other assets	38.0	38.3
Total assets	2,246.4	2,036.2
LIABILITIES AND STOCKHOLDERS' EQUITY
Notes payable and current portion of long-term debt	20.8	16.6
Accounts payable	102.4	62.6
Deferred revenue	453.7	420.2
Accrued expenses	36.3	35.0
Restructuring Reserve, Current	5.6	14.6
Accrued employee benefits and withholdings	137.9	176.4
Taxes Payable, Current	17.2	21.6
Other current liabilities	27.4	22.4
Total current liabilities	801.3	769.4
Long-term debt, net of current portion	756.9	484.8
Non-current deferred tax liabilities	16.9	19.3
Long-term income tax liabilities	30.9	31.5
Long-term deferred revenue	37.3	38.3
Other liabilities	68.0	59.5
Total liabilities	1,711.3	1,402.8
Stockholders' equity:
Preferred stock	0.0	0.0
Common stock	0.5	0.5
Additional paid-in capital	0.0	31.4
Retained earnings	691.7	737.5
Accumulated other comprehensive (loss) income	(157.1)	(136.0)
Total stockholders' equity	535.1	633.4
Total liabilities and stockholders' equity	$ 2,246.4	$ 2,036.2

XML 15 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets Parenthethical - $ / shares	Dec. 31, 2016	Jun. 30, 2016
Preferred Stock, Par or Stated Value Per Share	$ 0.01	$ 0.01
Preferred Stock, Shares Authorized	5,000,000	5,000,000
Preferred Stock, Shares Outstanding	0	0
Common Stock, Par or Stated Value Per Share	$ 0.01	$ 0.01
Common Stock, Shares Authorized	150,000,000	150,000,000
Common Stock, Shares, Outstanding	50,900,000	52,900,000

XML 16 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements Of Income - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2016	Dec. 31, 2015
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax	$ (26,000)	$ (12,200)	$ (22,200)	$ (27,200)
Revenues [Abstract]
Service revenue	534,400	518,500	1,031,100	1,030,600
Reimbursement revenue	77,800	85,700	157,600	158,800
Total revenue	612,200	604,200	1,188,700	1,189,400
Costs and Expenses [Abstract]
Direct costs	350,900	332,500	678,600	675,700
Reimbursable out-of-pocket expenses	77,800	85,700	157,600	158,800
Selling, general and administrative	95,600	97,400	187,800	192,300
Depreciation	19,100	17,900	38,400	35,900
Amortization of Intangible Assets	7,200	5,700	12,700	11,400
Restructuring charge (benefit)		10,400	300	25,200
Total costs and expenses	552,200	549,600	1,075,400	1,099,300
Income from operations	60,000	54,600	113,300	90,100
Interest Income (Expense), Net	(2,800)	(2,100)	(5,400)	(3,700)
Miscellaneous income (expense)	(17,700)	(100)	(18,500)	1,700
Total other income (expense)	(20,500)	(2,200)	(23,900)	(2,000)
Income before income taxes	39,500	52,400	89,400	88,100
Provision for income taxes	17,700	13,000	29,800	23,800
Net income	$ 21,800	$ 39,400	$ 59,600	$ 64,300
Earnings per common share
Basic	$ 0.42	$ 0.74	$ 1.14	$ 1.19
Diluted	$ 0.41	$ 0.73	$ 1.12	$ 1.17
Shares used in computing earnings per common share
Basic	52,000	53,300	52,400	54,100
Diluted	52,700	54,000	53,200	54,900

XML 17 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Comprehensive Income - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2016	Dec. 31, 2015
Net Income (Loss) Attributable to Parent	$ 21,800	$ 39,400	$ 59,600	$ 64,300
Unrealized gain (loss) on derivative instruments, net of taxes	(1,100)	(100)	1,100	(2,200)
Foreign currency translation adjustment	(26,000)	(12,200)	(22,200)	(27,200)
Total comprehensive income (loss)	$ (5,300)	$ 27,100	$ 38,500	$ 34,900

XML 18 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements Of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Cash flow from operating activities:
Net Income (Loss) Attributable to Parent	$ 59,600	$ 64,300
Depreciation and amortization	51,100	47,300
Share-based Compensation	10,400	9,900
Excess Tax Benefit from Share-based Compensation, Operating Activities	0	(2,700)
Provision for Other Credit Losses	20,300	0
Deferred income taxes	(1,500)	(7,100)
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings	(600)	8,200
Other Noncash (Income) Expense	100	(100)
Changes in operating assets and liabilities	(27,900)	(34,100)
Net cash provided by (used in) operating activities:	111,500	85,700
Cash flow from investing activities:
Payments to Acquire Businesses, Net of Cash Acquired	(148,300)	0
Purchases of property and equipment	(33,200)	(53,300)
Net cash used in investing activities	(181,500)	(53,300)
Cash flow from financing activities:
(Payments) proceeds from issuance of common stock	12,800	10,200
Payments for Repurchase of Common Stock	(200,000)	(200,000)
Excess Tax Benefit from Share-based Compensation, Financing Activities	0	2,700
Borrowing under credit agreement/facility	419,200	475,000
Repayments of Lines of Credit	(142,800)	(358,900)
Net cash (used in) provided by financing activities	89,200	(71,000)
Effect of exchange rate changes on cash and cash equivalents	(15,400)	(14,800)
Net increase (decrease) in cash and cash equivalents	3,800	(53,400)
Cash and cash equivalents at beginning of period	248,600	207,400
Cash and cash equivalents at end of period	252,400	154,000
Supplemental disclosures of cash flow information
Capital expenditure paid but incurred in prior periods	4,700	6,300
Interest	8,800	5,400
Income taxes, net of refunds	$ 22,500	$ 9,000

XML 19 R7.htm IDEA: XBRL DOCUMENT

Basis Of Presentation	6 Months Ended
Basis Of Presentation	Dec. 31, 2016
Basis Of Presentation [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	BASIS OF PRESENTATION The accompanying unaudited condensed consolidated financial statements of PAREXEL International Corporation (“PAREXEL,” the “Company,” “we,” “our” or “us”) have been prepared in accordance with generally accepted accounting principles ("GAAP") for interim financial information in the United States and the instructions of Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and notes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (primarily consisting of normal recurring adjustments) considered necessary for a fair presentation of the Company’s financial position as of December 31, 2016 and, results of operations for the three and six months ended December 31, 2016 and 2015 have been included. Operating results for the three and six months ended December 31, 2016 are not necessarily indicative of the results that may be expected for other quarters or the entire fiscal year. For further information, refer to the audited consolidated financial statements and footnotes thereto included in our Annual Report on Form 10-K for the fiscal year ended June 30, 2016 (the “2016 10-K”) filed with the Securities and Exchange Commission on September 9, 2016. In the three and six month periods ended December 31, 2016, we recorded $2.4 million and $8.3 million, respectively, of adjustments related to revenue arrangements recognized in prior periods. The adjustments were recorded as reductions to service revenues in the consolidated statements of income and comprehensive income for the three and six months ended December 31, 2016. We concluded that the effect of these errors was not material to our consolidated financial statements for the current period, or any of the prior periods and, as such, these consolidated financial statements are not materially misstated. Recently Issued Accounting Standards In May 2014, the FASB issued ASU No. 2014-09 (“ASU 2014-09”), Revenue from Contracts with Customers (Topic 606), which provides that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve this core principle, an entity should apply the following steps: (1) identify the contract(s) with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when (or as) the entity satisfies a performance obligation. As originally issued, ASU 2014-09 will be effective prospectively for fiscal years and interim periods within those years beginning after December 15, 2016. On July 9, 2015, the FASB approved the proposal to defer the effective date of this standard by one year. Early adoption is permitted for annual periods beginning after December 16, 2016. The Company will adopt ASU 2014-09 effective July 1, 2018. We are assessing the impact of adopting ASU 2014-09 on our consolidated financial statements. Subsequent to issuing ASU 2014-09, the FASB issued the following amendments concerning clarification of ASU 2014-09. In March 2016, the FASB issued ASU No. 2016-08 (“ASU 2016-08”), Revenue from Contracts with Customers (Topic 606), Principal versus Agent Considerations (Reporting Revenue Gross versus Net), which further clarifies the implementation guidance on principal versus agent considerations. The new guidance requires either a retrospective or a modified retrospective approach to adoption. In April 2016, the FASB issued ASU No. 2016-10, (“ASU 2016-10”) Revenue from Contracts with Customers (Topic 606), Identifying Performance Obligations and Licensing, which clarifies the identification of performance obligations and the licensing implementation guidance, while retaining the related principles for those areas. In May 2016, the FASB issued ASU No. 2016-12 (“ASU 2016-12”), Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients, which provides clarification on assessing the collectability criterion, presentation of sales taxes, measurement date for noncash consideration and completed contracts at transition. We are currently evaluating the impact these ASUs will have on our consolidated financial statements. In January 2016, the FASB issued ASU No. 2016-01 (“ASU 2016-01”), Financial Instruments—Overall (Subtopic 825-10)Recognition and Measurement of Financial Assets and Financial Liabilities. This ASU is intended to provide users of financial statements with more useful information on the recognition, measurement, presentation, and disclosure of financial instruments. ASU 2016-01 is effective for fiscal years beginning after December 15, 2017, with early adoption permitted. We are assessing the impact of adopting ASU No. 2016-01 on our consolidated financial statements. In February 2016, the FASB issued ASU No. 2016-02 (“ASU 2016-02”), Leases (Topic 842) Section A-Leases: Amendments to the FASB Accounting Standards Codification® Section B-Conforming Amendments Related to Leases: Amendments to the FASB Accounting Standards Codification® Section C-Background Information and Basis for Conclusions. This ASU requires an entity that leases assets to recognize on the balance sheet the assets and liabilities for the rights and obligations created by those leases. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, with early adoption permitted. We are assessing the impact of adopting ASU 2016-02 on our consolidated financial statements. In March 2016, the FASB issued ASU No. 2016-05 (“ASU 2016-05”), Derivatives and Hedging (Topic 815): Effect of Derivative Contract Novations on Existing Hedge Accounting Relationships (a Consensus of the Emerging Issues Task Force). This ASU clarifies that a change in the counterparty to a derivative instrument that has been designated as the hedging instrument under Topic 815 does not, in and of itself, require dedesignation of that hedging relationship provided that all other hedge accounting criteria continue to be met. ASU 2016-05 is effective for fiscal years beginning after December 15, 2016, with early adoption permitted. We are assessing the impact of adopting ASU 2016-05 on our consolidated financial statements. Recently Adopted Accounting Standards In the first quarter of our fiscal year ending June 30, 2017, the Company adopted ASU No. 2014-12 (“ASU 2014-12”), Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved After the Requisite Service Period. ASU 2014-12 requires that a performance target that affects vesting and could be achieved after the requisite service period be treated as a performance condition. A reporting entity should apply existing guidance in Accounting Standards Codification (“ASC”) 718, Compensation—Stock Compensation, as it relates to such awards. ASU 2014-12 permits using either of two methods: (i) prospective to all awards granted or modified after the effective date; or (ii) retrospective to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or modified awards thereafter, with the cumulative effect of applying ASU 2014-12 as an adjustment to the opening retained earnings balance as of the beginning of the earliest annual period presented in the financial statements. The adoption of this ASU did not have a material impact on our consolidated financial statements. In the first quarter of our fiscal year ending June 30, 2017, the Company adopted ASU No. 2015-16 (“ASU 2015-16”), Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments. This ASU requires adjustments to provisional amounts that are identified during the measurement period of a business combination to be recognized in the reporting period in which the adjustment amounts are determined. Acquirers are no longer required to revise comparative information for prior periods as if the accounting for the business combination had been completed as of the acquisition date. The adoption of this ASU did not have a material impact on our consolidated financial statements. In the first quarter of our fiscal year ending June 30, 2017, the Company adopted ASU No. 2015-03 (“ASU 2015-03”), Simplifying the Presentation of Debt Issuance Costs. ASU 2015-03 requires the presentation of debt issue costs in the consolidated balance sheets as a reduction to the related debt liability rather than as an asset. Amortization of debt issuance costs continues to be classified as interest expense. The adoption of this ASU did not have a material impact on our consolidated financial statements. In the first quarter of our fiscal year ending June 30, 2017, the Company adopted ASU No. 2016-09 (“ASU 2016-09”), Compensation-Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. This ASU simplifies the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The following summarizes the effects of the adoption on the Company's unaudited condensed consolidated financial statements: Income taxes - Upon adoption of this standard, all excess tax benefits and tax deficiencies (including tax benefits of dividends on share-based payment awards) are recognized as income tax expense or benefit in the income statement. The tax effects of exercised or vested awards are treated as discrete items in the reporting period in which they occur. The Company also recognizes excess tax benefits regardless of whether the benefit reduces taxes payable in the current period. As a result, the Company recognized discrete adjustments to income tax expense for six months ended December 31, 2016, in the amount of $2.3 million related to excess tax benefits. The Company has applied the modified retrospective adoption approach beginning in Fiscal Year 2017. This cumulative-effect adjustment related to tax assets that had previously arisen from tax deductions for equity compensation expenses that were greater than the compensation recognized for financial reporting. These assets had been excluded from the deferred tax assets and liabilities totals on the balance sheet as a result of certain realization requirements previously included in ASC 718. Prior periods have not been adjusted. Forfeitures - Prior to adoption, share-based compensation expense was recognized on a straight line basis, net of estimated forfeitures, such that expense was recognized only for share-based awards that are expected to vest. A forfeiture rate was estimated annually and revised, if necessary, in subsequent periods if actual forfeitures differed from initial estimates. Upon adoption, the Company will no longer apply a forfeiture rate and instead will account for forfeitures as they occur. As we previously estimated forfeitures to determine stock-based compensation expense, this change resulted in a cumulative-effect adjustment as of July 1, 2016 to reduce retained earnings by $0.6 million. Statements of Cash Flows - The Company historically accounted for excess tax benefits on the Statement of Cash Flows as a financing activity. Upon adoption of this standard, excess tax benefits are classified as an operating activity. The Company has elected to adopt this portion of the standard on a prospective basis beginning in Fiscal Year 2017. Prior periods have not been adjusted. Earnings Per Share - The Company uses the treasury stock method to compute diluted earnings per share, unless the effect would be anti-dilutive. Under this method, the Company will no longer be required to estimate the tax rate and apply it to the dilutive share calculation for determining the dilutive earnings per share. The Company has applied this methodology beginning in Fiscal Year 2017, and prior periods have not been adjusted. Upon adoption, no other aspects of ASU 2016-09 had a material effect on the Company's unaudited condensed consolidated financial statements or related footnote disclosures.

XML 20 R8.htm IDEA: XBRL DOCUMENT

Equity and Earnings Per Share

6 Months Ended

Dec. 31, 2016

Earnings Per Share [Abstract]

Equity and Earnings Per Share

EQUITY AND EARNINGS PER SHARE

We have authorized 5.0 million shares of preferred stock at $0.01 par value. As of December 31, 2016 and June 30, 2016, we had no shares of preferred stock issued and outstanding.



(in millions, except per share data)	Three Months Ended				Six Months Ended
	December 31, 2016		December 31, 2015		December 31, 2016		December 31, 2015
Net income attributable to common stock	$	21.8	$	39.4	$	59.6	$	64.3
Weighted average number of shares outstanding, used in computing basic earnings per share	52.0		53.3		52.4		54.1
Dilutive common stock equivalents	0.7		0.7		0.8		0.8
Weighted average number of shares outstanding used in computing diluted earnings per share	52.7		54.0		53.2		54.9
Basic earnings per share	$	0.42	$	0.74	$	1.14	$	1.19
Diluted earnings per share	$	0.41	$	0.73	$	1.12	$	1.17
Anti-dilutive equity instruments (excluded from the calculation of diluted earnings per share)	0.6		1.4		0.8		1.2

Share Repurchase Plan

Fiscal Year 2017 Share Repurchase

Fiscal Year 2016 Share Repurchase

XML 21 R9.htm IDEA: XBRL DOCUMENT

Accumulated Other Comprehensive Income

6 Months Ended

Dec. 31, 2016

Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]

Comprehensive Income

COMPREHENSIVE INCOME (LOSS)

The following table reflects the activity for the components of accumulated other comprehensive income (loss), net of tax, for the six months ended December 31, 2016:



(in millions)	Foreign Currency			Unrealized Gain/Loss on Derivatives			Total
Balance as of June 30, 2016	$	(130.5	)	$	(5.5	)	$	(136.0	)
Other comprehensive loss before reclassifications	(22.2		)	(3.6		)	(25.8		)
Loss reclassified from accumulated other comprehensive income	—			4.7			4.7
Net current-period other comprehensive (loss) gain	$	(22.2	)	$	1.1		$	(21.1	)
Balance as of December 31, 2016	$	(152.7	)	$	(4.4	)	$	(157.1	)



	Three Months Ended						Affected Line in the Consolidated Statements of Income
(in millions)	December 31, 2016			December 31, 2015			Affected Line in the Consolidated Statements of Income
Interest rate contracts	$	(0.2	)	$	(0.1	)	Interest expense, net
Foreign exchange contracts	(2.1		)	(0.2		)	Service Revenue
Foreign exchange contracts	(0.7		)	(1.8		)	Direct Costs
Total	$	(3.0	)	$	(2.1	)



	Six Months Ended						Affected Line in the Consolidated Statements of Income
(in millions)	December 31, 2016			December 31, 2015			Affected Line in the Consolidated Statements of Income
Interest rate contracts	$	(0.2	)	$	(0.3	)	Interest expense, net
Foreign exchange contracts	(4.8		)	(0.4		)	Service Revenue
Foreign exchange contracts	(0.8		)	(4.6		)	Direct Costs
Total	$	(5.8	)	$	(5.3	)

- Definition

The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e689-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=66004124&loc=SL7669619-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e640-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e716-108580

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e709-108580

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e637-108580

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e681-108580

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Reclassification Adjustments
-URI http://asc.fasb.org/extlink&oid=6522872

+ Details

XML 22 R10.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation

6 Months Ended

Dec. 31, 2016

Share-based Compensation, Allocation and Classification in Financial Statements [Abstract]

Stock-Based Compensation

STOCK-BASED COMPENSATION



(in millions)	Three Months Ended				Six Months Ended
	December 31, 2016		December 31, 2015		December 31, 2016		December 31, 2015
Direct costs	$	1.1	$	1.0	$	2.2	$	2.2
Selling, general and administrative	4.5		3.8		8.2		7.7
Total stock-based compensation	$	5.6	$	4.8	$	10.4	$	9.9

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References + Details

XML 23 R11.htm IDEA: XBRL DOCUMENT

Restructuring Charges

6 Months Ended

Dec. 31, 2016

Restructuring Charges [Abstract]

Restructuring and Related Activities Disclosure [Text Block]

Net restructuring charges by segment are as follows:



	Six Months Ended
(dollars in millions)	December 31, 2016			December 31, 2015
CRS	$	(0.7	)	$	12.2
PC	(0.1		)	0.7
PI	2.6			7.6
Segment Total	1.8			20.5
Corporate restructuring charges	(1.5		)	4.7
Total restructuring charges	$	0.3		$	25.2

2017 Restructuring Plan

In Fiscal Years 2015 and 2016, we recorded restructuring charges of $20.0 million and $27.8 million, respectively. In the first quarter of Fiscal Year 2017, we recorded a benefit of $1.3 million, while in the second quarter of Fiscal Year 2017, we recorded a restructuring charge of $1.6 million related to the Margin Acceleration Program.

Changes in the restructuring accrual during the first six months of Fiscal Year 2016 are summarized below:



	Balance at		Charges/(Benefits)			Payments/Foreign Currency Exchange/Other			Balance at
	June 30, 2016		Charges/(Benefits)			Payments/Foreign Currency Exchange/Other			December 31, 2016
2015 Margin Acceleration Program
Employee severance	$	10.5	$	(0.5	)	$	(6.8	)	$	3.2
Facilities-related	7.1		0.8			(2.8		)	5.1
Pre-Fiscal Year 2012 Restructuring Plans
Facilities-related	0.1		—			—			0.1
Total	$	17.7	$	0.3		$	(9.6	)	$	8.4

XML 24 R12.htm IDEA: XBRL DOCUMENT

Segment Information

6 Months Ended

Dec. 31, 2016

Segment Reporting [Abstract]

Segment Information

Net restructuring charges by segment are as follows:



	Six Months Ended
(dollars in millions)	December 31, 2016			December 31, 2015
CRS	$	(0.7	)	$	12.2
PC	(0.1		)	0.7
PI	2.6			7.6
Segment Total	1.8			20.5
Corporate restructuring charges	(1.5		)	4.7
Total restructuring charges	$	0.3		$	25.2

SEGMENT INFORMATION

We have three reportable segments: Clinical Research Services (“CRS”), PAREXEL Consulting Services (“PC”), and PAREXEL Informatics (“PI”).

•

Our segment results were as follows:



(in millions)	Three Months Ended				Six Months Ended
	December 31, 2016		December 31, 2015		December 31, 2016		December 31, 2015
Service revenue
CRS	$	408.9	$	407.1	$	785.2	$	817.3
PC	54.6		41.4		109.6		80.7
PI	70.9		70.0		136.3		132.6
Total service revenue	$	534.4	$	518.5	$	1,031.1	$	1,030.6
Direct costs
CRS	$	284.5	$	274.4	$	546.6	$	561.9
PC	30.9		20.8		61.3		41.0
PI	35.5		37.3		70.7		72.8
Total direct costs	$	350.9	$	332.5	$	678.6	$	675.7
Gross profit
CRS	$	124.4	$	132.7	$	238.6	$	255.4
PC	23.7		20.6		48.3		39.7
PI	35.4		32.7		65.6		59.8
Total gross profit	$	183.5	$	186.0	$	352.5	$	354.9

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8906-108599

+ Details

XML 25 R13.htm IDEA: XBRL DOCUMENT

Income Taxes	6 Months Ended
Income Taxes	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Income Taxes	INCOME TAXES We determine our global provision for corporate income taxes in accordance with ASC 740, “Income Taxes.” We recognize our deferred tax assets and liabilities based upon the effect of temporary differences between the book and tax basis of recorded assets and liabilities. Further, we follow a methodology in which we identify, recognize, measure, and disclose in our financial statements the effects of any uncertain tax return reporting positions that we have taken or expect to take. The methodology is based on the presumption that all relevant tax authorities possess full knowledge of those tax reporting positions, as well as all of the pertinent facts and circumstances. Our quarterly effective income tax rate reflects management’s estimates of our annual projected profitability in the various taxing jurisdictions in which we operate. Since the statutory tax rates differ in the jurisdictions in which we operate, changes in the distribution of profits and losses may have a significant impact on our effective income tax rate. For the three months ended December 31, 2016 and 2015, we had effective income tax rates of 44.8% and 24.8%, respectively. The tax rate for the three months ended December 31, 2016 was higher than the expected statutory rate of 35% primarily due to the non-deductibility of the unrealized loss on the fair value adjustment of $20.3 million in connection with the accelerated share repurchase program, which increased the tax rate by15.2%, and was partially offset by the favorable effect of statutory tax rates applicable to income earned outside the United States on the projected annual effective tax rate. The tax rate for the three months ended December 31, 2015 was lower than the expected statutory rate of 35% primarily as a result of the favorable effect of statutory tax rates applicable to income earned outside the United States on the projected annual effective tax rate. For the six months ended December 31, 2016 and 2015, we had effective income tax rates of 33.3% and 27.0%, respectively. The tax rates for these periods were lower than the expected statutory rate of 35% primarily as a result of the favorable effect of statutory tax rates applicable to income earned outside the United States on the projected annual effective tax rate. The tax rate for the six months ended December 31, 2016, benefited 2.5% from the adoption of ASU 2016-09 as discussed in Note 1 to these condensed consolidated financial statements, and increased by 6.1% due to the non-deductibility of the unrealized loss on the fair value adjustment of $20.3 million in connection with accelerated share repurchase program. As of December 31, 2016, we had $28.9 million of gross unrecognized tax benefits, of which $18.7 million would impact the effective tax rate if recognized. As of June 30, 2016, we had $29.5 million of gross unrecognized tax benefits, of which $18.9 million would impact the effective tax rate if recognized. The reserves for unrecognized tax positions primarily relate to exposures for income tax matters such as changes in the jurisdiction in which income is taxable. The $0.7 million net decrease in gross unrecognized tax benefits is primarily attributable to currency translation adjustments. As of December 31, 2016, we do not anticipate that the liability for unrecognized tax benefits for uncertain tax positions could decrease over the next 12 months primarily as a result of the expiration of statutes of limitations and settlements with tax authorities. We recognize interest and penalties related to income tax matters in income tax expense. As of December 31, 2016 and June 30, 2016, $3.5 million and $3.4 million, respectively, of gross interest and penalties were included in the liability for unrecognized tax benefits. For the six month periods ended December 31, 2016 and 2015, expenses of $0.2 million and $0.4 million, respectively, were recorded for interest and penalties related to tax matters. We are subject to U.S. federal income tax, as well as income tax in multiple states, local and foreign jurisdictions. Our U.S. federal, state and local income tax returns for the tax years 2005 to 2015 remain open for examination by the relevant tax authority. In foreign tax jurisdictions, the Company has open tax years dating back to 2002. The extended open tax years for these jurisdictions resulted from tax attributes carryover, including net operating losses or tax credits from those tax years. We are subject to on-going tax audits in various jurisdictions. Tax authorities may disagree with certain positions we have taken and assess additional taxes. We regularly assess the likely outcomes of these audits in order to determine the appropriateness of our tax provision and have established contingency reserves for material, known tax exposures.

XML 26 R14.htm IDEA: XBRL DOCUMENT

Credit Agreements

6 Months Ended

Dec. 31, 2016

Line of Credit Facility [Abstract]

Lines Of Credit

2016 Credit Agreement


•	0.63% by quarterly term loan amortization payments to be made commencing June 30, 2016 and made on or prior to March 31, 2017;


•	1.25% by quarterly term loan amortization payments to be made on or after June 30, 2017, but on or prior to March 31, 2019;


•	1.88% by quarterly term loan amortization payments to be made on or after June 30, 2019, but on or prior to March 31, 2020;


•	2.50% by quarterly term loan amortization payments to be made on or after June 30, 2020, but prior to March 11, 2021; and


•	72.50% (or if less, the remaining principal amount of the term loan) on March 11, 2021.

To the extent not previously paid, all borrowings under the 2016 Credit Agreement must be repaid on March 11, 2021.

2016 Term Loan Agreement

On February 10, 2016, PAREXEL entered into a short term unsecured term loan agreement with TD Bank, providing for a loan to the Company of $75.0 million (the “Loan”). The Loan would have matured on April 30, 2016 unless earlier payment had been required under the terms of the Company loan agreement with TD Bank. The Loan bore interest, at PAREXEL’s determination, at a base rate plus a margin (such margin not to exceed a per annum rate of 0.750%) based on a ratio of consolidated funded debt to consolidated earnings before interest, taxes, depreciation and amortization (EBITDA) for the prior four fiscal quarters (the “Leverage Ratio”), or at a LIBOR rate plus a margin (such margin not to exceed a per annum rate of 1.750%) based on the Leverage Ratio. The Loan could have been prepaid at any time in whole or in part without premium or penalty, other than customary breakage costs, if any, subject to the terms and conditions of the loan agreement.

The proceeds of the Loan were advanced to the Company on February 12, 2016 and were used to repay borrowings under the Company’s 2014 Facility.

As of December 31, 2016, all outstanding amounts under the Loan were fully repaid with the proceeds from the 2016 Credit Agreement.

Master Financing Agreement


•	$1.4 million made on or prior to July 1, 2015;


•	$2.8 million made on or prior to July 1, 2016; and


•	$2.9 million paid on or prior to July 1, 2017.

As of December 31, 2016, we had $2.9 million principal borrowed under the Master Financing Agreement.

2014 Credit Agreement

The 2014 Credit Agreement was superseded by the 2016 Credit Agreement, and as of December 31, 2016 all outstanding amounts under the 2014 Credit Agreement were fully repaid.

Note Purchase Agreement

Receivable Purchase Agreement

Additional Lines of Credit

XML 27 R15.htm IDEA: XBRL DOCUMENT

Debt, Commitments, Contingencies And Guarantees

6 Months Ended

Dec. 31, 2016

Commitments, Contingencies And Guarantees [Abstract]

Commitments, Contingencies And Guarantees

COMMITMENTS, CONTINGENCIES AND GUARANTEES

As of December 31, 2016, our future minimum debt obligations related to the 2016 Credit Agreement and the Notes described in Note 9 above were as follows:



(in millions)	FY 2017		FY 2018		FY 2019		FY 2020		FY 2021		Thereafter		Total
Debt obligations (principal)	$	8.0	$	22.8	$	22.5	$	32.5	$	695.0	$	—	$	780.8

XML 28 R16.htm IDEA: XBRL DOCUMENT

Derivatives

6 Months Ended

Dec. 31, 2016

Summary of Derivative Instruments by Hedge Designation [Abstract]

Derivatives

DERIVATIVES


•	Our interest rate hedging program is a cash flow hedge program designed to minimize interest rate volatility. We swap the difference between fixed and variable interest amounts calculated by reference to an agreed-upon notional principal amount, at specified intervals. Our interest rate contracts are designated as hedging instruments.

•

During three month ended December 31, 2016, we entered into a forward share repurchase contract in connection with our 2017 accelerated share repurchase program with HSBC.



(in millions)	December 31, 2016					June 30, 2016
	Notional Amount		Asset (Liability)			Notional Amount		Asset (Liability)
Derivatives designated as hedging instruments under ASC 815
Derivatives in an asset position:
Interest rate contracts	$	200.0	$	0.5		$	—	$	—
Foreign exchange contracts	59.9		2.4			81.2		3.5
Derivatives in a liability position:
Interest rate contracts	—		—			200.0		(1.3		)
Foreign exchange contracts	95.8		(7.6		)	103.3		(8.9		)
Total designated derivatives	$	355.7	$	(4.7	)	$	384.5	$	(6.7	)
Derivatives not designated as hedging instruments under ASC 815
Derivatives in an asset position:
Foreign exchange contracts	$	108.0	$	1.6		$	36.2	$	1.5
Forward share repurchase contract	$	200.0	$	19.7		$	—	$	—
Derivatives in a liability position:
Foreign exchange contracts	38.8		(1.7		)	48.0		(1.4		)
Total non-designated derivatives	$	346.8	$	19.6		$	84.2	$	0.1
Total derivatives	$	702.5	$	14.9		$	468.7	$	(6.6	)

The amounts recognized in other comprehensive income (loss), net of taxes, are presented below:



(in millions)	Three Months Ended						Six Months Ended
	December 31, 2016			December 31, 2015			December 31, 2016			December 31, 2015
Derivatives designated as hedging instruments under ASC 815
Interest rate contracts	$	1.4		$	0.7		$	1.9		$	0.2
Foreign exchange contracts	(2.5		)	(0.8		)	(0.8		)	(2.4		)
Total designated derivatives	$	(1.1	)	$	(0.1	)	$	1.1		$	(2.2	)

The unrealized losses recognized are presented below:



(in millions)	Three Months Ended						Six Months Ended
	December 31, 2016			December 31, 2015			December 31, 2016			December 31, 2015
Derivatives not designated as hedging instruments under ASC 815
Forward share repurchase contract	$	(20.3	)	$	—		$	(20.3	)	$	—
Foreign exchange contracts	(1.2		)	(0.1		)	(1.4		)	(0.7		)
Total non-designated derivative unrealized loss, net	$	(21.5	)	$	(0.1	)	$	(21.7	)	$	(0.7	)

- Definition

The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6441202&loc=d3e80720-113993

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4C
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5624171-113959

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64837297&loc=d3e41620-113959

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5624163-113959

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5579240-113959

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4D
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5624177-113959

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=35736893&loc=d3e80784-113994

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=64837297&loc=d3e41641-113959

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5579245-113959

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4H
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5624258-113959

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=35736893&loc=d3e80748-113994

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5708775-113959

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5708773-113959

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5618551-113959

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5580258-113959

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4E
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5624181-113959

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 25
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6886632&loc=d3e76258-113986

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=64837297&loc=d3e41638-113959

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(n))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

XML 29 R17.htm IDEA: XBRL DOCUMENT

Fair Value Measurements

6 Months Ended

Dec. 31, 2016

Fair Value Disclosures [Abstract]

Fair Value Measurements

FAIR VALUE MEASUREMENTS


•	Level 1 – Unadjusted quoted prices in active markets that are accessible to the reporting entity at the measurement date for identical assets and liabilities.


•	Level 2 – Inputs other than quoted prices in active markets for identical assets and liabilities that are observable either directly or indirectly for substantially the full term of the asset or liability. Level 2 inputs include the following:


◦	quoted prices for similar assets and liabilities in active markets


◦	quoted prices for identical or similar assets or liabilities in markets that are not active


◦	observable inputs other than quoted prices that are used in the valuation of the asset or liabilities (e.g., interest rate and yield curve quotes at commonly quoted intervals)


◦	inputs that are derived principally from or corroborated by observable market data by, correlation or other means


•	Level 3 – Unobservable inputs for the asset or liability (i.e., supported by little or no market activity). Level 3 inputs include management’s own assumptions about the assumptions that market participants would use in pricing the asset or liability (including assumptions about risk).

The following table sets forth by level, within the fair value hierarchy, our assets (liabilities) carried at fair value as of December 31, 2016:



(in millions)	Level 1		Level 2			Level 3			Total
Contingent consideration	$	—	$	—		$	(14.0	)	$	(14.0	)
Forward share repurchase contract	—		—			19.7			19.7
Interest rate derivative instruments	—		0.5			—			0.5
Foreign currency exchange contracts	—		(5.3		)	—			(5.3		)
Total	$	—	$	(4.8	)	$	5.7		$	0.9

The following table sets forth by level, within the fair value hierarchy, our assets (liabilities) carried at fair value as of June 30, 2016:



(in millions)	Level 1		Level 2			Level 3			Total
Contingent consideration	$	—	$	—		$	(5.2	)	$	(5.2	)
Interest rate derivative instruments	—		(1.3		)	—			(1.3		)
Foreign currency exchange contracts	—		(5.3		)	—			(5.3		)
Total	$	—	$	(6.6	)	$	(5.2	)	$	(11.8	)

Level 1 Estimates

Cash equivalents are measured at quoted prices in active markets. These investments are considered cash equivalents due to the short maturity (less than 90 days) of the investments.

Level 2 Estimates

Level 3 Estimates

The recurring Level 3 fair value measurements of our forward share repurchase contract asset include the following significant unobservable inputs:



	Forward Share
Unobservable Input	Repurchase Contract
Risk free rate	0.6%
Share price volatility	37.5
Contract term	0.4 years

The recurring Level 3 fair value measurements of our contingent consideration liability include the following significant unobservable inputs:



	Health Advances	ExecuPharm
Unobservable Input	Range	Range
Risk free rate	1.3%	0.7%
Revenue volatility	26%	29%
Projected period of payment	Approximately 2 years	Approximately 2 years

The following table provides a summary of the change in our valuation of the fair value of the contingent consideration liability, which was determined by Level 3 inputs:



(in millions)
Balance at June 30, 2016	$	5.2
Additions of contingent consideration due to ExecuPharm acquistion	9.4
Change in fair value of contingent consideration for Health Advances	(0.6		)
Balance at December 31, 2016	$	14.0

The following table provides a summary of the change in our valuation of the fair value of the forward share repurchase contract asset, which was determined by Level 3 inputs:



(in millions)
Balance at June 30, 2016	$	—
Additions of forward share repurchase contract	40.0
Change in fair value of forward share repurchase contract	(20.3		)
Balance at December 31, 2016	$	19.7

The carrying value of our current and long-term debt under the 2016 Credit Agreement approximates fair value because all of the debt bears variable-rate interest.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 30 R18.htm IDEA: XBRL DOCUMENT

Subsequent Event restructuring (Notes)

6 Months Ended

Dec. 31, 2016

Restructuring Cost and Reserve [Line Items]

Restructuring and Related Activities Disclosure [Text Block]

Net restructuring charges by segment are as follows:



	Six Months Ended
(dollars in millions)	December 31, 2016			December 31, 2015
CRS	$	(0.7	)	$	12.2
PC	(0.1		)	0.7
PI	2.6			7.6
Segment Total	1.8			20.5
Corporate restructuring charges	(1.5		)	4.7
Total restructuring charges	$	0.3		$	25.2

2017 Restructuring Plan

Changes in the restructuring accrual during the first six months of Fiscal Year 2016 are summarized below:



	Balance at		Charges/(Benefits)			Payments/Foreign Currency Exchange/Other			Balance at
	June 30, 2016		Charges/(Benefits)			Payments/Foreign Currency Exchange/Other			December 31, 2016
2015 Margin Acceleration Program
Employee severance	$	10.5	$	(0.5	)	$	(6.8	)	$	3.2
Facilities-related	7.1		0.8			(2.8		)	5.1
Pre-Fiscal Year 2012 Restructuring Plans
Facilities-related	0.1		—			—			0.1
Total	$	17.7	$	0.3		$	(9.6	)	$	8.4

XML 31 R19.htm IDEA: XBRL DOCUMENT

Acquisitions, Goodwill, and Other Intangible Assets (Tables)

6 Months Ended

Feb. 10, 2016

Dec. 31, 2016

Business Acquisition [Line Items]

Fair Value Assumptions, Weighted Average Volatility Rate

3750.00%

Health Advances Acquisition [Member]

Business Acquisition [Line Items]

Fair Value Assumptions, Weighted Average Volatility Rate

26.00%

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed

The components of the consideration transferred in conjunction with the Health Advances acquisition and the preliminary allocation of that consideration is as follows (in millions):



Total consideration transferred:
Cash paid, net of cash acquired	$	67.1
Fair value of contingent consideration	4.5
Net purchase price	$	71.6
Preliminary allocation of consideration transferred:
Accounts receivable	$	4.0
Other current assets	0.7
Property and equipment, net	1.0
Deferred tax assets	0.2
Definite-lived intangible assets	15.0
Goodwill	52.5
Total assets acquired	73.4
Current liabilities	1.8
Total liabilities assumed	1.8
Net assets acquired:	$	71.6

The components of the consideration transferred in conjunction with the Health Advances acquisition and the preliminary allocation of that consideration is as follows (in millions):



Total consideration transferred:
Cash paid, net of cash acquired	$	67.1
Fair value of contingent consideration	4.5
Net purchase price	$	71.6
Preliminary allocation of consideration transferred:
Accounts receivable	$	4.0
Other current assets	0.7
Property and equipment, net	1.0
Deferred tax assets	0.2
Definite-lived intangible assets	15.0
Goodwill	52.5
Total assets acquired	73.4
Current liabilities	1.8
Total liabilities assumed	1.8
Net assets acquired:	$	71.6

Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination

The following are the preliminary identifiable intangible assets acquired and their respective estimated useful lives, as determined based on preliminary valuations (dollars in millions):



	Amount		Estimated Useful Life (Years)
Customer relationships	$	11.6	10
Technology	1.8		3
Trade name	1.6		5
Total	$	15.0

ExecuPharm Inc. [Member]

Business Acquisition [Line Items]

Fair Value Assumptions, Weighted Average Volatility Rate

29.00%

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed

Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination

The Medical Affairs Company, LLC

XML 32 R20.htm IDEA: XBRL DOCUMENT

Equity and Earnings Per Share (Tables)

6 Months Ended

Dec. 31, 2016

Earnings Per Share [Abstract]

Computation Of Basic And Diluted Earnings Per Common Share



(in millions, except per share data)	Three Months Ended				Six Months Ended
	December 31, 2016		December 31, 2015		December 31, 2016		December 31, 2015
Net income attributable to common stock	$	21.8	$	39.4	$	59.6	$	64.3
Weighted average number of shares outstanding, used in computing basic earnings per share	52.0		53.3		52.4		54.1
Dilutive common stock equivalents	0.7		0.7		0.8		0.8
Weighted average number of shares outstanding used in computing diluted earnings per share	52.7		54.0		53.2		54.9
Basic earnings per share	$	0.42	$	0.74	$	1.14	$	1.19
Diluted earnings per share	$	0.41	$	0.73	$	1.12	$	1.17
Anti-dilutive equity instruments (excluded from the calculation of diluted earnings per share)	0.6		1.4		0.8		1.2

XML 33 R21.htm IDEA: XBRL DOCUMENT

Comprehensive Income (Tables)

6 Months Ended

Dec. 31, 2016

Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]

Schedule Of Comprehensive Income



(in millions)	Foreign Currency			Unrealized Gain/Loss on Derivatives			Total
Balance as of June 30, 2016	$	(130.5	)	$	(5.5	)	$	(136.0	)
Other comprehensive loss before reclassifications	(22.2		)	(3.6		)	(25.8		)
Loss reclassified from accumulated other comprehensive income	—			4.7			4.7
Net current-period other comprehensive (loss) gain	$	(22.2	)	$	1.1		$	(21.1	)
Balance as of December 31, 2016	$	(152.7	)	$	(4.4	)	$	(157.1	)

Schedule of Derivative Instruments, Effect on Other Comprehensive Income (Loss)



	Three Months Ended						Affected Line in the Consolidated Statements of Income
(in millions)	December 31, 2016			December 31, 2015			Affected Line in the Consolidated Statements of Income
Interest rate contracts	$	(0.2	)	$	(0.1	)	Interest expense, net
Foreign exchange contracts	(2.1		)	(0.2		)	Service Revenue
Foreign exchange contracts	(0.7		)	(1.8		)	Direct Costs
Total	$	(3.0	)	$	(2.1	)



	Six Months Ended						Affected Line in the Consolidated Statements of Income
(in millions)	December 31, 2016			December 31, 2015			Affected Line in the Consolidated Statements of Income
Interest rate contracts	$	(0.2	)	$	(0.3	)	Interest expense, net
Foreign exchange contracts	(4.8		)	(0.4		)	Service Revenue
Foreign exchange contracts	(0.8		)	(4.6		)	Direct Costs
Total	$	(5.8	)	$	(5.3	)

XML 34 R22.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation (Tables)

6 Months Ended

Dec. 31, 2016

Share-based Compensation, Allocation and Classification in Financial Statements [Abstract]

Classification Of Compensation Expense Within Consolidated Statements Of Income



(in millions)	Three Months Ended				Six Months Ended
	December 31, 2016		December 31, 2015		December 31, 2016		December 31, 2015
Direct costs	$	1.1	$	1.0	$	2.2	$	2.2
Selling, general and administrative	4.5		3.8		8.2		7.7
Total stock-based compensation	$	5.6	$	4.8	$	10.4	$	9.9

XML 35 R23.htm IDEA: XBRL DOCUMENT

Restructuring Charges (Tables)

6 Months Ended

Dec. 31, 2016

Restructuring Cost and Reserve [Line Items]

Segment Reporting Disclosure [Text Block]

Net restructuring charges by segment are as follows:



	Six Months Ended
(dollars in millions)	December 31, 2016			December 31, 2015
CRS	$	(0.7	)	$	12.2
PC	(0.1		)	0.7
PI	2.6			7.6
Segment Total	1.8			20.5
Corporate restructuring charges	(1.5		)	4.7
Total restructuring charges	$	0.3		$	25.2

SEGMENT INFORMATION

We have three reportable segments: Clinical Research Services (“CRS”), PAREXEL Consulting Services (“PC”), and PAREXEL Informatics (“PI”).

•

Our segment results were as follows:



(in millions)	Three Months Ended				Six Months Ended
	December 31, 2016		December 31, 2015		December 31, 2016		December 31, 2015
Service revenue
CRS	$	408.9	$	407.1	$	785.2	$	817.3
PC	54.6		41.4		109.6		80.7
PI	70.9		70.0		136.3		132.6
Total service revenue	$	534.4	$	518.5	$	1,031.1	$	1,030.6
Direct costs
CRS	$	284.5	$	274.4	$	546.6	$	561.9
PC	30.9		20.8		61.3		41.0
PI	35.5		37.3		70.7		72.8
Total direct costs	$	350.9	$	332.5	$	678.6	$	675.7
Gross profit
CRS	$	124.4	$	132.7	$	238.6	$	255.4
PC	23.7		20.6		48.3		39.7
PI	35.4		32.7		65.6		59.8
Total gross profit	$	183.5	$	186.0	$	352.5	$	354.9

Restructuring Charges by Segment [Table Text Block]

Net restructuring charges by segment are as follows:



	Six Months Ended
(dollars in millions)	December 31, 2016			December 31, 2015
CRS	$	(0.7	)	$	12.2
PC	(0.1		)	0.7
PI	2.6			7.6
Segment Total	1.8			20.5
Corporate restructuring charges	(1.5		)	4.7
Total restructuring charges	$	0.3		$	25.2

Schedule Of Charges Against The Restructuring Accrual



	Balance at		Charges/(Benefits)			Payments/Foreign Currency Exchange/Other			Balance at
	June 30, 2016		Charges/(Benefits)			Payments/Foreign Currency Exchange/Other			December 31, 2016
2015 Margin Acceleration Program
Employee severance	$	10.5	$	(0.5	)	$	(6.8	)	$	3.2
Facilities-related	7.1		0.8			(2.8		)	5.1
Pre-Fiscal Year 2012 Restructuring Plans
Facilities-related	0.1		—			—			0.1
Total	$	17.7	$	0.3		$	(9.6	)	$	8.4

- Definition

+ References

+ Details

XML 36 R24.htm IDEA: XBRL DOCUMENT

Segment Information (Tables)

6 Months Ended

Dec. 31, 2016

Segment Reporting [Abstract]

Service Revenue, Direct Costs And Gross Profit On Service Revenue Of Reportable Segment



(in millions)	Three Months Ended				Six Months Ended
	December 31, 2016		December 31, 2015		December 31, 2016		December 31, 2015
Service revenue
CRS	$	408.9	$	407.1	$	785.2	$	817.3
PC	54.6		41.4		109.6		80.7
PI	70.9		70.0		136.3		132.6
Total service revenue	$	534.4	$	518.5	$	1,031.1	$	1,030.6
Direct costs
CRS	$	284.5	$	274.4	$	546.6	$	561.9
PC	30.9		20.8		61.3		41.0
PI	35.5		37.3		70.7		72.8
Total direct costs	$	350.9	$	332.5	$	678.6	$	675.7
Gross profit
CRS	$	124.4	$	132.7	$	238.6	$	255.4
PC	23.7		20.6		48.3		39.7
PI	35.4		32.7		65.6		59.8
Total gross profit	$	183.5	$	186.0	$	352.5	$	354.9

XML 37 R25.htm IDEA: XBRL DOCUMENT

Debt, Commitments, Contingencies And Guarantees Schedule of Contractual Obligation (Tables)

6 Months Ended

Dec. 31, 2016

Schedule of Long-term Debt Obligation [Abstract]

Schedule of Maturities of Long-term Debt [Table Text Block]



(in millions)	FY 2017		FY 2018		FY 2019		FY 2020		FY 2021		Thereafter		Total
Debt obligations (principal)	$	8.0	$	22.8	$	22.5	$	32.5	$	695.0	$	—	$	780.8

XML 38 R26.htm IDEA: XBRL DOCUMENT

Derivatives (Tables)

6 Months Ended

Dec. 31, 2016

Summary of Derivative Instruments by Hedge Designation [Abstract]

Schedule Of Notional Amounts And Fair Values Of Derivatives



(in millions)	December 31, 2016					June 30, 2016
	Notional Amount		Asset (Liability)			Notional Amount		Asset (Liability)
Derivatives designated as hedging instruments under ASC 815
Derivatives in an asset position:
Interest rate contracts	$	200.0	$	0.5		$	—	$	—
Foreign exchange contracts	59.9		2.4			81.2		3.5
Derivatives in a liability position:
Interest rate contracts	—		—			200.0		(1.3		)
Foreign exchange contracts	95.8		(7.6		)	103.3		(8.9		)
Total designated derivatives	$	355.7	$	(4.7	)	$	384.5	$	(6.7	)
Derivatives not designated as hedging instruments under ASC 815
Derivatives in an asset position:
Foreign exchange contracts	$	108.0	$	1.6		$	36.2	$	1.5
Forward share repurchase contract	$	200.0	$	19.7		$	—	$	—
Derivatives in a liability position:
Foreign exchange contracts	38.8		(1.7		)	48.0		(1.4		)
Total non-designated derivatives	$	346.8	$	19.6		$	84.2	$	0.1
Total derivatives	$	702.5	$	14.9		$	468.7	$	(6.6	)

Schedule Of Change In The Fair Value Of Derivatives Designated As Hedging Instruments



(in millions)	Three Months Ended						Six Months Ended
	December 31, 2016			December 31, 2015			December 31, 2016			December 31, 2015
Derivatives designated as hedging instruments under ASC 815
Interest rate contracts	$	1.4		$	0.7		$	1.9		$	0.2
Foreign exchange contracts	(2.5		)	(0.8		)	(0.8		)	(2.4		)
Total designated derivatives	$	(1.1	)	$	(0.1	)	$	1.1		$	(2.2	)

Schedule Of Change In The Fair Value Derivatives Not Designated As Hedging Instruments



(in millions)	Three Months Ended						Six Months Ended
	December 31, 2016			December 31, 2015			December 31, 2016			December 31, 2015
Derivatives not designated as hedging instruments under ASC 815
Forward share repurchase contract	$	(20.3	)	$	—		$	(20.3	)	$	—
Foreign exchange contracts	(1.2		)	(0.1		)	(1.4		)	(0.7		)
Total non-designated derivative unrealized loss, net	$	(21.5	)	$	(0.1	)	$	(21.7	)	$	(0.7	)

XML 39 R27.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Tables)

6 Months Ended

Dec. 31, 2016

Fair Value Inputs, Liabilities, Quantitative Information [Line Items]

Schedule Of Fair Value Hierarchy, Assets (Liabilities) Carried At Fair Value



(in millions)	Level 1		Level 2			Level 3			Total
Contingent consideration	$	—	$	—		$	(5.2	)	$	(5.2	)
Interest rate derivative instruments	—		(1.3		)	—			(1.3		)
Foreign currency exchange contracts	—		(5.3		)	—			(5.3		)
Total	$	—	$	(6.6	)	$	(5.2	)	$	(11.8	)



(in millions)	Level 1		Level 2			Level 3			Total
Contingent consideration	$	—	$	—		$	(14.0	)	$	(14.0	)
Forward share repurchase contract	—		—			19.7			19.7
Interest rate derivative instruments	—		0.5			—			0.5
Foreign currency exchange contracts	—		(5.3		)	—			(5.3		)
Total	$	—	$	(4.8	)	$	5.7		$	0.9

Fair Value Inputs, Liabilities, Quantitative Information [Table Text Block]

The recurring Level 3 fair value measurements of our contingent consideration liability include the following significant unobservable inputs:



	Health Advances	ExecuPharm
Unobservable Input	Range	Range
Risk free rate	1.3%	0.7%
Revenue volatility	26%	29%
Projected period of payment	Approximately 2 years	Approximately 2 years

The recurring Level 3 fair value measurements of our forward share repurchase contract asset include the following significant unobservable inputs:



	Forward Share
Unobservable Input	Repurchase Contract
Risk free rate	0.6%
Share price volatility	37.5
Contract term	0.4 years

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]

The following table provides a summary of the change in our valuation of the fair value of the forward share repurchase contract asset, which was determined by Level 3 inputs:



(in millions)
Balance at June 30, 2016	$	—
Additions of forward share repurchase contract	40.0
Change in fair value of forward share repurchase contract	(20.3		)
Balance at December 31, 2016	$	19.7

The following table provides a summary of the change in our valuation of the fair value of the contingent consideration liability, which was determined by Level 3 inputs:



(in millions)
Balance at June 30, 2016	$	5.2
Additions of contingent consideration due to ExecuPharm acquistion	9.4
Change in fair value of contingent consideration for Health Advances	(0.6		)
Balance at December 31, 2016	$	14.0

- Definition

Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.

+ References + Details

XML 40 R28.htm IDEA: XBRL DOCUMENT

Basis Of Presentation (Details) - USD ($) $ in Millions	3 Months Ended	6 Months Ended
Basis Of Presentation (Details) - USD ($) $ in Millions	Dec. 31, 2016	Dec. 31, 2016
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Prior Period Reclassification Adjustment	$ 2.4	$ 8.3
Additional Paid-in Capital [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Cumulative Effect on Retained Earnings, before Tax		$ 0.6

XML 41 R29.htm IDEA: XBRL DOCUMENT

Basis Of Presentation change (Details) $ in Millions	6 Months Ended
Basis Of Presentation change (Details) $ in Millions	Dec. 31, 2016 USD ($)
Additional Paid-in Capital [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Employee Service Share-based Compensation, Tax Benefit Realized from Exercise of Stock Options	$ 2.3

XML 42 R30.htm IDEA: XBRL DOCUMENT

Basis Of Presentation prior period adjustment (Details) - USD ($) $ in Millions	3 Months Ended	6 Months Ended
	Dec. 31, 2016	Dec. 31, 2016
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Prior Period Reclassification Adjustment	$ 2.4	$ 8.3

XML 43 R31.htm IDEA: XBRL DOCUMENT

Acquisitions, Goodwill, and Other Intangible Assets (Details) - USD ($) $ in Thousands				6 Months Ended
	Oct. 03, 2016	Feb. 10, 2016	Jan. 19, 2016	Dec. 31, 2016	Dec. 31, 2015	Jun. 30, 2016
Business Acquisition [Line Items]
Payments to Acquire Businesses, Net of Cash Acquired				$ 148,300	$ 0
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net [Abstract]
Fair value of contingent consideration				14,000		$ 5,200
Goodwill				441,000		$ 389,200
ExecuPharm Inc. [Member]
Business Acquisition [Line Items]
Payments to Acquire Businesses, Net of Cash Acquired	$ 148,500
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	20,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net [Abstract]
Cash paid, net of cash acquired	148,900
Fair value of contingent consideration	9,400
Net purchase price		$ 167,200
Accounts receivable	29,200
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets	100
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment	900
Definite-lived intangible assets	87,100			87,100
Goodwill	58,600
Total assets acquired	175,900
Total liabilities assumed	8,700
Net assets acquired:	167,200
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities	8,700
ExecuPharm Inc. [Member] \| Customer relationships
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net [Abstract]
Definite-lived intangible assets				$ 85,500
Estimated Useful Life (Years)				15 years
ExecuPharm Inc. [Member] \| Trade Names [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net [Abstract]
Definite-lived intangible assets	$ 1,600
Estimated Useful Life (Years)	2 years
Health Advances Acquisition [Member]
Business Acquisition [Line Items]
Business Combination, Receivable from Working Capital Adjustment				$ 200
Payments to Acquire Businesses, Net of Cash Acquired		67,100	$ 67,100
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High			15,800
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net [Abstract]
Fair value of contingent consideration				4,500
Net purchase price		$ 71,600
Accounts receivable				4,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets				700
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment				1,000
Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets			200
Definite-lived intangible assets			15,000	15,000
Goodwill			52,500
Total assets acquired				73,400
Total liabilities assumed				1,800
Net assets acquired:				71,600
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities				1,800
Health Advances Acquisition [Member] \| Customer relationships
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net [Abstract]
Definite-lived intangible assets				$ 11,600
Estimated Useful Life (Years)				10 years
Health Advances Acquisition [Member] \| Technology
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net [Abstract]
Definite-lived intangible assets				$ 1,800
Estimated Useful Life (Years)				3 years
Health Advances Acquisition [Member] \| Trade Names [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net [Abstract]
Definite-lived intangible assets			$ 1,600
Estimated Useful Life (Years)			5 years
Payment Deferral [Member] \| ExecuPharm Inc. [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net [Abstract]
Fair value of contingent consideration	$ 9,300

XML 44 R32.htm IDEA: XBRL DOCUMENT

Acquisitions, Goodwill, and Other Intangible Assets goodwill (Details) - USD ($) $ in Millions	Dec. 31, 2016	Oct. 03, 2016	Jun. 30, 2016	Jan. 19, 2016
Goodwill [Line Items]
Goodwill	$ 441.0		$ 389.2
ExecuPharm Inc. [Member]
Goodwill [Line Items]
Goodwill		$ 58.6
Health Advances Acquisition [Member]
Goodwill [Line Items]
Goodwill				$ 52.5

XML 45 R33.htm IDEA: XBRL DOCUMENT

Acquisitions, Goodwill, and Other Intangible Assets intangibles (Details) - Health Advances Acquisition [Member] - USD ($) $ in Thousands		6 Months Ended
	Oct. 03, 2016	Dec. 31, 2016
Acquired Finite-Lived Intangible Assets [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	$ 87,100	$ 87,100
Customer Relationships [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life		15 years
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles		$ 85,500
Trade Names [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	2 years
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	$ 1,600

XML 46 R34.htm IDEA: XBRL DOCUMENT

Equity and Earnings Per Share (Computation Of Basic And Diluted Earnings Per Common Share) (Details) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended		6 Months Ended
	Feb. 10, 2016	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2016	Feb. 29, 2016	Dec. 31, 2015	Oct. 26, 2016	Jun. 30, 2016	Sep. 14, 2015
Class of Stock [Line Items]
Unrealized Gain (Loss) on Derivatives and Commodity Contracts		$ 20,300
Preferred Stock, Shares Authorized		5,000,000		5,000,000				5,000,000
Preferred Stock, Par or Stated Value Per Share		$ 0.01		$ 0.01				$ 0.01
Preferred Stock, Shares Outstanding		0		0				0
Common Stock, Shares Authorized		150,000,000		150,000,000				150,000,000
Common Stock, Par or Stated Value Per Share		$ 0.01		$ 0.01				$ 0.01
Common Stock, Shares, Outstanding		50,900,000		50,900,000				52,900,000
Disclosure of Repurchase Agreements [Abstract]
PercentOfSharesReceivedUnderASR				80.00%		80.00%
Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]
Net income attributable to common stock		$ 21,800	$ 39,400	$ 59,600		$ 64,300
Weighted average number of shares outstanding, used in computing basic earnings per share		52,000,000	53,300,000	52,400,000		54,100,000
Dilutive common stock equivalents		700,000	700,000	800,000		800,000
Weighted average number of shares outstanding used in computing diluted earnings per share		52,700,000	54,000,000	53,200,000		54,900,000
Basic earnings per share		$ 0.42	$ 0.74	$ 1.14		$ 1.19
Diluted earnings per share		$ 0.41	$ 0.73	$ 1.12		$ 1.17
Anti-dilutive options (excluded from the calculation of diluted earnings per share)		600,000	1,400,000	800,000		1,200,000
FY2017StockRepurchasePlan [Member] [Domain] [Domain]
Disclosure of Repurchase Agreements [Abstract]
Stock Repurchase Program Authorized Amount							$ 200,000
Treasury Stock, Shares, Acquired						2,800,000
Treasury Stock, Value, Acquired, Cost Method		$ 200,000
Accelerated Share Repurchases, Initial Price Paid Per Share				$ 57.51
FY2016StockRepurchasePlan [Member] [Member] [Domain]
Disclosure of Repurchase Agreements [Abstract]
Stock Repurchase Program Authorized Amount									$ 200,000
Treasury Stock, Shares, Acquired	900,000				3,200,000	2,300,000
Accelerated Share Repurchases, Final Price Paid Per Share		$ 62.92
Accelerated Share Repurchases, Initial Price Paid Per Share						$ 70.35

XML 47 R35.htm IDEA: XBRL DOCUMENT

Equity and Earnings Per Share buyback (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions		3 Months Ended	6 Months Ended
	Feb. 10, 2016	Dec. 31, 2016	Dec. 31, 2016	Feb. 29, 2016	Dec. 31, 2015	Oct. 26, 2016	Sep. 14, 2015
Accelerated Share Repurchases [Line Items]
Fair Value Assumptions, Weighted Average Volatility Rate			1.00%
PercentOfSharesReceivedUnderASR			80.00%		80.00%
Accelerated Share Repurchases, Cash or Stock Settlement		160
Fair Value Assumptions, Weighted Average Volatility Rate			3750.00%
Fair Value Assumptions, Expected Term			4 months 24 days
FY2016StockRepurchasePlan [Member] [Member] [Domain]
Accelerated Share Repurchases [Line Items]
Stock Repurchase Program, Authorized Amount							$ 200.0
Treasury Stock, Shares, Acquired	0.9			3.2	2.3
Accelerated Share Repurchases, Initial Price Paid Per Share					$ 70.35
FY2017StockRepurchasePlan [Member] [Domain] [Domain]
Accelerated Share Repurchases [Line Items]
Stock Repurchase Program, Authorized Amount						$ 200.0
Treasury Stock, Shares, Acquired					2.8
Accelerated Share Repurchases, Initial Price Paid Per Share			$ 57.51
Health Advances Acquisition [Member]
Accelerated Share Repurchases [Line Items]
Fair Value Assumptions, Weighted Average Volatility Rate			1.00%
Fair Value Assumptions, Weighted Average Volatility Rate	26.00%

XML 48 R36.htm IDEA: XBRL DOCUMENT

Comprehensive Income (Schedule Of Comprehensive Income) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Jun. 30, 2016
Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax	$ (152,700)		$ (152,700)		$ (130,500)
Other comprehensive income before reclassifications			(25,800)
Amounts reclassified from accumulated other comprehensive income to earnings, net of tax			4,700
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax	(26,000)	$ (12,200)	(22,200)	$ (27,200)
Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Net of Tax	(1,100)	(100)	1,100	(2,200)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent			(21,100)
Accumulated Other Comprehensive Income (Loss), Cumulative Changes in Net Gain (Loss) from Cash Flow Hedges, Effect Net of Tax	(4,400)		(4,400)		(5,500)
Accumulated Other Comprehensive Income (Loss), Net of Tax	(157,100)		(157,100)		$ (136,000)
Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net	(3,000)	(2,100)	(5,800)	(5,300)
Other Comprehensive Income (Loss), Reclassification Adjustment on Derivatives Included in Net Income, Tax	700	800	1,200	2,100
Interest Rate Contract [Member]
Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net	(200)		(200)
Accumulated Translation Adjustment [Member]
Amounts reclassified from accumulated other comprehensive income to earnings, net of tax			0
Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges [Member]
Other comprehensive income before reclassifications			(3,600)
Amounts reclassified from accumulated other comprehensive income to earnings, net of tax			4,700
Interest Expense [Member] \| Interest Rate Contract [Member]
Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net		(100)		(300)
Sales Revenue, Services, Net [Member] \| Foreign Exchange Contract [Member]
Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net	(2,100)	(200)	(4,800)	(400)
Cost of Sales [Member] \| Foreign Exchange Contract [Member]
Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net	$ (700)	$ (1,800)	(800)	$ (4,600)
Japan, Yen
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax			$ 3,000
Foreign Currency Exchange Rate Change, Percentage			12.10%
United Kingdom, Pounds
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax			$ 8,400
Foreign Currency Exchange Rate Change, Percentage			8.20%
Euro Member Countries, Euro
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax			$ 8,600
Foreign Currency Exchange Rate Change, Percentage			4.90%

XML 49 R37.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation (Classification Of Compensation Expense Within Consolidated Statements Of Income) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2016	Dec. 31, 2015
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based Compensation	$ 5,600	$ 4,800	$ 10,400	$ 9,900
Cost of Sales [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based Compensation	1,100	1,000	2,200	2,200
Selling, General And Administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based Compensation	$ 4,500	$ 3,800	$ 8,200	$ 7,700

XML 50 R38.htm IDEA: XBRL DOCUMENT

Restructuring Charges (Narrative) (Details) - USD ($) $ in Thousands		3 Months Ended		6 Months Ended		12 Months Ended
	Jan. 06, 2017	Sep. 30, 2016	Dec. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Jun. 30, 2016	Jun. 30, 2015
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Current				$ 5,600		$ 14,600
Restructuring Reserve				8,400		17,700
Restructuring Charges			$ 10,400	300	$ 25,200
2015 Margin Acceleration Program [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges		$ 1,600				27,800	$ 20,000
Restructuring Reserve, Accrual Adjustment		$ (1,300)
Two Thousand Fifteen Restructuring Plan [Member] [Domain]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve						10,500
Employee Severance [Member] \| Two Thousand Fifteen Restructuring Plan [Member] [Domain]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve				3,200
Restructuring Charges				(500)
Facilities Related Charges [Member] \| Two Thousand Fifteen Restructuring Plan [Member] [Domain]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve				5,100		$ 7,100
Restructuring Charges				$ 800
Minimum [Member] \| 2017 Restructing Plan [Member]
Restructuring Cost and Reserve [Line Items]
Subsequent Event, Description	25
Maximum [Member] \| 2017 Restructing Plan [Member]
Restructuring Cost and Reserve [Line Items]
Subsequent Event, Description	35

XML 51 R39.htm IDEA: XBRL DOCUMENT

Restructuring Charges (Schedule Of Charges Against The Restructuring Accrual) (Details) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Dec. 31, 2015	Dec. 31, 2016	Dec. 31, 2015
Restructuring Cost and Reserve [Line Items]
Balance at June 30, 2013		$ 17,700
Provisions/Adjustments	$ 10,400	300	$ 25,200
Balance at September 30, 2013		8,400
Restructuring Reserve, Translation Adjustment		(9,600)
Two Thousand Fifteen Restructuring Plan [Member] [Domain]
Restructuring Cost and Reserve [Line Items]
Balance at June 30, 2013		10,500
Balance at September 30, 2013
Two Thousand Fifteen Restructuring Plan [Member] [Domain] \| Employee Severance [Member]
Restructuring Cost and Reserve [Line Items]
Provisions/Adjustments		(500)
Balance at September 30, 2013		3,200
Restructuring Reserve, Translation Adjustment		(6,800)
Two Thousand Fifteen Restructuring Plan [Member] [Domain] \| Facilities-Related Charges [Member]
Restructuring Cost and Reserve [Line Items]
Balance at June 30, 2013		7,100
Provisions/Adjustments		800
Balance at September 30, 2013		5,100
Restructuring Reserve, Translation Adjustment		(2,800)
Two Thousand Eleven Restructuring Plan [Member] \| Facilities-Related Charges [Member]
Restructuring Cost and Reserve [Line Items]
Balance at June 30, 2013		100
Provisions/Adjustments		0
Balance at September 30, 2013		100
Restructuring Reserve, Translation Adjustment		0
Operating Segments [Member]
Restructuring Cost and Reserve [Line Items]
Provisions/Adjustments		1,800	20,500
Operating Segments [Member] \| CRS [Member]
Restructuring Cost and Reserve [Line Items]
Provisions/Adjustments		(700)	12,200
Operating Segments [Member] \| PC [Member]
Restructuring Cost and Reserve [Line Items]
Provisions/Adjustments		(100)	700
Operating Segments [Member] \| PI [Member]
Restructuring Cost and Reserve [Line Items]
Provisions/Adjustments		2,600	7,600
Corporate, Non-Segment [Member]
Restructuring Cost and Reserve [Line Items]
Provisions/Adjustments		$ (1,500)	$ 4,700

XML 52 R40.htm IDEA: XBRL DOCUMENT

Segment Information (Service Revenue, Direct Costs And Gross Profit On Service Revenue Of Reportable Segment) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2016	Dec. 31, 2015
Segment Reporting Information [Line Items]
Service revenue	$ 534,400	$ 518,500	$ 1,031,100	$ 1,030,600
Direct costs	350,900	332,500	678,600	675,700
Gross profit	183,500	186,000	352,500	354,900
CRS [Member]
Segment Reporting Information [Line Items]
Service revenue	408,900	407,100	785,200	817,300
Direct costs	284,500	274,400	546,600	561,900
Gross profit	124,400	132,700	238,600	255,400
PC [Member]
Segment Reporting Information [Line Items]
Service revenue	54,600	41,400	109,600	80,700
Direct costs	30,900	20,800	61,300	41,000
Gross profit	23,700	20,600	48,300	39,700
PI [Member]
Segment Reporting Information [Line Items]
Service revenue	70,900	70,000	136,300	132,600
Direct costs	35,500	37,300	70,700	72,800
Gross profit	$ 35,400	$ 32,700	$ 65,600	$ 59,800

XML 53 R41.htm IDEA: XBRL DOCUMENT

Income Taxes (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
Income Taxes (Details) - USD ($) $ in Millions	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Jun. 30, 2016
Income Tax Holiday [Line Items]
Gross unrecognized tax benefits	$ 28.9		$ 28.9		$ 29.5
Gross unrecognized tax benefits that would impact the effective tax rate if recognized	18.7		18.7		18.9
Net change in liability for unrecognized tax benefits for uncertain tax positions			0.7
Interest and penalties included in liability for unrecognized tax benefits	$ 3.5		3.5		$ 3.4
Interest and penalties included in income tax expense			$ 0.2	$ 0.4
Effective income tax rate	44.80%	24.80%	33.30%	27.00%

XML 54 R42.htm IDEA: XBRL DOCUMENT

Credit Agreements (Details) $ in Thousands, € in Millions	1 Months Ended	3 Months Ended	6 Months Ended
Credit Agreements (Details) $ in Thousands, € in Millions	May 31, 2013 USD ($)	Sep. 30, 2016 USD ($)	Dec. 31, 2016 USD ($)	Dec. 31, 2016 EUR (€)	Dec. 31, 2016 USD ($)	Sep. 30, 2016 EUR (€)	Sep. 30, 2016 USD ($)	Jun. 30, 2016 USD ($)	Mar. 11, 2016 USD ($)	Oct. 01, 2015	Sep. 30, 2015 USD ($)	Jun. 12, 2015 USD ($)	Jul. 25, 2013	Sep. 30, 2011
Line of Credit Facility [Line Items]
Derivative, Notional Amount					$ 702,500			$ 468,700
Letters of Credit Outstanding, Amount					10,200
Long-term Debt, Gross					780,800							$ 7,100
Interest rate swap, fixed interest rate	0.73%									1.104%
JP Morgan [Member]
Line of Credit Facility [Line Items]
Transfers of Financial Assets Including Debt Activity			$ 700
Other Short-term Borrowings											$ 0
HSBC [Member]
Line of Credit Facility [Line Items]
Investment Interest Rate Range End			2.00%
Credit agreement maximum borrowing capacity \| €				€ 100.0
Investment Interest Rate Range Start			1.00%
Remaining borrowing available under revolving credit facility \| €				100.0
JP Morgan UK [Member]
Line of Credit Facility [Line Items]
Credit agreement maximum borrowing capacity							$ 4,500
Remaining borrowing available under revolving credit facility							$ 4,500
ING Bank NV [Member]
Line of Credit Facility [Line Items]
Credit agreement maximum borrowing capacity \| €				€ 7.5
Minimum [Member] \| JPMorganLOC [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Interest Rate During Period		2.00%
Maximum [Member] \| JPMorganLOC [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Interest Rate During Period		4.00%
Senior Notes due in 2020 [Member]
Line of Credit Facility [Line Items]
Deferred Finance Costs, Noncurrent, Net											200
Revolving Credit Facility [Member]
Line of Credit Facility [Line Items]
Remaining borrowing available under revolving credit facility					165,000
Interest Rate Swap [Member]
Line of Credit Facility [Line Items]
Interest rate swap, fixed interest rate														1.30%
Principal amount of debt hedged with an interest rate swap agreement	$ 100,000	$ 100,000
Uncommitted Overdraft Facility [Member] \| Unsecured Debt [Member] \| ING Bank NV [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Unused Borrowing Capacity, Amount \| €						€ 7.5
Uncommitted Overdraft Facility [Member] \| Unsecured Debt [Member] \| Minimum [Member] \| ING Bank NV [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Interest Rate, Stated Percentage								2.00%
Uncommitted Overdraft Facility [Member] \| Unsecured Debt [Member] \| Maximum [Member] \| ING Bank NV [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Interest Rate, Stated Percentage								4.00%
2016 Credit Agreement [Member]
Line of Credit Facility [Line Items]
Long-term Debt					285,000
Max commitment fee on revolving loan unused amount, percentage		0.25%
2016 Credit Agreement [Member] \| Swingline Loan [Member]
Line of Credit Facility [Line Items]
Line of Credit Facility, Current Borrowing Capacity									$ 0
2016 Credit Agreement [Member] \| Revolving Credit Facility [Member]
Line of Credit Facility [Line Items]
Line of Credit Facility, Current Borrowing Capacity									0
Line of credit facility amount outstanding									0
2016 Credit Agreement [Member] \| Term Loan [Member]
Line of Credit Facility [Line Items]
Long-term Debt					392,500				$ 0
Senior Notes due in 2020 [Member] \| Senior Notes [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Interest Rate, Stated Percentage													3.11%
Long-term Debt, Gross											$ 100,000
Designated as Hedging Instrument [Member]
Line of Credit Facility [Line Items]
Derivative, Notional Amount					$ 355,700			$ 384,500

XML 55 R43.htm IDEA: XBRL DOCUMENT

Credit Agreements 2014 Credit Agreement (Details) - USD ($)	1 Months Ended	3 Months Ended	6 Months Ended	9 Months Ended
	May 31, 2013	Sep. 30, 2016	Dec. 31, 2016	Mar. 31, 2015	Mar. 11, 2016	Oct. 01, 2015	Sep. 30, 2015	Jun. 12, 2015	Oct. 15, 2014	Jul. 25, 2013	Sep. 30, 2011
Debt Instrument [Line Items]
Derivative, Fixed Interest Rate	0.73%					1.104%
Long-term Debt, Gross			$ 780,800,000					$ 7,100,000
Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Remaining Borrowing Capacity			165,000,000
Senior Notes due in 2020 [Member]
Debt Instrument [Line Items]
Deferred Finance Costs, Noncurrent, Net							$ 200,000
2016 Credit Agreement [Member]
Debt Instrument [Line Items]
Long-term Debt			$ 285,000,000
Credit facility, maximum borrowing capacity									$ 750,000,000
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage		0.25%
2016 Credit Agreement [Member] \| LIBOR Plus Margin [Member]
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate		2.00%
2016 Credit Agreement [Member] \| Federal Funds Plus Margin [Member]
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate			0.50%
2016 Credit Agreement [Member] \| One Month LIBOR Plus Rate [Member]
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate		1.00%
2016 Credit Agreement [Member] \| Term Loan [Member]
Debt Instrument [Line Items]
Long-term Debt			$ 392,500,000		$ 0
2016 Credit Agreement [Member] \| Term Loan [Member] \| Debt Instrument, Redemption, Period One [Member]
Debt Instrument [Line Items]
Term Loan, Quarterly Principal Payment Percentage					0.63%
2016 Credit Agreement [Member] \| Term Loan [Member] \| Debt Instrument, Redemption, Period Two [Member]
Debt Instrument [Line Items]
Term Loan, Quarterly Principal Payment Percentage					1.25%
2016 Credit Agreement [Member] \| Term Loan [Member] \| Debt Instrument, Redemption, Period Three [Member]
Debt Instrument [Line Items]
Term Loan, Quarterly Principal Payment Percentage					1.88%
2016 Credit Agreement [Member] \| Term Loan [Member] \| Debt Instrument, Redemption, Period Four [Member]
Debt Instrument [Line Items]
Term Loan, Quarterly Principal Payment Percentage					2.50%
2016 Credit Agreement [Member] \| Swingline Loan [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Current Borrowing Capacity					$ 0
2016 Credit Agreement [Member] \| Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Long-term Line of Credit					0
Line of Credit Facility, Current Borrowing Capacity					0
Letters of Credit, maximum issuance amount					10,000,000
2014 Credit Agreement [Member]
Debt Instrument [Line Items]
Credit facility, maximum borrowing capacity									500,000,000
Debt Instrument, Face Amount					0.005
2014 Credit Agreement [Member] \| LIBOR Plus Margin [Member]
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate				1.75%
2014 Credit Agreement [Member] \| One Month LIBOR Plus Rate [Member]
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate		1.00%
2014 Credit Agreement [Member] \| One Month LIBOR Plus Margin [Member]
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate				0.75%
2014 Credit Agreement [Member] \| Term Loan [Member]
Debt Instrument [Line Items]
Long-term Debt									200,000,000
Debt Instrument, Face Amount					$ 0.003
2014 Credit Agreement [Member] \| Swingline Loan [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Current Borrowing Capacity									100,000,000
2014 Credit Agreement [Member] \| Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Current Borrowing Capacity									300,000,000
Letters of Credit, maximum issuance amount									$ 10,000,000
Senior Notes due in 2020 [Member] \| Senior Notes [Member]
Debt Instrument [Line Items]
Long-term Debt, Gross							$ 100,000,000
Debt Instrument, Interest Rate, Stated Percentage										3.11%
Interest Rate Swap [Member]
Debt Instrument [Line Items]
Amount Of Debt Hedged By Interest Rate Derivatives	$ 100,000,000	$ 100,000,000
Derivative, Fixed Interest Rate											1.30%

XML 56 R44.htm IDEA: XBRL DOCUMENT

Credit Agreements Master Financing Agreement (Details) - USD ($) $ in Millions	Dec. 31, 2016	Jun. 12, 2015
Master Financing Agreement [Line Items]
Long-term Debt, Gross	$ 780.8	$ 7.1
Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months	8.0	1.4
Long-term Debt, Maturities, Repayments of Principal in Year Two	22.8	2.8
Long-term Debt, Maturities, Repayments of Principal in Year Three	$ 22.5	$ 2.9

XML 57 R45.htm IDEA: XBRL DOCUMENT

Credit Agreements 2016 Credit Agreement (Details) - USD ($) $ in Millions		1 Months Ended	3 Months Ended
	Mar. 11, 2016	May 31, 2013	Sep. 30, 2016	Dec. 31, 2016	Oct. 01, 2015	Oct. 15, 2014	Sep. 30, 2011
Line of Credit Facility [Line Items]
Derivative, Fixed Interest Rate		0.73%			1.104%
2016 Credit Agreement [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Term	5 years
Long-term Debt				$ 285.0
Credit facility, maximum borrowing capacity						$ 750.0
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage			0.25%
Revolving Credit Facility [Member] \| 2016 Credit Agreement [Member]
Line of Credit Facility [Line Items]
Long-term Line of Credit	$ 0.0
Line of Credit Facility, Current Borrowing Capacity	0.0
Letters of Credit, maximum issuance amount	10.0
Term Loan [Member] \| 2016 Credit Agreement [Member]
Line of Credit Facility [Line Items]
Long-term Debt	0.0			$ 392.5
Swingline Loan [Member] \| 2016 Credit Agreement [Member]
Line of Credit Facility [Line Items]
Line of Credit Facility, Current Borrowing Capacity	$ 0.0
LIBOR Plus Margin [Member] \| 2016 Credit Agreement [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Basis Spread on Variable Rate			2.00%
One Month LIBOR Plus Rate [Member] \| 2016 Credit Agreement [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Basis Spread on Variable Rate			1.00%
Debt Instrument, Redemption, Period One [Member] \| Term Loan [Member] \| 2016 Credit Agreement [Member]
Line of Credit Facility [Line Items]
Term Loan, Quarterly Principal Payment Percentage	0.63%
Debt Instrument, Redemption, Period Two [Member] \| Term Loan [Member] \| 2016 Credit Agreement [Member]
Line of Credit Facility [Line Items]
Term Loan, Quarterly Principal Payment Percentage	1.25%
Debt Instrument, Redemption, Period Three [Member] \| Term Loan [Member] \| 2016 Credit Agreement [Member]
Line of Credit Facility [Line Items]
Term Loan, Quarterly Principal Payment Percentage	1.88%
Debt Instrument, Redemption, Period Four [Member] \| Term Loan [Member] \| 2016 Credit Agreement [Member]
Line of Credit Facility [Line Items]
Term Loan, Quarterly Principal Payment Percentage	2.50%
Debt Instrument, Redemption, Period Five [Member] \| Term Loan [Member] \| 2016 Credit Agreement [Member]
Line of Credit Facility [Line Items]
Term Loan, Quarterly Principal Payment Percentage	72.50%
Interest Rate Swap [Member]
Line of Credit Facility [Line Items]
Amount Of Debt Hedged By Interest Rate Derivatives		$ 100.0	$ 100.0
Derivative, Fixed Interest Rate							1.30%

XML 58 R46.htm IDEA: XBRL DOCUMENT

Credit Agreements 2016 Term Loan Agreement (Details) - USD ($) $ in Millions		3 Months Ended
	Feb. 10, 2016	Sep. 30, 2016	Dec. 31, 2016	Mar. 11, 2016	Jun. 12, 2015
Short-term Debt [Line Items]
Long-term Debt, Gross			$ 780.8		$ 7.1
2016 Credit Agreement [Member]
Short-term Debt [Line Items]
Long-term Debt			285.0
Senior Notes [Member] \| 2016 Term Loan Agreement [Member]
Short-term Debt [Line Items]
Long-term Debt, Gross	$ 0.0
2016 Term Loan Agreement [Member]
Short-term Debt [Line Items]
Debt Instrument, Basis Spread on Variable Rate	0.75%
LIBOR Plus Margin [Member] \| 2016 Credit Agreement [Member]
Short-term Debt [Line Items]
Debt Instrument, Basis Spread on Variable Rate		2.00%
LIBOR Plus Margin [Member] \| 2016 Term Loan Agreement [Member]
Short-term Debt [Line Items]
Debt Instrument, Basis Spread on Variable Rate		1.75%
Term Loan [Member] \| 2016 Credit Agreement [Member]
Short-term Debt [Line Items]
Long-term Debt			$ 392.5	$ 0.0

XML 59 R47.htm IDEA: XBRL DOCUMENT

Credit Agreements 2016 Credit Agreement (Details)1 - USD ($) $ in Millions	3 Months Ended	6 Months Ended
	Sep. 30, 2016	Dec. 31, 2016	Mar. 11, 2016	Oct. 15, 2014
2016 Credit Agreement [Member]
Line of Credit Facility [Line Items]
Credit facility, maximum borrowing capacity				$ 750.0
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage	0.25%
Long-term Debt		$ 285.0
Term Loan [Member] \| 2016 Credit Agreement [Member]
Line of Credit Facility [Line Items]
Long-term Debt		392.5	$ 0.0
Revolving Credit Facility [Member]
Line of Credit Facility [Line Items]
Line of Credit Facility, Remaining Borrowing Capacity		$ 165.0
Revolving Credit Facility [Member] \| 2016 Credit Agreement [Member]
Line of Credit Facility [Line Items]
Line of Credit Facility, Current Borrowing Capacity			0.0
Letters of Credit, maximum issuance amount			10.0
Long-term Line of Credit			0.0
Swingline Loan [Member] \| 2016 Credit Agreement [Member]
Line of Credit Facility [Line Items]
Line of Credit Facility, Current Borrowing Capacity			$ 0.0
LIBOR Plus Margin [Member] \| 2016 Credit Agreement [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Basis Spread on Variable Rate	2.00%
Federal Funds Plus Margin [Member] \| 2016 Credit Agreement [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Basis Spread on Variable Rate		0.50%
One Month LIBOR Plus Rate [Member] \| 2016 Credit Agreement [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Basis Spread on Variable Rate	1.00%
Debt Instrument, Redemption, Period Five [Member] \| Term Loan [Member] \| 2016 Credit Agreement [Member]
Line of Credit Facility [Line Items]
Term Loan, Quarterly Principal Payment Percentage			72.50%
Minimum [Member] \| JPMorganLOC [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Interest Rate During Period	2.00%

XML 60 R48.htm IDEA: XBRL DOCUMENT

Debt, Commitments, Contingencies And Guarantees Schedule of Contractual Obligation (Details) - USD ($) $ in Millions	Dec. 31, 2016	Jun. 12, 2015
Contractual Obligation [Abstract]
Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months	$ 8.0	$ 1.4
Long-term Debt, Maturities, Repayments of Principal in Year Two	22.8	2.8
Long-term Debt, Maturities, Repayments of Principal in Year Three	22.5	2.9
Long-term Debt, Maturities, Repayments of Principal in Year Four	32.5
Long-term Debt, Maturities, Repayments of Principal in Year Five	695.0
Long-term Debt, Maturities, Repayments of Principal after Year Five	0.0
Long-term Debt, Gross	$ 780.8	$ 7.1

XML 61 R49.htm IDEA: XBRL DOCUMENT

Commitments, Contingencies And Guarantees (Details) $ in Millions	Dec. 31, 2016 USD ($)
Business Acquisition, Contingent Consideration [Line Items]
Letters of Credit Outstanding, Amount	$ 10.2
Expected Asset Retirement Obligation	14.1
Fair Value, Inputs, Level 3 [Member]
Business Acquisition, Contingent Consideration [Line Items]
Business Combination, Contingent Consideration, Liability	$ 14.0

XML 62 R50.htm IDEA: XBRL DOCUMENT

Derivatives (Schedule Of Notional Amounts And Fair Values Of Derivatives) (Details) - USD ($) $ in Millions	1 Months Ended	3 Months Ended			6 Months Ended
	May 31, 2013	Dec. 31, 2016	Sep. 30, 2016	Dec. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Jun. 30, 2016	Oct. 01, 2015	Sep. 30, 2011
Derivatives, Fair Value [Line Items]
Forward Contract Indexed to Issuer's Equity, Classification		40
Derivative, Fixed Interest Rate	0.73%							1.104%
Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net		$ (0.6)		$ (0.7)	$ (0.4)	$ (1.7)
Notional Amount		702.5			702.5		$ 468.7
Asset (Liability)		14.9			14.9		(6.6)
Unrealized Gain (Loss) on Derivatives and Commodity Contracts		20.3
Derivatives Not Designated As Hedging Instruments [Member]
Derivatives, Fair Value [Line Items]
Notional Amount		346.8			346.8		84.2
Asset (Liability)		19.6			19.6		0.1
Derivatives Designated As Hedging Instruments [Member]
Derivatives, Fair Value [Line Items]
Notional Amount		355.7			355.7		384.5
Asset (Liability)		(4.7)			(4.7)		(6.7)
Interest Rate Swap [Member]
Derivatives, Fair Value [Line Items]
Amount Of Debt Hedged By Interest Rate Derivatives	$ 100.0		$ 100.0
Derivative, Fixed Interest Rate									1.30%
Interest Rate Contract [Member] \| Derivatives Designated As Hedging Instruments [Member]
Derivatives, Fair Value [Line Items]
Derivative Liability, Fair Value, Gross Liability		0.0			0.0		(1.3)
Derivative Asset, Fair Value, Gross Asset		0.5			0.5		0.0
Derivative Liability, Notional Amount		0.0			0.0		200.0
Derivative Asset, Notional Amount		200.0			200.0		0.0
Foreign Exchange Contracts [Member] \| Derivatives Not Designated As Hedging Instruments [Member]
Derivatives, Fair Value [Line Items]
Derivative Liability, Fair Value, Gross Liability		(1.7)			(1.7)		(1.4)
Derivative Asset, Fair Value, Gross Asset		1.6			1.6		1.5
Derivative Liability, Notional Amount		38.8			38.8		48.0
Derivative Asset, Notional Amount		108.0			108.0		36.2
Foreign Exchange Contracts [Member] \| Derivatives Designated As Hedging Instruments [Member]
Derivatives, Fair Value [Line Items]
Derivative Liability, Fair Value, Gross Liability		(7.6)			(7.6)		(8.9)
Derivative Asset, Fair Value, Gross Asset		2.4			2.4		3.5
Derivative Liability, Notional Amount		95.8			95.8		103.3
Derivative Asset, Notional Amount		59.9			59.9		81.2
Forward Contracts [Member] \| Derivatives Not Designated As Hedging Instruments [Member]
Derivatives, Fair Value [Line Items]
Derivative Asset, Fair Value, Gross Asset		19.7			19.7		0.0
Derivative Asset, Notional Amount		$ 200.0			$ 200.0		0.0
Derivatives Designated As Hedging Instruments [Member] \| Interest Rate Contract [Member]
Derivatives, Fair Value [Line Items]
Notional Amount							$ 100.0

XML 63 R51.htm IDEA: XBRL DOCUMENT

Derivatives (Schedule Of Change In The Fair Value Of Derivatives Designated As Hedging Instruments) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2016	Dec. 31, 2015
Derivative Instruments, Gain (Loss) [Line Items]
Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Tax	$ 300	$ 400	$ (500)	$ (400)
Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net	(600)	(700)	(400)	(1,700)
Estimated net amount of existing losses that are expected to be reclassified into earnings			6,300
Derivatives Designated As Hedging Instruments [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative instruments, gain (loss) recognized in other comprehensive income, effective portion, net, total	(1,100)	(100)	1,100	(2,200)
Interest Rate Contract [Member] \| Derivatives Designated As Hedging Instruments [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative instruments, gain (loss) recognized in other comprehensive income, effective portion, net, total	1,400	700	1,900	200
Foreign Exchange Contracts [Member] \| Not Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net	(900)	(3,300)	(800)	(3,600)
Foreign Exchange Contracts [Member] \| Derivatives Designated As Hedging Instruments [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative instruments, gain (loss) recognized in other comprehensive income, effective portion, net, total	$ (2,500)	$ (800)	$ (800)	$ (2,400)

XML 64 R52.htm IDEA: XBRL DOCUMENT

Derivatives (Schedule Of Change In The Fair Value Of Derivatives Not Designated As Hedging Instruments) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2016	Dec. 31, 2015
Derivative Instruments, Gain (Loss) [Line Items]
Unrealized Gain (Loss) on Derivatives and Commodity Contracts	$ 20,300
Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net	(600)	$ (700)	$ (400)	$ (1,700)
Derivatives Not Designated As Hedging Instruments [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Unrealized Gain on Foreign Currency Derivatives, before Tax	(21,500)	(100)	(21,700)	(700)
Forward Contracts [Member] \| Derivatives Not Designated As Hedging Instruments [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Unrealized Gain (Loss) on Derivatives	(20,300)		(20,300)
Foreign Exchange Contracts [Member] \| Derivatives Not Designated As Hedging Instruments [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Fair value of derivatives not designated as hedging instruments	(900)	(3,300)	(800)	(3,600)
Unrealized Gain on Foreign Currency Derivatives, before Tax	$ (1,200)	(100)	$ (1,400)	(700)
Cross-Currency Interest Rate Swap Contracts [Member] \| Derivatives Not Designated As Hedging Instruments [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Unrealized Gain on Foreign Currency Derivatives, before Tax		$ 0		$ 0

XML 65 R53.htm IDEA: XBRL DOCUMENT

Goodwill (Details) - USD ($) $ in Millions	Dec. 31, 2016	Jun. 30, 2016
Goodwill [Line Items]
Goodwill	$ 441.0	$ 389.2

XML 66 R54.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Schedule Of Fair Value Hierarchy, Assets (Liabilities) Carried At Fair Value) (Details) - USD ($) $ in Thousands				6 Months Ended
	Oct. 03, 2016	Feb. 10, 2016	Jan. 19, 2016	Dec. 31, 2016	Dec. 31, 2015	Jun. 30, 2016
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Payments to Acquire Businesses, Net of Cash Acquired				$ 148,300	$ 0
Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value				14,000		$ 5,200
Long-term Debt, Fair Value				$ 96,500
Fair Value Inputs, Discount Rate				1.00%
Interest Rate Derivative Instruments				$ 500		(1,300)
Foreign Currency Fair Value Hedge Derivative at Fair Value, Net				(5,300)		(5,300)
Business Acquisition, Contingent Consideration, at Fair Value				(14,000)		(5,200)
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings				600	$ (8,200)
Liabilities, Fair Value Disclosure, Recurring				900		(11,800)
Fair Value, Inputs, Level 1 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Interest Rate Derivative Instruments				0		0
Foreign Currency Fair Value Hedge Derivative at Fair Value, Net				0		0
Business Acquisition, Contingent Consideration, at Fair Value				0		0
Total				0		0
Fair Value, Inputs, Level 2 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Interest Rate Derivative Instruments				500		(1,300)
Foreign Currency Fair Value Hedge Derivative at Fair Value, Net				(5,300)		(5,300)
Business Acquisition, Contingent Consideration, at Fair Value				0		0
Liabilities, Fair Value Disclosure, Recurring				(4,800)		(6,600)
Fair Value, Inputs, Level 3 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Interest Rate Derivative Instruments				0		0
Foreign Currency Fair Value Hedge Derivative at Fair Value, Net				0		0
Business Acquisition, Contingent Consideration, at Fair Value				(600)		(5,200)
Business Combination, Expected Contingent Consideration Payment				14,000
Liabilities, Fair Value Disclosure, Recurring				$ 5,700		$ (5,200)
Health Advances Acquisition [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Business Combination, Consideration Transferred		$ 71,600
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High			$ 15,800
Payments to Acquire Businesses, Net of Cash Acquired		67,100	$ 67,100
Fair Value Inputs, Discount Rate				1.00%
Business Acquisition, Contingent Consideration, at Fair Value				$ (4,500)
Health Advances Acquisition [Member] \| Fair Value, Inputs, Level 3 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Business Acquisition, Contingent Consideration, at Fair Value				$ (4,600)
ExecuPharm Inc. [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Business Combination, Consideration Transferred		$ 167,200
Payments to Acquire Businesses, Gross	$ 148,900
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	20,000
Payments to Acquire Businesses, Net of Cash Acquired	148,500
Fair Value Inputs, Discount Rate				1.00%
Business Acquisition, Contingent Consideration, at Fair Value	$ (9,400)

XML 67 R55.htm IDEA: XBRL DOCUMENT

Fair Value Measurements Unobservable Inputs (Details) - USD ($) $ in Millions				6 Months Ended
	Oct. 03, 2016	Feb. 10, 2016	Jan. 19, 2016	Dec. 31, 2016	Dec. 31, 2015
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Payments to Acquire Businesses, Net of Cash Acquired				$ 148.3	$ 0.0
Fair Value Inputs, Discount Rate				1.00%
Fair Value Assumptions, Weighted Average Volatility Rate				3750.00%
ClinIntel Acquisition [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Payments to Acquire Businesses, Net of Cash Acquired		$ 67.1	$ 67.1
Fair Value Inputs, Discount Rate				1.00%
Fair Value Assumptions, Weighted Average Volatility Rate		26.00%
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High			$ 15.8
Fair Value, Measurement Inputs, Disclosure [Text Block]				Approximately 2 years
ExecuPharm Inc. [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Payments to Acquire Businesses, Net of Cash Acquired	$ 148.5
Fair Value Inputs, Discount Rate				1.00%
Fair Value Assumptions, Weighted Average Volatility Rate		29.00%
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	$ 20.0
Fair Value, Measurement Inputs, Disclosure [Text Block]				Approximately 2 years

XML 68 R56.htm IDEA: XBRL DOCUMENT

Fair Value Measurements Level 3 Rollforward (Details) - USD ($) $ in Millions		3 Months Ended	6 Months Ended
	Oct. 03, 2016	Dec. 31, 2016	Dec. 31, 2016	Dec. 31, 2015
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair Value Assumptions, Expected Term			4 months 24 days
Fair Value Inputs, Discount Rate			1.00%
Accelerated Share Repurchases, Cash or Stock Settlement		160
Contingent Consideration [Roll Forward]
Balance at June 30, 2015			$ 5.2
Additions of contingent consideration due to Health Advances acquisition	$ 9.4
Change in fair value of contingent consideration			(0.6)	$ 8.2
Balance at March 31, 2016		$ 14.0	$ 14.0
Forward Contract Indexed to Issuer's Equity, Classification		40
ExecuPharm Inc. [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair Value Inputs, Discount Rate			1.00%
Fair Value, Measurement Inputs, Disclosure [Text Block]			Approximately 2 years
Forward Contracts [Member]
Contingent Consideration [Roll Forward]
Balance at June 30, 2015			$ 0.0
Additions of contingent consideration due to Health Advances acquisition			40.0
Change in fair value of contingent consideration			(20.3)
Balance at March 31, 2016		$ 19.7	$ 19.7

XML 69 R57.htm IDEA: XBRL DOCUMENT

Fair Value Measurements Fair Value Measurements Narrative (Details) - USD ($) $ in Millions			3 Months Ended	6 Months Ended
	Feb. 10, 2016	Jan. 19, 2016	Dec. 31, 2016	Dec. 31, 2016	Dec. 31, 2015	Jun. 30, 2016
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Unrealized Gain (Loss) on Derivatives and Commodity Contracts			$ 20.3
Forward Contract Indexed to Issuer's Equity, Classification			40
Forward Contract Indexed to Issuer's Equity, Settlement Alternatives, Cash, at Fair Value			$ 19.7	$ 19.7
Business Combination, Contingent Consideration, Liability			14.0	14.0		$ 5.2
Payments to Acquire Businesses, Net of Cash Acquired				148.3	$ 0.0
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings				0.6	$ (8.2)
Long-term Debt, Fair Value			96.5	96.5
Health Advances Acquisition [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Business Combination, Contingent Consideration, Liability			4.5	4.5
Payments to Acquire Businesses, Net of Cash Acquired	$ 67.1	$ 67.1
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High		$ 15.8
Fair Value, Inputs, Level 3 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Business Combination, Contingent Consideration, Liability			0.6	0.6		$ 5.2
Fair Value, Inputs, Level 3 [Member] \| Health Advances Acquisition [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Business Combination, Contingent Consideration, Liability			$ 4.6	$ 4.6

EXCEL 70 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 71 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 72 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 74 FilingSummary.xml IDEA: XBRL DOCUMENT 3.6.0.2 html 198 231 1 false 73 0 false 5 false false R1.htm 0001000 - Document - Document And Entity Information Sheet http://www.parexel.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 1001000 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.parexel.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 1001001 - Statement - Condensed Consolidated Balance Sheets Parenthethical Sheet http://www.parexel.com/role/CondensedConsolidatedBalanceSheetsParenthethical Condensed Consolidated Balance Sheets Parenthethical Statements 3 false false R4.htm 1002000 - Statement - Condensed Consolidated Statements Of Income Sheet http://www.parexel.com/role/CondensedConsolidatedStatementsOfIncome Condensed Consolidated Statements Of Income Statements 4 false false R5.htm 1002001 - Statement - Condensed Consolidated Statements of Comprehensive Income Sheet http://www.parexel.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome Condensed Consolidated Statements of Comprehensive Income Statements 5 false false R6.htm 1003000 - Statement - Condensed Consolidated Statements Of Cash Flows Sheet http://www.parexel.com/role/CondensedConsolidatedStatementsOfCashFlows Condensed Consolidated Statements Of Cash Flows Statements 6 false false R7.htm 2101100 - Disclosure - Basis Of Presentation Sheet http://www.parexel.com/role/BasisOfPresentation Basis Of Presentation Notes 7 false false R8.htm 2104100 - Disclosure - Equity and Earnings Per Share Sheet http://www.parexel.com/role/EquityAndEarningsPerShare Equity and Earnings Per Share Notes 8 false false R9.htm 2105100 - Disclosure - Accumulated Other Comprehensive Income Sheet http://www.parexel.com/role/AccumulatedOtherComprehensiveIncome Accumulated Other Comprehensive Income Notes 9 false false R10.htm 2106100 - Disclosure - Stock-Based Compensation Sheet http://www.parexel.com/role/StockBasedCompensation Stock-Based Compensation Notes 10 false false R11.htm 2107100 - Disclosure - Restructuring Charges Sheet http://www.parexel.com/role/RestructuringCharges Restructuring Charges Notes 11 false false R12.htm 2108100 - Disclosure - Segment Information Sheet http://www.parexel.com/role/SegmentInformation Segment Information Notes 12 false false R13.htm 2109100 - Disclosure - Income Taxes Sheet http://www.parexel.com/role/IncomeTaxes Income Taxes Notes 13 false false R14.htm 2110100 - Disclosure - Credit Agreements Sheet http://www.parexel.com/role/CreditAgreements Credit Agreements Notes 14 false false R15.htm 2111100 - Disclosure - Debt, Commitments, Contingencies And Guarantees Sheet http://www.parexel.com/role/DebtCommitmentsContingenciesAndGuarantees Debt, Commitments, Contingencies And Guarantees Notes 15 false false R16.htm 2112100 - Disclosure - Derivatives Sheet http://www.parexel.com/role/Derivatives Derivatives Notes 16 false false R17.htm 2114100 - Disclosure - Fair Value Measurements Sheet http://www.parexel.com/role/FairValueMeasurements Fair Value Measurements Notes 17 false false R18.htm 2115101 - Disclosure - Subsequent Event restructuring (Notes) Notes http://www.parexel.com/role/SubsequentEventRestructuringNotes Subsequent Event restructuring (Notes) Notes 18 false false R19.htm 2303301 - Disclosure - Acquisitions, Goodwill, and Other Intangible Assets (Tables) Sheet http://www.parexel.com/role/AcquisitionsGoodwillAndOtherIntangibleAssetsTables Acquisitions, Goodwill, and Other Intangible Assets (Tables) Tables 19 false false R20.htm 2304301 - Disclosure - Equity and Earnings Per Share (Tables) Sheet http://www.parexel.com/role/EquityAndEarningsPerShareTables Equity and Earnings Per Share (Tables) Tables http://www.parexel.com/role/EquityAndEarningsPerShare 20 false false R21.htm 2305301 - Disclosure - Comprehensive Income (Tables) Sheet http://www.parexel.com/role/ComprehensiveIncomeTables Comprehensive Income (Tables) Tables 21 false false R22.htm 2306301 - Disclosure - Stock-Based Compensation (Tables) Sheet http://www.parexel.com/role/StockBasedCompensationTables Stock-Based Compensation (Tables) Tables http://www.parexel.com/role/StockBasedCompensation 22 false false R23.htm 2307301 - Disclosure - Restructuring Charges (Tables) Sheet http://www.parexel.com/role/RestructuringChargesTables Restructuring Charges (Tables) Tables http://www.parexel.com/role/RestructuringCharges 23 false false R24.htm 2308301 - Disclosure - Segment Information (Tables) Sheet http://www.parexel.com/role/SegmentInformationTables Segment Information (Tables) Tables http://www.parexel.com/role/SegmentInformation 24 false false R25.htm 2311301 - Disclosure - Debt, Commitments, Contingencies And Guarantees Schedule of Contractual Obligation (Tables) Sheet http://www.parexel.com/role/DebtCommitmentsContingenciesAndGuaranteesScheduleOfContractualObligationTables Debt, Commitments, Contingencies And Guarantees Schedule of Contractual Obligation (Tables) Tables 25 false false R26.htm 2312301 - Disclosure - Derivatives (Tables) Sheet http://www.parexel.com/role/DerivativesTables Derivatives (Tables) Tables http://www.parexel.com/role/Derivatives 26 false false R27.htm 2314301 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.parexel.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.parexel.com/role/FairValueMeasurements 27 false false R28.htm 2401401 - Disclosure - Basis Of Presentation (Details) Sheet http://www.parexel.com/role/BasisOfPresentationDetails Basis Of Presentation (Details) Details http://www.parexel.com/role/BasisOfPresentation 28 false false R29.htm 2401402 - Disclosure - Basis Of Presentation change (Details) Sheet http://www.parexel.com/role/BasisOfPresentationChangeDetails Basis Of Presentation change (Details) Details 29 false false R30.htm 2401403 - Disclosure - Basis Of Presentation prior period adjustment (Details) Sheet http://www.parexel.com/role/BasisOfPresentationPriorPeriodAdjustmentDetails Basis Of Presentation prior period adjustment (Details) Details 30 false false R31.htm 2403402 - Disclosure - Acquisitions, Goodwill, and Other Intangible Assets (Details) Sheet http://www.parexel.com/role/AcquisitionsGoodwillAndOtherIntangibleAssetsDetails Acquisitions, Goodwill, and Other Intangible Assets (Details) Details http://www.parexel.com/role/AcquisitionsGoodwillAndOtherIntangibleAssetsTables 31 false false R32.htm 2403403 - Disclosure - Acquisitions, Goodwill, and Other Intangible Assets goodwill (Details) Sheet http://www.parexel.com/role/AcquisitionsGoodwillAndOtherIntangibleAssetsGoodwillDetails Acquisitions, Goodwill, and Other Intangible Assets goodwill (Details) Details http://www.parexel.com/role/AcquisitionsGoodwillAndOtherIntangibleAssetsTables 32 false false R33.htm 2403404 - Disclosure - Acquisitions, Goodwill, and Other Intangible Assets intangibles (Details) Sheet http://www.parexel.com/role/AcquisitionsGoodwillAndOtherIntangibleAssetsIntangiblesDetails Acquisitions, Goodwill, and Other Intangible Assets intangibles (Details) Details http://www.parexel.com/role/AcquisitionsGoodwillAndOtherIntangibleAssetsTables 33 false false R34.htm 2404402 - Disclosure - Equity and Earnings Per Share (Computation Of Basic And Diluted Earnings Per Common Share) (Details) Sheet http://www.parexel.com/role/EquityAndEarningsPerShareComputationOfBasicAndDilutedEarningsPerCommonShareDetails Equity and Earnings Per Share (Computation Of Basic And Diluted Earnings Per Common Share) (Details) Details http://www.parexel.com/role/EquityAndEarningsPerShareTables 34 false false R35.htm 2404403 - Disclosure - Equity and Earnings Per Share buyback (Details) Sheet http://www.parexel.com/role/EquityAndEarningsPerShareBuybackDetails Equity and Earnings Per Share buyback (Details) Details 35 false false R36.htm 2405402 - Disclosure - Comprehensive Income (Schedule Of Comprehensive Income) (Details) Sheet http://www.parexel.com/role/ComprehensiveIncomeScheduleOfComprehensiveIncomeDetails Comprehensive Income (Schedule Of Comprehensive Income) (Details) Details http://www.parexel.com/role/ComprehensiveIncomeTables 36 false false R37.htm 2406402 - Disclosure - Stock-Based Compensation (Classification Of Compensation Expense Within Consolidated Statements Of Income) (Details) Sheet http://www.parexel.com/role/StockBasedCompensationClassificationOfCompensationExpenseWithinConsolidatedStatementsOfIncomeDetails Stock-Based Compensation (Classification Of Compensation Expense Within Consolidated Statements Of Income) (Details) Details http://www.parexel.com/role/StockBasedCompensationTables 37 false false R38.htm 2407402 - Disclosure - Restructuring Charges (Narrative) (Details) Sheet http://www.parexel.com/role/RestructuringChargesNarrativeDetails Restructuring Charges (Narrative) (Details) Details http://www.parexel.com/role/RestructuringChargesTables 38 false false R39.htm 2407403 - Disclosure - Restructuring Charges (Schedule Of Charges Against The Restructuring Accrual) (Details) Sheet http://www.parexel.com/role/RestructuringChargesScheduleOfChargesAgainstRestructuringAccrualDetails Restructuring Charges (Schedule Of Charges Against The Restructuring Accrual) (Details) Details http://www.parexel.com/role/RestructuringChargesTables 39 false false R40.htm 2408402 - Disclosure - Segment Information (Service Revenue, Direct Costs And Gross Profit On Service Revenue Of Reportable Segment) (Details) Sheet http://www.parexel.com/role/SegmentInformationServiceRevenueDirectCostsAndGrossProfitOnServiceRevenueOfReportableSegmentDetails Segment Information (Service Revenue, Direct Costs And Gross Profit On Service Revenue Of Reportable Segment) (Details) Details http://www.parexel.com/role/SegmentInformationTables 40 false false R41.htm 2409401 - Disclosure - Income Taxes (Details) Sheet http://www.parexel.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://www.parexel.com/role/IncomeTaxes 41 false false R42.htm 2410401 - Disclosure - Credit Agreements (Details) Sheet http://www.parexel.com/role/CreditAgreementsDetails Credit Agreements (Details) Details http://www.parexel.com/role/CreditAgreements 42 false false R43.htm 2410402 - Disclosure - Credit Agreements 2014 Credit Agreement (Details) Sheet http://www.parexel.com/role/CreditAgreements2014CreditAgreementDetails Credit Agreements 2014 Credit Agreement (Details) Details 43 false false R44.htm 2410403 - Disclosure - Credit Agreements Master Financing Agreement (Details) Sheet http://www.parexel.com/role/CreditAgreementsMasterFinancingAgreementDetails Credit Agreements Master Financing Agreement (Details) Details 44 false false R45.htm 2410404 - Disclosure - Credit Agreements 2016 Credit Agreement (Details) Sheet http://www.parexel.com/role/CreditAgreements2016CreditAgreementDetails Credit Agreements 2016 Credit Agreement (Details) Details 45 false false R46.htm 2410405 - Disclosure - Credit Agreements 2016 Term Loan Agreement (Details) Sheet http://www.parexel.com/role/CreditAgreements2016TermLoanAgreementDetails Credit Agreements 2016 Term Loan Agreement (Details) Details 46 false false R47.htm 2410406 - Disclosure - Credit Agreements 2016 Credit Agreement (Details)1 Sheet http://www.parexel.com/role/CreditAgreements2016CreditAgreementDetails1 Credit Agreements 2016 Credit Agreement (Details)1 Details 47 false false R48.htm 2411402 - Disclosure - Debt, Commitments, Contingencies And Guarantees Schedule of Contractual Obligation (Details) Sheet http://www.parexel.com/role/DebtCommitmentsContingenciesAndGuaranteesScheduleOfContractualObligationDetails Debt, Commitments, Contingencies And Guarantees Schedule of Contractual Obligation (Details) Details http://www.parexel.com/role/DebtCommitmentsContingenciesAndGuaranteesScheduleOfContractualObligationTables 48 false false R49.htm 2411403 - Disclosure - Commitments, Contingencies And Guarantees (Details) Sheet http://www.parexel.com/role/CommitmentsContingenciesAndGuaranteesDetails Commitments, Contingencies And Guarantees (Details) Details 49 false false R50.htm 2412402 - Disclosure - Derivatives (Schedule Of Notional Amounts And Fair Values Of Derivatives) (Details) Sheet http://www.parexel.com/role/DerivativesScheduleOfNotionalAmountsAndFairValuesOfDerivativesDetails Derivatives (Schedule Of Notional Amounts And Fair Values Of Derivatives) (Details) Details http://www.parexel.com/role/DerivativesTables 50 false false R51.htm 2412403 - Disclosure - Derivatives (Schedule Of Change In The Fair Value Of Derivatives Designated As Hedging Instruments) (Details) Sheet http://www.parexel.com/role/DerivativesScheduleOfChangeInFairValueOfDerivativesDesignatedAsHedgingInstrumentsDetails Derivatives (Schedule Of Change In The Fair Value Of Derivatives Designated As Hedging Instruments) (Details) Details http://www.parexel.com/role/DerivativesTables 51 false false R52.htm 2412404 - Disclosure - Derivatives (Schedule Of Change In The Fair Value Of Derivatives Not Designated As Hedging Instruments) (Details) Sheet http://www.parexel.com/role/DerivativesScheduleOfChangeInFairValueOfDerivativesNotDesignatedAsHedgingInstrumentsDetails Derivatives (Schedule Of Change In The Fair Value Of Derivatives Not Designated As Hedging Instruments) (Details) Details http://www.parexel.com/role/DerivativesTables 52 false false R53.htm 2413403 - Disclosure - Goodwill (Details) Sheet http://www.parexel.com/role/GoodwillDetails Goodwill (Details) Details 53 false false R54.htm 2414402 - Disclosure - Fair Value Measurements (Schedule Of Fair Value Hierarchy, Assets (Liabilities) Carried At Fair Value) (Details) Sheet http://www.parexel.com/role/FairValueMeasurementsScheduleOfFairValueHierarchyAssetsLiabilitiesCarriedAtFairValueDetails Fair Value Measurements (Schedule Of Fair Value Hierarchy, Assets (Liabilities) Carried At Fair Value) (Details) Details http://www.parexel.com/role/FairValueMeasurementsTables 54 false false R55.htm 2414403 - Disclosure - Fair Value Measurements Unobservable Inputs (Details) Sheet http://www.parexel.com/role/FairValueMeasurementsUnobservableInputsDetails Fair Value Measurements Unobservable Inputs (Details) Details 55 false false R56.htm 2414404 - Disclosure - Fair Value Measurements Level 3 Rollforward (Details) Sheet http://www.parexel.com/role/FairValueMeasurementsLevel3RollforwardDetails Fair Value Measurements Level 3 Rollforward (Details) Details 56 false false R57.htm 2414405 - Disclosure - Fair Value Measurements Fair Value Measurements Narrative (Details) Sheet http://www.parexel.com/role/FairValueMeasurementsFairValueMeasurementsNarrativeDetails Fair Value Measurements Fair Value Measurements Narrative (Details) Details 57 false false All Reports Book All Reports prxl-20161231.xml prxl-20161231.xsd prxl-20161231_cal.xml prxl-20161231_def.xml prxl-20161231_lab.xml prxl-20161231_pre.xml true true ZIP 76 0000799729-17-000015-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000799729-17-000015-xbrl.zip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
\[$>:I@2R6+VS+I(2D?^_SZ M!4A62;)%LHA"58%T]T1T:R2BB/SR*R SD9G />ZH^ML)&D,CEYD3B &5V!G' MN042:D^MU8V,R'-[>8Y13L5V3@Y,@_$Z*7,QGE*13+G4-%(D/*$6J2"-(TXR M0:5KY-+A6\MSG3+HJ$,:Z7FXC*7O$WED1W1_8F1%%(SA=VFP%Q 8X"W?.HG$ M$JH1+[#G[\#'#'D!*X0@:G$;6P,M;[=7UN_#!.FL>?5Q%8R)+@+I +3 ,$$\PJC5!8:JY(#!^&>P M$\/_=TY3Q P1(HDP1FOM(0AKB *@P0Q@FMY;<^J$NJR4'1#2:7;\MXM]Z+>) MZSW;9W1]%_YVO#XDX6D555#3H ?H$!-,2<98NU,AR--C[E.GS^79[X< <9*$ MN?"RA.?,'G8+=S1;VM2Y]7<=%$M)C5NW,_SUK(RX5\95VZNTF7;>>H8U5]H[ M!(E&!&#'L4^ZK#?345JKAN?4FCW,%C?U^_NZ?C50^_P@H0VD-(MAT_[SV#G< M8%]:A4T>,D4U\#B@;0QS"NZ1-BJ\%N4ENO7BR_=G=Z4 6W0^VX\BGCC>>7U MY:4%P@5U.*\(,49X21M("+3I-\,/G,-6 DM>#Y[V0WCDV/JSR78-K?\PI-*Q MCS^W#(37VBI,.(&DD1!(+LL^C.FKMI,LZ(72-?*AR).64F@PE3,_='\&1(E0 ML1S+. ^-XY BNY?;(N[28TA#'[3T4&%">X;S8)HRUM,W>]Y+QKD3!F!L/7=> M$FX:28'@Z=GS R>.%&AY9,3YDG.A V:2:008C16@0H7E&3>24DDNN6UR9R6> MDQ2=AM MLVPK1_IK9V4=:9>H-H> B0KJ\2 BC#&+98:0PH8A*Y M8('OY3>,I$<_1S@ESK@,# /795=2$2F@TAP":@2B807TH'TUB,#IIN((I[H9 MJ9$3I$LKJZ16!OF0E88B9(DWUF]M:X&\ATRDU]:R2Z- ?W2*2- ;L2S*?FM-/9V&ZDW&^^7&-T:WL&KC,FA;O/>6Q^A$@%+9@%V^V:62$ MVEU@Q"NG8CL7MZ3!>)V4N9@06)%,F88A_ M,D$95&<==2B#.@^7ZSFM500 Z8*DV#HAC"',^#9YR\'TZ,D$W?13^9 ?IXD< MH#>!UU_KVP_+-^OU8[U:NW\_QE*;?1O5G3G7W3OJ\K1*4ZB-M-)AI+GVEDE* M(3$ ,2F8=*,6VY[K.F5-9AP)M_)B?YA5 4I MHYY0&)9/!C1$DO-VBP70I!ND(P3J%1SAS& 8OI:'^GEOP+J^^8^/RR\!WH#0)O(?[W^.S,?/F+_[[3/1 M7]8$O<+1$R,JP[7QTFGM:<":4 =5D^_G!!9%'S/D8%->?";8!5_KGO[K?/;G M_"%8=MVVQ*./J(B@6$/HE0NNBZ!40MV$[9VD)-T5&^$48J#],2=@A5!&K=<= M][C#PRM'F2,R=OV1EC$(K::MIXL%3U],^%51)06L\6G2$OKD'M-Y;.61A"(X M@M!8;KD$\=;MO(I%>62@NE2!YD!J?'5L.)S#CE7$5I3XX%(PH0JTF7%JJ MFU0O'R_ 3F:%O%16]$>ID&VEJ^-T:'"EB+*:,RB8XM!%PQLTZ:!>JAYI=$]M M+R^-')FPFJ9!QC0ML:PDUCCA ;:*><^=43&D&;M**$A]CW#PA<6#1T!OQ-X8 MV[R.:^MSX0AD0FKKA/4Z@ T@%=XY(S!S/ORM"U<'.M:YLCX7C(EH<4,KE'44 M <,\V2-MM?)C'CKWZ'/1F2_C];DX#]BB^UP,47EJE:)6$**%PHP0S*!WC<:" MZS=F?Y52<4 M&*;A=D;3Q:$ M+[&Y#D&>AY<.X/"F$..=-$'$O83A][KLK::OVKIVV4E#Z1KY4.3&4@H-IE'_ M:ROGB0WET) 8E?9<:@^9EEYZ$3S1%C)@U)C94Y>^I63">$H6G5Q&#@^J!,(> M.H8QY%XJ8!#"M'WY)'1E;RS]E=>!#;V0NE9>%+G!E$2'D?7B3Y)T;JFSRYVWH>Z4CB#Y&%Y!D+PZ^J9@K/OOE86/[4D"K8 M 8YI3!WER"F"":)_>2&6YZ';]Q$!R'8J>'_MX!74016)#F8**>"(8@ZT\ MQ*7?OYDI[IU/(]V:ZS"JPI)Q!#R1W#$ !";.D 8.BW!Q MP>D\NCU.E!X I64"=U7]P7WUQP]5 $MO"(0 (2^\A@8 V\S;>,K*M*^R:N05 M+?<"YW*46Y215(A.Q]1E]!A/:#)^I*)<&8^H -I9ZYR0RK4+EB(Z/4*;/4]E MT$TZ 8MA]*?";&[CC/S#[.,!!;[X3&4]M)P!!1T.GG_XAT+9S%JJ'I>;9Z\S M'$2#?< 8]A5\5Z_FR^"3W-K7:P4/?K;R%DE 91<$>MT<+>PVTOAG*7I(<[L M%8*#OI1]0!E6M7Z^OID]_%<]6_GPFU.6[W>?KKQRRC+F!0'>"40)$JTDG)/T MSO#9"^H&56\_6,90$Z W57\[/.5E0 +[@)1)7!2&$$1:Z2AO$>GQ>QU;B,H M.1V88=2\"Q3]47^KV6+S^^S3H17ZM8]6$D%@)9148*JX)4*X7T MZ<7.V2O*!M1L/U"&4>VN6^NS3>.X877HXQ5FBAL,-29&"&P"/$8WLF!BTQW7 M[!5A@R@X$RY#OKY^_E"O3)C3Q^7J^,O[XI,5UUI!+3$+Y@.E%%G+&_?-&4G2 M;[3/7M4UX*O;!Y)!U^18Y;%XOUG>_/7^?K:JUV\?-^O-;'$[7QQR1RG0^BH0_K=OV?XE'=;+4(TUL'RW [ MYP,G=?NY#/*5^O';G[.;OZ:^O%;=W-3AG8UMU[;3^J/^_+BZN9^MZZ>;B8\< M9'<97@G.,$<8\["Z6\>-#^YS<*2=P^$/KEMO[]&E/U6H 5 M@C@HO5:$&F,8;T!!P4LM[5 RO[:_3P?) M1H*4&OS#;^N*I/5S6<'%LACHB5 MS 3#&#@.HL2DD9ES7.C!9C9-=F!&#KQ^#JX4=4Y:+D7.I<:!%J#_J&=6&]W.GDDP:JU3MV+_C!I9#@;46"O M^TW8+Z.1LNU+^_9NZTF=,!P.CJD\5P9;:*7%&BOJ*>6MH<:,'[/O:QFF0RZH MQJ+#\VF>W %^_'#E/0YKH>,R&.LH0$25;'$*OT1EFP<9M/7]95NY(+H6 A2Y MYQ>A]TS;O/^O^+OM%S^M8N\>9OMM:/?O@YH]]Q%5E( ("23!$$F/O#:TD4IH M..H-(]VV_SZJ68Z"4C_=\X-3VDVF@^Z[/:(2S"-AM)::&(Z@X]M;$'92 :L* MO#2.P DX8!*7BEE",:"NG)NE>Y&"71 Q*CWQ0)1L6[X(K7<>[3'9?_T=] M4\^_U+?_7 18U?L_#AD3)X95"&%#I40,&L4I4QIXULP>.92^90QVN\(@BAX MJ[%>_B-XO(E:F3V\6\UOZG>S^>WWI]WGG6H>>EJE%3&(>*F]T %>'"]3:G!Q M5J47<0QVI$41YZ9("R 6F:VOG^[VJV']6:S.VY-X]6KCZH(\\Y"("F-G4BP M=L;[!A$ >'I=YF#7,$Q%JASXC>[SJ/7Z\=/GJ)KUO^KYQ_MXZ]^7(-_'^C^7 M\4;!V"*^JR?4]5D5H5"9@#>W6 F*N51/"[@5(-U;'NR^AG'\HX$ G))4[NOG M^B;(\:%>?3J30\^'5DX0H+&R&"$ 8+#\A6MB$YQZF&X(#W:#P^B4Z8'79/E^ M9OGI\^-FFP+Y]D[/UO.;\"$[?W@,=SLUPZ)>:]^OD(N M[ ?"Q'I@H"#C2(IX0[,B4$)%32Z6SE-)>$=&50Y[ M@KTEBC$D'0]+ER9[64$TL4K)O^NIJ>\C&=D0*3K7+N^A.3'04^&#T0V4E)PB MHD4##)=@S*9^9QV:9U%VY_/R\U"ZE.-2P3 $X34SG"B)@ED#,6VEPH!I!]L#G8HE4OG0V'43^MO/]>+\,-?]>990+*#LH^, MJ[S%EBL>9@\T8<@X3V$3(]'(I)?<#W9&E%7'^:!)5NW[^O-F^X7A3RCUI3[K M(16RTH45"<8>IUYS'>\<:"1CG*5W-AKL$">7TH?$J3\#$E[P+F.K8'PXRBG6 M5@>8/',&-8Y( ,NFI[,/=@*37=_YX!DK)E/");A:4BVE5\X+RR%#*/@R\1I7 MI@ 5'A?NY_<_"1@!M+'H]"X\JUZMPE+W+ &O3:3'?(<>OV@,I1IQEUWFIB MH WV$^*FW4"Q3B?'*+&"W.3(!-.4*\;QGD\=1U: 2(P8H,A(Y)2FA&B\EQ=) MZ=*KK4<))@RS9J3C,]HAT?=-JCIM'T=&54%$+X'7POIXZQ7" #:&%]+$IH<2 M1PDP].=!/FPFX$#"KM%A=.5(;#4J/*36,"VA=Z;9,!$F/=:&40(263F1":/) MUH=NF\7QWG=0LF!!(P(DA@IYC15O)74R/3PU2J1B@!4B'9RQ:!!K!!^6Z\=5 M_?;NR==6'U?U]K!]K?Y<;QVE(Y3H^HC8T$(SH(+KSA!Q%B%GF@0=Y'V/)E^C M!#;ZTV,@H*ZO5M-B:17F1@B.A :(<=$_U6'5[+SP'!A> M*0^#L)Q@(%#8]BTUKDD[1,KY=&-WL+#(N"M0'MPF84PSZWU-6)Q\AQ6HZR,J MZ638EI%%!EJ+J0'2/>W1 J7W+QHLD#(N<_)A5UKS >V0A-R1@ 3TVF.(71LF MPI*E=\C.?F5"7@]H ' *L%%&ZC8 &7#*J1PYK]T81B_ M>7C0)BO+W%8N':JQS' 90UN^^MMV?=VMUB-_W:N__'VV6FV/Y:ZHR-O=758Y*RJVF!FO M@Z$:%A&^1Y59.6HZS=%RVFDI=:A>?AHM%%W"VV*CO[4__F,>-K:PF7W[M?Y2 M/YRHY^WV@(H%GPH;;217P<6R1%"E]I#Q8)NG!S8&+NZ=CCN'2)P3Y[$,UN-[ M<"O&R<+1LYY324? 99J1^<"=F$0G38.CXRJDPE((@G@>8&X H<&; M:V1%DH.R3<@L6NS&C%YX73='BC0=RZ/&1*GR]4-XYL=?ZD6]FCVHQ:VZ_10T M$9.DXIEW;""].-8L(NDYE0".4*0P9H98!X!36#98:&72N[T/9HAFTNWWN?(# MHC9Z8%1_:W;M7:_;[D>$/XZK*+.(>R*X$$ 9P+'0KI$UYNR-F+-ZF19,3GA' MIU)_\+Z7NOLISU#?77$GF:$$(1P -A8;*%"#>7BA"[_]-Q.?ADO"R(KZWXP? M _LB+<-K)?HT!"^AVQ2!#L9S:T8X\8(2CT%KS_.PB99G;1:5*#<"YJ,MM\O5 M?\]6M\TTWRQNZZ_U[8?EF_7ZL5ZM=\G/VY=J?C??6?C'%M#SGU8QJZQUQCBN ME'&4A+>VM>$),NG760P6I2V*B\-#7A05GRZ-4P^;>K78O7'Q5CFU:?72EZ&= MOJ02'!O,@)0>(N^,H SO0N>.(ZAT>J/FP6I0+X^X0VAB[./IL!?\.5]L48O" M!H#C31C+8'O=QL*8+9A[ZZ7#@?493ZN,5P1:C[&%'FOK)4'->RX!]^E+ZV!E MKD4Q='C(QZ+BN]FW;6;:A^7^.+$1K5[_7F_>WFU?J---'X]H8$+/<2 M:]"C']%@S;^![S6+P%[B6Z[6C?>VYO%S)Z9_#[('"I#+968(02Y=LH (7$3Z);.X_3DI,%:LA7%\5(559[]J5:K6?CM M=D7X(_[T]N[MXR8>[ZWW>>P?[[.8IEV^J$+6(6V\9TIH*A&4@.(&3<]P@:WF MBJ+]I-H8B]N_+A]RI\6/QZ([>R !Y@JWEVFC/O6#*Q3K#':J*H!Y-FB^AD4%G2@W=R. \ M+93=R"#8!$&\V<.;Q3I,:AM:/9&6]/J(B@-OL7%$.JVL1X1*'K7#2+Q\!<@Q M.[U.FY#4F1W?TS0+L&.97!^"L;B^JU?Q>/-]@&1^$T!Z>_>*$.L/86+KU_]T M,@ M7A\%&+QQ(:447F%*B-,2R<9(,SU:]DE\-H3*4V\65-9X34F5,)&5AC>G[(MQ"Q:/*L6/@VOZ^9(D99A>=28AA+3 MM$G@DA.K)'%6*P.)$9#P=ED6/=KX3-0FH;-N>[5). ^URVZ3 (-UQPE "B L M=/@_S\Z,49!^Q)J'R[1@Z;%LJ M$Y]&KQY/0_UOQH^!?9&6X;42?6*"J_7Z\=/G./]U-&MN-O5M3#KMPL\#0RMO MN$%N>[,8#WLA45;B1F)N;?I5?I?5_J!W>ET>?$=GU*[H(]Z+&>_=_B-8YEW( M]..H2@%A!>, "6J0D!YBTLJ)O$F_1O:R6A?TYE%O:*>L/WN:_.Z6U0_UUXT. M7_]7%U)U>4YE@&!22:$)!=I*P@QML8 .%'C9=9DT&P#LL8AWY!K-6 C\=K6[ M.+[MEG"$>^<^JA)>"4^@!11XRZ"+G:(;1 #ND9=V65T$4NDW,-X7Z'"8V=>+Z%#F8I]G5B)6&UGIH;0$0">ETZ:16^@>MT=>@N^:B:UC:R$] MM_GNKK[9+._JKV&_"%.(/O?!:1Y,>C[G(94#0DK#?'#0K>-2Q;ZJC61$RO1+ M&2[!;\S)KR%AGZBP;X)>RI(%A$E8T(4/+YP)_R6VP06;'D5>E]45+SF,,3CD MD[2[>7]S7]\^/M1O[WZ\F5JMU_5F_0Q\$];O>7W[K+UN,2OY[3""?QT152R+&X$A'A$'&0 Z1B#2FW'CAM M.[F-PY^?!PVKQ>WQ-RQ\X/?E8O7BA>O<[:;O=U26.<*H!,A(HG"P$Q3E.QR= M4Q*D]](>JLW-X(0YM1I)XX14P#3C8PC%YF)8] M.AX]SBA\.0_5RRYJ@)8X)[%32D&O81!0H4969(0L.UDSBQ;/JFY(P^NZ.5)D M>F-YU/B9"E^8I9 QJ0AGQFH;G1K28.&!'/7BL!R%+YUUVZOPY3S4+J^IBZ'Q M>K,@7]BMD2 ^1D(:^1P7Z<7X8S5UF(*]_NMJ>!<;K"R00 M6GNJ.6U0\%2P]-2'"3NZ=,9_F1N?,GJZ8* !L!AS"QG@&$ #&_/*.TI4>>DL M ^DT&T8]WM'9P^9>W7Z)\<+U&2_KT6&5U%Y9([ 7$+N+?&P<;F\$B!](1XL M#V.PMS8G4-,UU@KK"U-&>VT-#\3D8=*-)>L%-NFAQ\%2%092: 9TQK*UMK>F MG/#=VL]47&/$E1:6&"R-8XC8QAOUAH+TT]FQFBM-YJVE8C@J#TY&?)Y]JM(@ MF)M84"T=\QA10EK3TS/F4=D^5X(^7M-H+RPN5[=%^DCCJG0:5?X6(/WT^.FD M,E]\KG)*0V"-<]I!JX'B0(KFR-9H6F!Y1)(FEODP&$V?LZ_=]/G\)E(PL++EUYOE$6??; 8(*.4#]F*FTO[>K>&NK( RJM."?8<:L0 MX](CR@1HI!>DAR$V5H^HR0RQ00">LE!C_:,8W?O?='E.!:"U&#..@$&6AI<+ M6-UB09$KV]++K? .%1"YH?RYZ56DL7E1K)J83;L"H"TH\/15,8='5<& XY3& MJSF#4(1P+T0K)T9ZU*.;,Y/#\^KQ>!N:'IA-R0V4Q W4G'&06)R#,4+. N6A M)K"U[YGN<1/N\.6OHW,C#;,IN8&3N+$?57D&D(?>8>'"Z@N(X PW=L7/\!\3U>BIZM7%,*(J5,Y9C #P"#;B0ARVYX)UJ+#Z-#7(RN7Z;K?ZJ M-S$@\3[&*'9AC-DF_O3M7;V:+U]K"M5Q9(6M<%3C&+%&EDNM &Z68*@ '?,J MDZ*)DAW*L7:S=SNRKC\L]Z?.#>7K=0!M?2Q.>&IHY96FDCHH%&.",.@X;FP[ M2!U/CQ$/WS=@[%TK,Y;3VD+[]?'%MJN>UL?U-A+_]N[MXR8FMZ_W]N3'^[.M MI=0OJ@0WT@2-$ 06WL997-T+4*9*QGHE?ETN/L9K'&S] MYU,3F",$?O7S50!:&6"5BB420A-CVA ",H2GTTU>'=UR #C1\4*&2S2YQ@ VNCBGY8TVE\Y3&DQG"M,0&6&4*#A];(3DR/.FAX?:<,0R ZVNJS7-7SCPL3K,QZ MA86$#A-.4+!AL7<<2-M@@[WOP;;K.8,8$^'QTHU_ MC)3O!#O&L2.CJN#V"(@=4 ;RV,W:8PT;.87CZ>U#X?4<4N3'L3S?LO4)LOB) M[=,J@@"V/KC;BBIIA14$T 879_LD!U[?.<;P^/8^A'\VM>:^O0-3?-?M!/[L M!VZ+@XSB#$@IF*,JO'C;XB"!A2.PQ_$[O)[SAU$A+CT*?)FW' C)).4D*)UK M%EYEZF43B<"8"C#CL;#$$^ZA M]@!QVN2\AZU&I M H6 K?R(FAXNZO5%^X?!](E3(W9ZWQ;W%="I?9\1_03L_WV$ =T 1#@OO\7Z0'PX7&G=&\31?<3^E[E\ M+W7WJMFAOKL*FJ,*.RB U(YY "&P#>;8"WHQA=Q]^#367Q71IR'X>1WN/'-<.TD-$H(38@!5II'!J5%OT2UY;T\%;%2EG]7R3&'L M/#W/NJ[20+>J%TC7PHRG; M]XI1J\O>A'(KO%?#NS0H?VYZ%;FG712K)F93WY:Y'^JO&QWF^%<7RF7[LDIP M0"ER4' AG%0:(H!;"D$X@ P!ETC.&)]\LY'BO^-SH"#J0'G M05GN\3%1+EXNY*5BP6)%P =A&CF46@H3X8WE38(!)U\9+5G2P4D%'ODCG_9K3.FCAZT]UY&(S7>B+EIKO@ M0#''@S.% <0T<-S2!A&KI2_P5H\L^NR!P=BM(9Y?G7S/T<7"G2]BN/(N=2XT"+&!,^$CN[/3R;R4%KX<2(RAEL MA5506QPV7V68Y(U=;"'J83<,9@=FU,-R"(R2]?J/>K47I8M.7_]T9;T6$D-( M@7$8842!QLUT-LNG8'.[L:3+LY@4I6L_L:C-=W][/5IS>+F_\XKMO7/AOF M&6Q89RUF(FQ%+D#A6SHR!].#J(,U;1M(H1G0&K$-?FA=PJG/@%A/E ^4H1LW,5)QR9%'X?W"P 7'F39R(M,CMW_X M/)X2.)4/VN3MY[LIO%LM_]Q7&R_OU,W]O/[RO)_2A]GJXZLMDI.?56$A:'A+ MF/""4 4@T!0U;MXZ==LZY_U?./]YOZ5GVI5[./]7\N M'P)H4;JN*U;79U72..8IIH)(RR0CCCC1FO26%6A#%4'"L0 ?.P1V:;?\!1N7 M>4L4P Q#AT$P>EMSF5F6O@T/WV6W!/I.JHWDG?N56>OY0QCW\9?E[,$^1OR. M]PX^?FENKN=7"AE"A2=<.^XUM_I9M-19!Y+9.7QSW,EW^(F4,&7UUI,MO&NI M>5:6=Y?G5!)K[2PG%"A/A5.$ =(&8X.GEDS(X7OFEK!<#@GVT!G;ORR7M_\= M7J"I4[*;>;3:.$+N'SY;68N1% 8S)#CAA%'JD7?.".2@$;23SS2,7.]O[NO; MQX>P+S:S/I73?&!$1;02"'INF-,6.:V]Y'L9@32DF%ZC/;2S' *)HM.#XP:U M?)C?;E>B+5HG\EA>'U!IYH73PS*OX-"0*HA'F"4 M0H-IU-_VYF]\G/>[C>C4EG!T7"40$%Q#YK 7T$ +H36-K!;8=+-AX 3'W#M# M3I1&8\1NBB=7@1>?"YXM -QQPV40B&O*B+&MN>4@+'LKR*2G[[6? :'+UGJ1 M"WX)RLX4?7QGCJ>J-'^O%%142 "(TF$90XAK(9OY ,1'[0?:+=B2B.>RO_2C MEFYUKM*D0GMK3;PB&B@9C!,(<2.#8CY]2QVXX6?N+345D8(+\JA%P!"I@?%6 M<\V%T8T M2"PEDHU) ,-F4F!J?;YP:"((8YT@?*_&[XX0]E/(\4V_+S<3WM+6[Z1"0B04 M50I;%JQ:QRG&VBKE33"+% 43MFW)>%+A"07 ""RM)H!R2JGJNXVTG%>?!<8F3: M, *$5 C9L(]I)#G'L)'0>UQX0Y.^:NL:HDY#Z1KY4*1=7@H-KNJDPGFH.&7* M!7=&&N4@](VLP; M]O:KW#M#3I3*CEG'5'OMF:!< 20DYIBTKTMT3\O>"C+I MZ6CP.@VAR]9ZD0M^"BD4% D-X#:ZK8>.(BGHI( MN?%3Y(+UH94@B#HJD&92X$8.:*@L>[%.T,>10&H:%I>KVR*7Y'%5.DU0=;L( M'8IU9@BIOEG$6IT/LZ\C?;M5/ZQ=;>^=0GB'AQ3>8,I480&[CFEE4=: M \%M98)A;HEV8TCYZE0[JN?KPAF1@8/UL4\#(N)L=3OY>.]&B!F#N1FT- R M/QY%AW-; =7CYGZYFF^^G3#Q7A]046J%9\@&"PFI>.\ ")CL(8'$I->R#1S. M[:G@0W3I \Y8YL&/DSWIP!T:4AEDE#)0*06-P@99I&#S?A&,"[^XNJ_:3K*@ M%TK7R(^#9/6]2+@OSFV%1P841&BA0!&.0UQ M6$BYXUH_;;9JU,!.M^2,_(9#'FQ&?_6_[PC\U:SJVS!OOUS5\X^=EH(3CZB( M(99"PS1#QDE,$/.J00!!46 7Q0'-RKQ@3;Q4?+B?;?ZU?'RX??/I\^QFX^[N MZIMX>U:4\WACFK0'5A@H;KBBE@(23]PPA[9!APN9;G0.UB)IM(4F+W03$VO7 MJB%@MZIGZ]K6N_^>SZ?7GU,! @#!6E(H/>.<*D?;EPR346_;+HU&61!+KJ50 MB\W\9OXY\+6]B?1;,X>P0AZ8\_8O-_5J$Y ,OWZWW'72?,V2&>!;*@"-QXH" M"QS#A&L*.6VQD3TJ+@?K.92/3=/C.;K%Y+[./NT;T+RK%[.'V(%$+6YCN^M5 MO=ZHFYO5X]%>I6<^J;*82RRT48 I(..;9UF#AQ<]>EH-UC5H0/MI$,S&XE"8 M7?T0FQ+5M^_O9ZOZC_KSX^KF/KPFZS=1.[.'=ZOY3?UN-K\-Z_#V(T=XE/"T MRE$3DY2H0Y8BI2UASC6XA+[KYWJ18DMU M>6I%('->2:5L\'JA=^%M:W4B;(^;L,3E\&L\_,;B6>M,/+FQX>W9=5M[G"\^ MOOV\[[1V+'C4_2&59Q *:1##$CE/%548-RA(Z=+M@Q8H)*S T5%C6JD8[WZ'4+P:7S;$@@ M)[#8MXOK?B$.2^YJ]GGKYL90_<-6K\^.#(];[%V>5$7+TWB/N,;(>X<1ETW, M5TK%>F2V7U! ?%C0AL[#^2-LRJO'F\VNK^A];!@^8*+,:]_V^VP5%_@O]=2I M,R\GMPQ.UN(V_*Y>?:E_[9!%TV5XY2%B#E((.=#$0>T8-U BRKUU@DLU74+- M4W[H"T&V0CQ$'R**M.Y>,7GR*16EA (9F&\XAII;#ZW=8Z$U \544>95[,'" MRMR %9V=,6 R9I1J1X)0J8E40G,$@-G,DW4X>K:0RHW(/YF&?AU*Y MN;HV9B01:[ 6%@+#/%!L*X>%'D%(RTZY2=#'D:3=-"PN5[=%IL^,J])I5)EV M(;Q% L4\<@ 0M=IRKJ"+LC!D;;1GRTN(2=+$T0OAS\-@-'TF70CO.2=&*(YI M<&R#2^()B%9,C/TRHG5Z=MLH%$GZ[,'!J,MM<\-B'$ M[.3SV!6>W]Q39Z<8T NCZ^-"F<99$13(E1<4?L6;.>QG<+SKZN$153!4G7$< M>X3#OA7,4RY8,^>8[UV@<=87_>40R"1K\\? T>M[]N$/5P8SX3#2V(5I&8*@ M"%_32 Z0'3$1M)@-.QM<^11[<,D]]O%*$ZV
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
E\56)/(L-8\/;>ZEV7'?I)MJ"X@O M>I ;WVA3=^;"(H=M:XULO>FBK!P3AF-6':1^VQ6W9;;_5NE5&R%^+# 7?]4N MIG6JDI "PA.* F ^#^/@&0!1D;@ ] M0A'B!/D4HN@]!K,@T1XOG>E9->8_T]01JCHG797[%-H 7J&EZWP.T&OP>J;O M:#_(=6Y50N@-4K8(\P*ZNEHRK+ ^1-7* 2D=3MS, @A @D0QXH74QX%/ .N4 MB$.LE.@;%FTYA939 ]$B&'D<@_Y@/@P#CW$>4QA%(9^ M[".UZXPF)*I,8JW+BJV2YVNLB@]2F\!5CB"G!E2-%3LD>_7.VE7/R(02H W0 MGTG(E\%Y1BUZ^?2T<;2D"NGN(,;-W8=B]_5+MG^@V>WAYG:;?ZTG=)^M!F*( M4!=A'WO02WP&44!K9DTXCU#$9&IH8\(LSL3N8$IQYU1*_B0RRP>G4M,YZ:E7 M.IN#6J%JG@5RO8+9&/1RU;(L,I<*9>/(+J!&-F]387,L*F9QO?A?TD-[^?FY M*B_VZP")7$S$?_&(L( )T:[;J0% H'2YV+CPJ0[HBIZ- R)D$-B M$(8<\>HKG[D(A>^]23SBD^U-DTX?IXGZ6C6I)EH*!:A]U/2J377TY,K*-^V] M5$.. V-( PIC T4M':GB\#B,$(BYX<0XS@2>C"EY0X#\FROGF[*Z:X[FT9KR0QZ0.Y8D4!GTLEC V(%U#86#&KL#PT=??#GNF"=IM/V38]9!M2 ME(>SLU6>CZA'@(]=RKP$^C@(2:L%]D.U7KNF94^U&U8MX;;S$GU-\UUY<+[< M9\[SF8O6Z_TQW>KN@QGRANHVV/2.&!.AJM.BK89.K>*"-K^DD)3:^S+KDX4D M]+:LN[CS90/%D20K_I'MOV7XZ8OX-%'["U7.2HX0ASSV&.4T!""* 8:TTR3V M/&" :$?)G_#HP?-)WVI=I425WO6REM#@MCG]UGN[)NZE!_ MM]N5B&-,741$G AHP+P@B%#<')*@87710';R&Q9K<>)WFC83^TQ%I]%18P/- MT 17PW!HWQ4$?=0^%\3/>3OU[_#**! M":<'Y3*FDZ;NA8G!I#85;@[WV?Z-&?C;;I^EV_Q_LLW/:;ZK%+C9T6R??ZN[ M&)5HGY?5ED@=DC^*[Q<;H>W-W9?T^XH ,46C)(XBD(0HB*(H))VBG,>*3_?- MH*#U W\GW9UJFG<7.V?06.-7RT?[8WD#>975L/:3?!VX<6YFNYO$? MF/,S.GL9Q#$G ,5B)IX9"JM4X\4^R[_NR'$O MWZZ2YDGALB M'A&OD^@A-UX=BD.ZE:.A,7*4JI5>)6DF^5+]B;-^MGJ0M]5+G1\I=UK11U1N M@68J,-468]Y+:(8'(!P@&Y- +\,SC1BR>NF*(;0D3JO MU@R;^^R0K]-MOW CF#$1Y.CY$+#0A1$-0+MPD_A)"'V9LU%ZGVQO9CW31^]& MA298"H>:[(.F=WQ)&3RY,TIOFGOI--(X;!9P[FBD 86Q<:+4C'-7?_8QW;YQ MF1_'R \QYB2(@,=@E$<$HP#0D(2$X=$&G"\8D4-D)LJ.!Y1VCYQTCKL[Z M251/,W6J5Q5$K[RHT9Q*?:?27ZU$L^0DN>)M?O^H!1-KKK%SMT\'W8&*SZZW MEE$+6K;QY;7""1"UQ]:BLETEA%$,@(MP(")(X (_]%I=*(Q=;I>M9318,EL+ M_6VSM923;+&U:?],R-9#KED(6PL5C;*UBK=^5+96LG$T6ZLC:H&MT9V8 [TZ MD>O[W">>3[@'(:?,Y7ZG#@V9TLEU:THLD+/3RH ):%O16\:9VYZC[).WK(_F MYN]G&)NA<#VW_7 LKFFF/I&/P57] A):KX\/Q_KJT]#.^8N[IPPD'F)A $,2 M49< AEG0K!>+,B%AJGWM+6MC_33,LYN@;^S#ZEX\LN0<.09?DE?4B/S\0M*9 M[DZM_-L7%=J#TLNYF*2%^= ]AHF\N0Q^G\S:BY>7ID!9G>U/!S:O3\>,N_.< MU[NS:QH\WZ4B'J7;C]F^?LA#X'[2DP<>II#Y$?0]%A.,(HPZ/1G&6)?_I])O MNH@@*.ADE'-]?KB;W=UEZT-U_/M=8M(-()/Y6S6D+-'1:D'FDE=_KD_V+RV< M&,);*L!,[=NEA9S)[;\8A.;QA$X1\N]COL\V0HO\D'T0^FZN=P;-,V9JYP##FCOLM#&/H\!E$@8B?@G'E!E,1 LQ^"#4TL+RT] MSW8;]9U&_Y]J YR3!4YM0G4?OS;"J:UH:4J[/8(5[ZG7*/,Z;DR%8L-GULL3 M9;@EBQ-[;EQ:G+!JZT!A8AMAJ>.!['NV/GZ\3_.KXT":0&GUL;I7Y@:+HIW?H[E051V^[KAE'!\>9\_EJW$.(P9A 12 M$@:![U,?(-1*Q#Q BI6'?)==BZ*G7)'0Y<#C* ES4*BM6!F;=(%<(S.8!M;S?*/A6F% %R %JM.*/97"E'=.*"<:S M<3;]9Y9_O3]D&R0R@/1K]EN9W1VW'_*[;)4 1"$+ L[=.." @B2&K4K5$\6* M3[A95<5ZIO-RTF_?GO173F>#TQKA-%8XE1F+8X&+@(]CA?%^_&%8PH"IZJQA M"E]9%L''LGKFL"3%PVV^JQ/!3]FZ^+JK.LE<;[+=(;_+TUZ]S@*TVWP0W\ZW M]3D9\;/CP[DMY0J$@8=H0!ER@Q#!T*=1T&GK,2JY5#"WEM:YIS/,.;.L.LW6 MV>:<&]=E'SUA5?VTSPQT6@NO+J4O$_>HLN2U 0*;>YPL@]MF1Z%8UNP=W_.E M.)SMMD4$"C&, .A!!B(8QK"YC(U"A!*,52K3T<(L5Z/C3\N-AU.NPIP42;6J M!8S"E66H>;2J<)=_3[ M!.[9.6.W]BV[5G63?SE>U=_NM^Q0R_O^HSP@=0)@&A\O M(R9,;O7%4P%3HJZZ=/"^%J>E4#^! 0YQQ%$0X)AY<13"1A/J <*5HHD-^98C MQUOD,D0FVGL\5GPC%P[F=HL:]=OPB-7%% 58)19*;#AI&=QMU<(+"QSVT)0Z ML_7&.@O[_IBMZV?3WE3G8W.]<842BCFC3)0?"+L!\?RP"1"0^U&($X6#7?:4 MF&DQ]A(77/5+KT\CCX1I0W;IW)A]'RS@<-D$1A:3CFNETYF-Y'K!]%-VR/?- M/8&^C]N*AEX0)-2%,0*)BUG$DZBG%Q#*/T$^7I3EG*I3L#V'?5+QK VA0D=' M ] .YTDSH*J6$BT/4(4VF=,"J],WX'A\I%C4_@M($08-*:P,L;4 M"NXVH)1?BG:+K(M)6?GSOGJ+"OH$N2A G-+(1UX$D=LVHX@A8)[B$T^CQ5E/ MV#H-JS;YK8[.2"^C #-G3F%I7*K-/IJ5^===^O^Z MN[;FR&TK_9Y?P;>UJY1=@B (\B55 ':4S47E3SKI"H/73TM2F+<:LXVN\?C M_/H%>.O6I2D !$C&>4B-1R.>[WS ^7!P.ZCC_N?\]EYD?*=;F^VYZ0"%,8G\ M.$YY!E*. 0I$P-,@]"$+,"E_).<,6PYK6 SZ]>SW1U0('& M@9BTV0C+"$NK'I7NNJQ:+P&D$F$5?GFO^_+;__3^"KC"[9_EI$%SR+K M#39>B29;_,T;0=:\*.WV*MUAK#.7K8O]K^OM\4DA@GY-:Q7&"%( ,L)3SF*$ M$D!A9SY!8:(WEEDR.MF =EK89_EI5F0@!@(@RG##"<^2Q!N[68HB(&9Z)E:FR4C5)UON6)85^JF M(-=&WF=A'FM#XR[0I21P8ZE>FKJ-]N>BM-EA2E_7:O5\9A.A+,$X"DF(& UQ MPA!-.IO=I'&1QA%*MS?(Q=AQG7!TT[X1- M[<*O?4+5M&LJ+O5$RYA&)\HUP-& 9-E@=AE:9<63TGZ_TU.GFWPCB^@6=\6F M/K?WZ7A0>AFDN57G$XYYFL2M$]:SMP$[N%Z']\K[4B/V!&3-4GE6&T%M M8)F-?[W!PB+UCAZH4*=Q0,V=M,8R%-J-:R_>M'#&GZJ2OJM/]4NA;V3\W4XH MC3SG'V6,AV%$F)C,9%382& HS*5A#'! XDQ'-8V-.%;($ZXV-[OR.FAZ4FC. MHIKL34*@GL29<.=$RRYQ,Z!;H^E$P8VPI>F&(_H5,C&%!J6+0R\TU\J4Z[->;PRK T,<$^EG( &EW1ZD666\>Z*\J\'Q2WY?5WL@WXMJ%?,,$(PBPJ,L2E+"Q=2JM8DY")#> M <5QMIR?3>S0B*@0>*:N #W$S<#X:X?398S&EGQY7H/9(D/ZM?M;8S?YUW)_ MJ,MIW)7[QUJYZ1_M#YM]4H8 PI %:4@3F,:4A:PI>I.D2>CKO4KBPK[C^C]LY@7\E:[MV_&%E^WV+KJ$TPYFX8O?S+39LXKJ"O3.R0JCILIH5H MK4L/+U;!=\6FG6PG8&&0T)#3)*8I)AFA/NYL9HE/5KO\8"/3><1^Z=)>%2I74@0VO%%*^'18T@YL!H3K'Q<%[L50;$/,A@D89;A)*!Q M#*/6!@F ;AE+O6\[GR:-$]%M,"\#IG709N#28V5S@D9-5OM',.LVI+G, 67 MECTM$;> I4];GI3VNY6&=%^O]_GW?"O??3ANY:A.=KG@J[/0J6>PK<0O1-&3X#T&I2C MU-X>TQJZ/POC9B/ -;GA_^#O7V$^U6)>;310)>;2N&"=V 6,$/9]*EUV19U1 M(]]+[^NCWNT*UJ9ZM]NT%D/(($X9",(XC%B"TQB#?HH10J7SU3;LN!XAWAGI MUDCN5,:%Z6C3' UZ8-X9,GE<< XF=71_.D8-U7X$LXH*/TC!15VW0]P2U-R2 M)Z7];F6T5OG:)L3[_I8.8)#X- B2&,NG2"!"2=J9]C.]DY=6#+K>?AW:WAMQ M+],.V8J;JU/SK+F;.IYBEPO)@[2]O;YLA_5%+3M;2VDJWZR/$.%N0O<#.G12#87(D%CO7BN.E984:Y]6>SEY;VO M]4.ZN_NTK [5BC#"N#!%*6,^XB"@*.E,80RY5HE>$P..):;!Y&TD%LVRED9T MJ8F+9I]WEV';\L@]9 ,[F79NO?Y*C4#L3"6S&7$ MQ6@O7MP'M<&*:KQ<*D#T7@1J5N[SXGZ7'O?[?+?YX_-^O:L$$EG0:'=;_]?V M67DC,2OX=/=Y_7V%8@$R\3%*, :$X#1KUR $6( IU!EP9X+H>.P>*&GV@_3L MQ[Z>S?-J4LU46MZKF+S2C9NF&)"(F=M^&0HS-PGEHN)1M]9GO6Q1G60T0"EC M(>*)ST.* 4RR]M(>2!B/M91)^^..-:7#HWW1W9PMM;3)*5%Z^9(.1X[J1#[E M8D#]C&E;AFZ9PW]13W$4#^I:43Q^.8JH:_98:ILK'T8)#H,01-S'*65!FO+. M5.ICS4+O!@:<:\89)K,M#C/>5)7#,66ZZG'.ULT;;#G2CY>,#&K(" *7HB-C M7'BA):/YT,T]5IB!&((L9?)-,)]Q&$/:?SZCZ>I0'M9;O9SCS8]JZ49O7SD2 M/LM?,=4+55[TL@NKE)AE%?.D$@HIA#(W2PEY7=@74@9-OY5+)LN-"S&E:8MV MG3*3*!63%9Y"B)*,^ADA).C-P2S52A>,C3A.&6I@R]&6\&\^+#]OA14=_/MUUN8RL>M&5#^2<,Y3X MOI]@SFD$&(+]U(AKKF^86YEHTB(AR?_?5KN?DM/WAYVP#Z.F3(I[H0 MN:=27XGD,O(3-F>I&7J1G3>4:!RCRY&BD7Z\HD4VF%$_%+\5/[W_*=_E^_56 MB""Y?2QVA13 NAI[:YP&41:&0103GB0!!Y&/@\YX%& M9;)DTK%,M2BOO/L& M9SWJKY\@U3T1;X=I-OY_>F,WZ<@Y]$S->8&Q,TR]A1DR=GS.B)D!(ICEY0/UD>T!(CGI:A&&;07[Q_;NR_:O231WD?Y]_-"Y=W M[W8'T4$*D7>1JLH/U0KPC)(XC$"(810QYLC-,$\#"F2)X&5HDBUG2B>=4'>'2F1'Q\WA MN)>'\1_6^_N\6D4LX GWPY@#X-.$TYC%G2E*@U2O J.1"9V0,BS$>(;*V]2P MO!^^B-3QKCC\./4NSDN&!G=T1A"ZC! :Y\*+G9[1?)CN^M05X!%*$I(PS@"' M)#O-)>*$^CH;N]H?GV2#=]/O5I@OK.I19K:Q8Y6ML1LZ\^[B:.S>*+.V#-TP MA__&;HTF#\J'Z[M[;J<#LBO.0@@(]@D),X1\#/RL'\AYF' =R3#YOF/5:(^P MR[;SR@9>N=/4#"/:U&3#-6-ZRG&ZR?KDY/_$9_I?4C*@(&,(7(:(C/+@^5'X MT6SHON[8&&IU2U["QTF 8H8X$KD.P@"!V$?][Z3I*FB=85^Y&F'*O1AZ+:Y%OQ5WEYK+RB MC:EV>G1Y\'9"JF+6,QV?F@E0?0GR'-D+C9KA@N-%IH;R(CL4+T.J;#GSVL5! M6QRIRM9E>SX6<[T8 $XC%B#&.>&=/8(8U9J)F5N99!6GK.-LG%2-(%)-I:;A M4$^@%B1-)JHTGM)E")(%/TK;G? MU]_SZD.Q*_?%X8\NSR.[VZ=?X?]W%#_^D!\>2O&3;WESH;I:88Z02//$S),& MD=PMXFEWY)@P'X4ZPK8DW-,L7;55%UJQ/$B/=&>8RZ%,JZS-,B"[G >?+;(U M2Y0G5[V3KUT7:#SP&A>\,Q^NNJ&@9N)*)K!"R X"TK89)QI*YJB_,TD;#D[6 ME]>3EC&&+9*95VL/+0RCP3@KD+7#.6VV]%=!#'CL4Q\$'(60P)2'W;DO @-* M]0XUF%IQ?J[A>E]^*RIY7$@TT^@QS(!&G?'&+7]&8X. U.WB>C_068Z#7.#F M3U;"PKRLL,^>%L#RA$0M48P)P#2@%-XX!U>T DDB^^ZRPM M:'W9<8XL"X\UJC+QY/>A"DA*,8@BZ#X'^_-08QU-@&,C3A>_N]P>2(G\@31CV*PK23 M:2/B$CT#P3&:T67$R7@W2LL];5STT'55;%84)!!@>6(@#GC$8I+V]\0)PDAK M']_,@N.XJ4',&R,U!(T T>-MF=&AZ<,;H6'"B&EG]A94. MJM=B]1JP\CI;VSIG>*^\-GAF*XFDR^R 6CIKI&7(J#OWRHDZNQOA;5(D/X H MS2*6I="/9=&Y%,%>_-- ZUD\NY;_?&F^%C\6 E:/Y_^L:-7TS3!431@<&:?M MP/("RBI(8AH2'. X R$#$2<@Z%%$F=*#ZZYL_QFG'9H_/91;P6_5;![W(SL,$@X@"&%&PC0DOBS= V0M,X@C MAGVF6MC*BC%W.?/I,2>9)9\A_*_N3,I5[5RP)AR M69O-)M_*DQ^M#MSD7T6/?5A7>?59EA5<80 93&/NQPE*PRAEB/1F=4OZC3;F M>+ \P]?,7+TSA-X_:XR:U8_'\ZNF=Y-2JR=UXUAU4^;F#;8&Y,T:TGM_3LZ_[[=O5SOMX>'LCMM[7PO2(;(:!5(<^T?=U^+PS@-X_&XC* 2?]K<,(!&T0J3#P2@!9 M)6[>X+'K2NF@8UE+ MX7N_R=R$ZJ58PCB ,(,0Q3QG&:4=$A6M.00]]2(J!N M<-YD0.+T:J#V,@(-LD=G!6YXMIH9J% \=7K0TV:6(NBSOO@TP< E]53!E"]5 MYBT0;Q MRPA"*YZ4]KNE[C)@N?GM%.+7^_)^OWXDQ\-#N2_^G=^21PD K.*$,4BC*.0Q M"5D6>A6 ,]&P>]%NJ5=P+K-6BG7A=48G!P9=!N&RPC M*JU[]6)UT 5K&K45;O.JN-_)T;F=A( ,(!!%3(S C/ DI#R-LBQF&(641CC3 MBTP3"\ZC\&-Y\%B/REM7WL_Y[7US\U/6(JU7[G6GTM:*!#SG:R#FQK"[C/@: MY<'+D@ CV= JI?3*"^K_N]N+*;Z,VY_6Q4Y>X/BT8_F^^%8_8%&1O9CO[^Y9 M7>GV6OQ]>2L?3JRG+<8TXVH+5_,@'?>!\Y'L9LG?4!A-.Q=]*Z[KC!Y.5@7[30PU,W:+98Q MXLU+P8NGN69O#^6W/];50[8M?Y=3_;R#^+FDN8"Y75=5<5?DMW\O#@_%[O/O M^?9;_J'<'1ZJ%8U!'$&*,,@8"7'DQW'2HF&40\W",ZY0.!_%>'4H'NOE$C'< M>.MZ64J>;LR_%U5](TL.9"+Y/CRLQ8_W>?W^%W_ZVU^ZOQ'_]V5=Y7_[R_\#4$L#!!0 ( #>82$I^:AD[ M@+$ !0["0 5 <')X;"TR,#$V,3(S,5]P&UL['U;=]M(DN;[_HK: MVN?JROMESO;NR6NW][A*'MLUO?N$0U.0C"F*U)"4R^Y?OPF2@&2)%P"9 "%6 MSYEJRS(2R/CBR\S(R,B(__F_O][-?OB2+U?%8O[7'^%?P(\_Y//IXKJ8W_[U MQ]\^_*0^F#=O?OS?_^N__<___M-/_U>_?_N#74P?[O+Y^@>SS"?K_/J'/XKU MYQ_^<9VO?O_A9KFX^^$?B^7OQ9?)3S]M&_VP^6%6S'__M_)_/DU6^0]?5\6_ MK::?\[O)V\5TLMY\^_-Z??]O/__\QQ]__.7KI^7L+XOE[<\( /QSW>K@$^7? M?JH>^ZG\U4\0_83A7[ZNKG_\(4@X7VV^W> CU>-?7SS_!]X\#:64/V_^M7YT M5>Q[,+P6_OQ_?WG[82/G3\5\M9[,I_F/_^N__?##%H[E8I:_SV]^*/_\[?V; M[UYR/UGF7_/97Z:+NY_+?_]930/L#[,2\:OUYWQI%G?WR_QS/E\57_(W065W M9=\W[_V\S&_^^N/]\NLL8 $91%LD_D>+5ZR_W>=__7%5W-W/PN]^[MSG_WHH M5D6IW]7?%HOK/XK93,VW'W\S#W#<%I]FN5JM\O7*YNM),5N=EJ'S*X>7J?KW M'F0[\.KA97S\>Q\J//SVX27]=;'.DPKWW0N'E^?CI(0UI4#?OS&-1'JR*E97 M-^^6^2HL.INUXE27CS3IK4_F1U:60)B^I=L7G]RBSFZV!'!7NJR%=AS/SM8;*9&LV%9YLF*I_\^OPC?PZ_+!:S(KK MTF#3DUEI/7[XG(=Y]G1'F[YAJ!Z_"TWF8_KT=I/H1Y)-^, MQ$#4R>JSGRW^Z*:'HV\:2H+VFX>8=PXD52)!>NG[,K\NUNIVF6^_3KVK'RDZ M=GB0OOTR6:WSI2_F82D,YF LR U?ET86FW]:-[)H3TG1^D4#]_^I23M?+R?3 M]<-D=O5I5MRVV7SU]+EQ8=',\.[G:ZF06!9?PMN_-!'CQ:/)^_ $@8U'XFCUK]/;^^#7B^F:_6RX\0H="4,FLE,W2T>PH?#2*N[O'JFU.YH=/U(S9IFZ:7[K\>PNO+[TR6\\#.U;M\^>%S>.I4%T\V[+E_ M^N';I\GT]X9\;?F:GOM>[J\?MM[,JYO2Q3D-#]EB]A#FB2?/ENOD8KYI$2MF M]!=[1J39B&W8/$U?Z[GKEWRR>E@VV^P?;=1CO_;^\M?))M>FIE.W MMZ61I&440Z^1"=7+JS^;=N;Y\VE[TR@R8._#:?O1; CL?SI-3ZI3L:^GN['G MT>1]:$C9PRW2].A]7N[>INN'9; _PO9O>7L:GF-M^NM5V]6_S3OZZ_5W>^OR M%^IV4L;;??>LFDZ7#Y.FLUCBS_0G>[,Q?[IEFAY^R&_+I:G%KO5PB[YZ]"$L MF<4TO.%+/@\&2K',IVNS6&U\#W];+E:K=\O%3;&^>O;@UH[5[: MD$L#=J$OS)JQ[%2[1+U;+Z:_A^UH>8)[=Y_/5\UX=K15GSTSL\EJ5=P4T]U. M^NF_N:_EC_D_BO7G8G[\0+HIV0;L0Y^H-61<@[:)>OD0;.W_>@AHN"\MAO[1 M5KWTK)$Q>JQ-+[WZ;@'JTL7#+^BEOPWI=ZQ1IWX]O94@MSV;Y[?E:'P[^90_ MV^_L:S=;+K]K5EZ'D.5U",@V7=[WML0]_35?I^WL\Q+^?\R7JSQMSU^^,G6?%^O)+'&?7[PR79\[$&/]LIL-67#_ M).CZ;?C%[OGROK31M"'U4^W MD\G]S^54_G,^6Z^JWVPF]Y\ W%T=^Q^[7V=[^A*FI*N;CY.OZM-J$V=0]6U6 MHO37'T,_LA:M,T25LDI!:JV@$')",0Y_]T91!<+OOA=]5EZ:6RQWP \O>UA] M/P;X=?CB[RT%?]HT8X9C2)PA'')'&*>"BTIJ);5N(O53PJGE](?%\CI?_O5' M^.,/X5]N\N5RM]8=N?NWX=_ZQ:PQ64Y?T/;[AKLG?K[?1"/_-/U3;UF-?:FHR^R6_^Y0O MC[!J[_,99MX)X 35#BLO$$*VQHU9#_]$/&JK[45Z?(?BSIYI^\02>*!%I@A5 M&'./A,*, 6 A]95\CG$7P1\T/OX,MO"E@?N<="I_7.;YR<7N9-L,0((1\59P M3JDT%'L*=C)C+1&YK"DJ6O,-F!2#[VE.O3S7*'^3N:_Y].'=Y\GR[LU\^I># MR]7!9S,"+03:,($\(!HYXXVN^JF81Y?/@XYZ6Z1%MC,#_IY/9NO/ZOI+>?'^ MJ6#'R7"B668,9AA@@PSVA!-HA'=U[X6@0RY!7_+EI\7K9$9:F#N31*UGD]5Q M0CQY),.:6"\$@=('TU]C04 M:K"W;(3R\9]F4N@.:&$OFN6)" M5NO%7;Y\G\^VISZ?B_O#1E2#5L':@TI RC66U#-, 7&TDA,[$F-4ORZFQ;'@ M^;EZ,L2'8M;'?/IYOI@M;K]MPF)?H'.*8XW:9Y@ :CD'P@/->+!6$,0[V2FR M=- MW.6PK0_L!^/=A8411%4S82B(&"+LLPVTP M-L7!?$9?]-OPBS?K_*[E^4;=+ /!NJ $<2^6$]FC]E^#SDK.K\P TI"1ZS$ MC$+%H!;*U>-)A)\NR^1*H_S%&9 ?^(!_]7&Q<_54 N:K3:!GF>UU]R_71V:V M-J_)A":*6$094H(()H 1U4D =4;ARS+$DG)P +R'7D.?C*0Z2=ZZO-)7!(WN M]+LLLX]M!'Y?_G1U<_6P+N.%5[O<'K>?VT6T1GPH$QQ"X$F8XX-5PB%@GHL* M34K\A1E^O;#WK!HY([_#2K&XG1?_#$;T=9"HN"DFM1E=C58UOWZ2G";\V\/= MYC)9M]#M%%_,+);*<&2D=L0K3B5EML97H)CY>H26Z5",/X-J1F!4;#(%=#,D M-DTSZP40%&@HJ"<*0-AP2.V3CXZ7)D[7/C^?E?L,8)134DECG*;*\@IY+%",6VW$)O*(!\FY5?SJ!]>[ M97X_*:YWB9:J2\[;?SO':#O6GPQQ&79EVCC' .*>$)KXC!-8W:H]%_#[VS# M+Z'.7^-X?+=M#C5JGJ?DWT/SZI&,<\ $T(9;AH25R 5[M9) 600B>"G_QGQCZ&W!#\B]U#SKJ=-/H:Q\D3 MT^QI^9^MPV%XT_]E'[+R0J4DB('RBJ5F5K$ZV%E3+J,2?(TX.O,21U5*1;_& MP?;D-P,-K2>_R=#F>CFC4G& @<=8^2?68U2V!MC^P/U%GN1_#:0AU#KR8?,D M?^Q>+:0?-J>^F%EEB56P?>7'[N2PI_25?3F[SWU;YS[1TQB"&+E 2F M/E/2$HF81(4C/D=,&NDZ(/XCG^"/G6\.;QZ]_'"F.2SO@P/NF=5&;J_25:X1 M3&*RVXSX%&^T<=W1&GH<#^/(@'^TJNJ F?"?]/-%DOYB-9TMRNJT#>Y7M'I/ MQ@*/)&(.8\.%5@(S:[P7EG/$.&P6D](/'H]W;[\KJWI$\@,M,BREI6%>EM13 MHP04QJE*1HAYS+GE"/T5/>G_8"K\&*Q?7Y)?(;$SRACME*(!.<,PWLG''1<7 MEGDS6LL-<_FV0_5"Q#>AW\Q9 MI0"I>B\-C7%SO=9 >P M<-;MI L_RD%)]/K,E22@GH\R)XV40TTR+KP4TGCNG<5",JXTJR1$-LKG,L(U M*5;-)UG3"=6A>%/7(J\FX%VM^5,SSM%V&7!8<6"ADEX!C* )H9) MA^R9&71ROCG:+M,$.(E-V"E"1P54EEI=R4KBSE)'./\DT7HS)G7"=R@N;9)T MG9A[ZFGGFFZXC@H%TYF5G[R5*8L MAIYH!8"#DO!@Q*L*"8G@I94>Z*"_?0SHA-W0-V;>-DB/_.+9S +E-#?&TW)$ M,.:MKNPVZ7"4)3+""(74\T,LGF.\5>6#Q,PP#1T3SE$0]OQR)X'"!%W8*6&$ M!@_=AVH'X-A"2IY<$?QS1I48;+ *,SPK_5M& ..(@,1[!W&8\UVCS M]1Y6< M#@%\6EFG>>Q)A_=F6I0^000\Y11Y01@FE@A$K_&GE]<2PN M;,7"KHX86,+).,&"[.23DML+BSX8B L-HUW:87\9T2Y"&J0%XUK;8!( ZA"& MMAES;^M/'"'C9<^G2 M,.5KY!$0V"B,B=("TPH/J/&%Q:/WPI3(TJ7M-#!8!$_RTJ6""L>YX=90C!&R MB"BUDU-[')6Q;92K;6\\:%&\M!WF0W$KIH@DTM)I[E18#D09=@G"BE%)9"6Y ML+H 0W$H$N8178!NUC]O M9E-",5066Z< IJHLE,UPA2\,,].0UL'%,'XJOBW5^OJ/4/3I9=:MW M6#?+).?2*D2XHT1QQQ6!U"KEC9*:,M_(5368M(^'U MQ>>UO[";,VGH\3QXKF?0!S.RZD'Z\JBL*B!U]*!L,W2;'&TD_E(F15@R."D7 M'XD0X,IX4^%)I(X)TQNA0=<+B<^KDC/$+&\NSUWG-X=/H6MQ5^\FR_7CTO7$ MU=R8\?U^...2<2%I69"$:JF@T:[:M2EN0
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end